[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 1305
1. Steffen J, Maneva G, Popławska L, Varon R, Mioduszewska O, Sperling K: Increased risk of gastrointestinal lymphoma in carriers of the 657del5 NBS1 gene mutation. Int J Cancer; 2006 Dec 15;119(12):2970-3
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Increased risk of gastrointestinal lymphoma in carriers of the 657del5 NBS1 gene mutation.
  • The NBS1 gene mutation, 657del5, frequent in the Slavic populations of Central Europe, is found in most patients with Nijmegen breakage syndrome (NBS), a recessive autosomal disorder with a very high incidence of non-Hodgkin lymphoma (NHL).
  • We have previously described 2 heterozygous 657del5 mutation carriers among 42 adult NHL probands from Central Poland.
  • Here we report 6 additional carriers of the 657del5 mutation and 2 carriers of the pathogenic NBS1 R215W mutation, among 186 other NHL patients also from Central Poland.
  • Interestingly, 4 of these carriers were found among 37 patients with gastrointestinal lymphoma (OR 19.52, 95% CI: 5.82-65.42, p = 0.0002).
  • These findings imply that heterozygous NBS1 germline mutations may contribute significantly to the overall incidence of NHL, especially of the gastrointestinal tract, in Central Europe.
  • [MeSH-major] Cell Cycle Proteins / genetics. Gastrointestinal Neoplasms / pathology. Lymphoma / pathology. Mutation / genetics. Nuclear Proteins / genetics
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Gene Frequency. Germ-Line Mutation / genetics. Heterozygote. Humans. Lymphoma, Non-Hodgkin / genetics. Lymphoma, Non-Hodgkin / pathology. Middle Aged. Mutation, Missense / genetics. Odds Ratio. Poland. Risk Factors. Sequence Deletion

  • MedlinePlus Health Information. consumer health - Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2006 Wiley-Liss, Inc.
  • (PMID = 16998789.001).
  • [ISSN] 0020-7136
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cell Cycle Proteins; 0 / NBN protein, human; 0 / Nuclear Proteins
  •  go-up   go-down


2. Petridou ET, Sergentanis TN, Dessypris N, Vlachantoni IT, Tseleni-Balafouta S, Pourtsidis A, Moschovi M, Polychronopoulou S, Athanasiadou-Piperopoulou F, Kalmanti M, Mantzoros CS: Serum adiponectin as a predictor of childhood non-Hodgkin's lymphoma: a nationwide case-control study. J Clin Oncol; 2009 Oct 20;27(30):5049-55
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Serum adiponectin as a predictor of childhood non-Hodgkin's lymphoma: a nationwide case-control study.
  • PURPOSE: To our knowledge, this is the first study exploring the association of childhood non-Hodgkin's lymphoma (NHL) with serum adiponectin and leptin levels in a nationwide case-control series.
  • In addition, expression of adiponectin receptors in NHL specimens was assessed, and the association between adipokines and childhood NHL survival and prognosis was examined.
  • PATIENTS AND METHODS: We studied 121 incident childhood (0 to 14 years) NHL cases registered in the Nationwide Registry for Childhood Hematological Malignancies (1996 to 2006) and an equal number of matched controls, for whom sociodemographic, lifestyle, prenatal characteristics, and fasting blood serums were collected.
  • Immunohistochemisty for adiponectin receptors expression was performed on commercially available adult NHL specimens (n = 30) and in a subset of childhood NHL cases (n = 6) that were available.
  • RESULTS: Higher serum adiponectin, but not leptin, levels were independently associated with childhood NHL (odds ratio, 1.82; 95% CI, 1.30 to 2.56), after adjusting for obesity and established risk factors.
  • Higher adiponectin levels at diagnosis were positively associated with relapse and poor survival, but hormone levels did not differ among NHL subtypes.
  • Adiponectin receptors 1 and 2 were present in 90% and 57% of adult samples and in 83% and 100% of childhood NHL samples, respectively.
  • CONCLUSION: Elevated serum adiponectin, but not leptin, levels are independently associated with childhood NHL and poor prognosis.
  • Adiponectin receptors are expressed in NHL, suggesting that adiponectin may represent not only a potential clinically significant diagnostic and prognostic marker but also a molecule that may be implicated in NHL pathogenesis.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Exp Clin Cancer Res. 2006 Dec;25(4):537-41 [17310845.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2007 Feb;16(2):308-13 [17301264.001]
  • [Cites] Eur J Cancer. 2007 Jun;43(9):1430-6 [17512191.001]
  • [Cites] Cancer Causes Control. 2007 Nov;18(9):1031-7 [17653828.001]
  • [Cites] Int J Cancer. 2008 Jan 1;122(1):144-54 [17708556.001]
  • [Cites] Curr Pharm Des. 2007;13(36):3676-80 [18220805.001]
  • [Cites] Am J Clin Nutr. 2007 Sep;86(3):s858-66 [18265479.001]
  • [Cites] Endocr Relat Cancer. 2008 Mar;15(1):289-99 [18310295.001]
  • [Cites] J Clin Endocrinol Metab. 2008 Aug;93(8):3051-7 [18492759.001]
  • [Cites] Arch Dis Child. 2008 Dec;93(12):1027-32 [18676433.001]
  • [Cites] Mol Pathol. 1999 Oct;52(5):269-74 [10748876.001]
  • [Cites] J Immunol. 2002 Jan 15;168(2):875-82 [11777985.001]
  • [Cites] J Clin Invest. 2002 Oct;110(8):1093-103 [12393845.001]
  • [Cites] J Clin Endocrinol Metab. 2003 Mar;88(3):993-7 [12629074.001]
  • [Cites] Circulation. 2004 May 4;109(17):2046-9 [15096450.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2004 May;13(5):779-86 [15159310.001]
  • [Cites] Biochem Biophys Res Commun. 2004 Oct 15;323(2):630-5 [15369797.001]
  • [Cites] Proc Natl Acad Sci U S A. 1992 Mar 1;89(5):1890-3 [1371884.001]
  • [Cites] Blood. 1992 Sep 1;80(5):1289-98 [1325212.001]
  • [Cites] Blood. 1993 Oct 1;82(7):2169-74 [8400266.001]
  • [Cites] J Clin Invest. 1994 Jan;93(1):424-8 [8282815.001]
  • [Cites] Cancer Res. 1996 Dec 1;56(23):5499-505 [8968107.001]
  • [Cites] J Immunol. 1997 Jun 15;158(12):5596-602 [9190906.001]
  • [Cites] Environ Health Perspect. 1998 Apr;106 Suppl 2:679-81 [9599716.001]
  • [Cites] Am J Pathol. 1998 Oct;153(4):1229-37 [9777954.001]
  • [Cites] Am J Physiol. 1999 Jan;276(1 Pt 2):R136-42 [9887187.001]
  • [Cites] Br J Haematol. 1999 Aug;106(2):504-9 [10460612.001]
  • [Cites] Ann Hematol. 2005 Jan;84(1):1-12 [15480663.001]
  • [Cites] Clin Endocrinol (Oxf). 2005 Mar;62(3):366-71 [15730421.001]
  • [Cites] J Clin Endocrinol Metab. 2005 Mar;90(3):1618-24 [15613407.001]
  • [Cites] J Clin Endocrinol Metab. 2005 Mar;90(3):1625-31 [15613409.001]
  • [Cites] Br J Cancer. 2005 Oct 3;93(7):811-6 [16160698.001]
  • [Cites] J Clin Endocrinol Metab. 2005 Oct;90(10):5876-9 [16030165.001]
  • [Cites] J Natl Cancer Inst. 2005 Nov 16;97(22):1688-94 [16288122.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 May 30;103(22):8481-6 [16714386.001]
  • [Cites] Eur J Cancer. 2006 Sep;42(13):2050-63 [16919770.001]
  • [Cites] Exp Oncol. 2006 Sep;28(3):241-4 [17080020.001]
  • [Cites] Diabetes Obes Metab. 2007 May;9(3):344-9 [17391161.001]
  • (PMID = 19738128.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] ENG
  • [Grant] United States / NIDDK NIH HHS / DK / R01 DK058785; United States / NIDDK NIH HHS / DK / R01 DK058845; United States / NIDDK NIH HHS / DK / R56 DK058785; United States / NIDDK NIH HHS / DK / DK58845; United States / NIDDK NIH HHS / DK / DK58785; United States / NIDDK NIH HHS / DK / DK79929; United States / NIDDK NIH HHS / DK / R01 DK079929
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adipokines; 0 / Adiponectin; 0 / Leptin; 0 / Receptors, Adiponectin
  • [Other-IDs] NLM/ PMC2799057
  •  go-up   go-down


3. Smedby KE, Hjalgrim H, Chang ET, Rostgaard K, Glimelius B, Adami HO, Melbye M: Childhood social environment and risk of non-Hodgkin lymphoma in adults. Cancer Res; 2007 Nov 15;67(22):11074-82
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Childhood social environment and risk of non-Hodgkin lymphoma in adults.
  • Better hygiene and sanitation and decreasing family size parallel the increasing incidence of non-Hodgkin lymphoma (NHL) in many populations around the world.
  • However, whether sibship size, birth order, and crowding are related to adult NHL risk is not clear.
  • We investigated how family structure and childhood social environment were related to the risk of NHL and NHL subtypes in a large Scandinavian population-based case control study with 6,242 participants aged 18 to 74 years.
  • Having four or more siblings was associated with a moderately increased risk of NHL, compared with having no siblings (OR 1.34, 95% CI 1.11-1.62, P(trend) < 0.001).
  • High household crowding was also positively associated with risk of NHL.
  • Results were slightly stronger for diffuse large B-cell and T-cell lymphomas than for other major NHL subtypes.
  • Our findings add to the evidence that large sibship size, late birth order, and childhood crowding are associated with an elevated risk of NHL.
  • [MeSH-major] Environment. Lymphoma, Non-Hodgkin / diagnosis. Lymphoma, Non-Hodgkin / etiology
  • [MeSH-minor] Adolescent. Adult. Aged. Case-Control Studies. Denmark. Female. Humans. Male. Middle Aged. Odds Ratio. Risk. Risk Factors. Social Class. Sweden


Advertisement
4. Setty BA, Termuhlen AM: Rare pediatric non-hodgkin lymphoma. Curr Hematol Malig Rep; 2010 Jul;5(3):163-8
Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Rare pediatric non-hodgkin lymphoma.
  • Of the cases of non-Hodgkin lymphoma (NHL) diagnosed in children and adolescents, 10% comprise a diverse mixture of unusual B-cell or T-cell disease, some types of which are more commonly seen in adults.
  • Understanding of these rare types of NHL comes from small pediatric case series or the adult literature.
  • Some rare pediatric NHL is similar to adult NHL, but other types have different molecular and cytogenetic characteristics.
  • [MeSH-major] Lymphoma, Non-Hodgkin / therapy
  • [MeSH-minor] Adolescent. Child. Humans. Lymphoma, B-Cell / diagnosis. Lymphoma, B-Cell / therapy. Lymphoma, B-Cell, Marginal Zone / diagnosis. Lymphoma, B-Cell, Marginal Zone / therapy. Lymphoma, Follicular / diagnosis. Lymphoma, Follicular / therapy. Lymphoma, T-Cell, Peripheral / diagnosis. Lymphoma, T-Cell, Peripheral / therapy

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 2003 Dec 1;102(12):3871-9 [12933571.001]
  • [Cites] Pediatr Blood Cancer. 2006 Aug;47(2):210-4 [16123999.001]
  • [Cites] Blood. 2007 Apr 1;109(7):2773-80 [17132719.001]
  • [Cites] Pediatr Dev Pathol. 2005 Jan-Feb;8(1):52-60 [15719203.001]
  • [Cites] Br J Dermatol. 2006 Dec;155(6):1197-200 [17107389.001]
  • [Cites] J Dermatol. 2009 Jul;36(7):392-402 [19583687.001]
  • [Cites] Blood. 2006 May 15;107(10):4047-52 [16424389.001]
  • [Cites] Hematology Am Soc Hematol Educ Program. 2008;:349-58 [19074109.001]
  • [Cites] Leuk Lymphoma. 2006 May;47(5):865-9 [16753871.001]
  • [Cites] Cancer Genet Cytogenet. 2006 Oct 15;170(2):158-62 [17011988.001]
  • [Cites] Pediatr Blood Cancer. 2009 May;52(5):566-70 [19058208.001]
  • [Cites] Blood. 2005 May 15;105(10):3768-85 [15692063.001]
  • [Cites] Blood. 2005 Jan 1;105(1):74-6 [15353484.001]
  • [Cites] J Clin Oncol. 2001 Mar 15;19(6):1855-64 [11251018.001]
  • [Cites] Pediatr Blood Cancer. 2010 Feb;54(2):212-5 [19856396.001]
  • [Cites] Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2009 Mar;107(3):393-7 [19121958.001]
  • [Cites] N Engl J Med. 1996 May 9;334(19):1238-48 [8606720.001]
  • [Cites] Blood. 2006 Feb 15;107(4):1255-64 [16210342.001]
  • [Cites] Blood. 1994 Sep 1;84(5):1361-92 [8068936.001]
  • [Cites] Blood. 2008 Jun 15;111(12):5496-504 [18385450.001]
  • [Cites] Pediatr Dev Pathol. 2004 Jul-Aug;7(4):407-13 [15455481.001]
  • [Cites] Blood. 2000 Jun 15;95(12):3922-8 [10845929.001]
  • [Cites] Eur J Haematol. 2009 Sep;83(3):165-74 [19548917.001]
  • [Cites] Ann Oncol. 2006 Jan;17(1):123-30 [16236753.001]
  • [Cites] Semin Diagn Pathol. 1995 Nov;12(4):314-24 [8578026.001]
  • [Cites] J Clin Oncol. 2003 May 1;21(9):1782-9 [12721255.001]
  • [Cites] Clin Lymphoma. 2004 Mar;4(4):250-2 [15072617.001]
  • [Cites] Am J Clin Pathol. 2004 Dec;122 Suppl:S98-109 [15690646.001]
  • [Cites] Pediatr Blood Cancer. 2008 Jul;51(1):29-33 [18300314.001]
  • [Cites] J Cutan Pathol. 2006 Sep;33 Suppl 2:1-5 [16972944.001]
  • [Cites] Lancet Oncol. 2002 Apr;3(4):229-34 [12067685.001]
  • [Cites] Am J Surg Pathol. 1992 May;16(5):455-66 [1599024.001]
  • [Cites] J Clin Oncol. 2005 Feb 1;23(4):676-84 [15613699.001]
  • [Cites] Haematologica. 2000 Oct;85(10):1109-11 [11025614.001]
  • [Cites] Lancet. 1993 Sep 4;342(8871):571-4 [8102718.001]
  • [Cites] Br J Haematol. 1998 Oct;103(1):220-3 [9792312.001]
  • [Cites] Leuk Lymphoma. 2003 Feb;44(2):241-9 [12688340.001]
  • [Cites] Am J Hematol. 2004 Apr;75(4):195-9 [15054808.001]
  • [Cites] Blood. 2006 Jul 1;108(1):311-8 [16543468.001]
  • [Cites] Ann Oncol. 2002 Jan;13(1):140-9 [11863096.001]
  • [Cites] Haematologica. 2002 Dec;87(12):1258-64 [12495899.001]
  • [Cites] Blood. 2008 Sep 1;112(5):1600-9 [18567836.001]
  • [Cites] Ann Oncol. 2004 Oct;15(10):1467-75 [15367405.001]
  • [Cites] Arch Pathol Lab Med. 2009 Jan;133(1):142-6 [19123728.001]
  • [Cites] Blood. 1997 Jun 1;89(11):3909-18 [9166827.001]
  • [Cites] Arch Dermatol. 2007 Dec;143(12):1520-6 [18087001.001]
  • [Cites] Blood. 1995 Jul 1;86(1):28-37 [7795234.001]
  • [Cites] Cancer. 1981 Nov 15;48(10):2223-35 [7028244.001]
  • [Cites] Cancer. 1984 Jun 1;53(11):2515-24 [6424928.001]
  • [Cites] Br J Haematol. 2008 Jul;142(3):329-47 [18537979.001]
  • [Cites] Leuk Lymphoma. 2004 Feb;45(2):315-20 [15101717.001]
  • [Cites] Blood. 2002 Mar 15;99(6):1959-64 [11877266.001]
  • (PMID = 20490722.001).
  • [ISSN] 1558-822X
  • [Journal-full-title] Current hematologic malignancy reports
  • [ISO-abbreviation] Curr Hematol Malig Rep
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 57
  •  go-up   go-down


5. Mai W, Meng H, Jin J, Wang L: Treatment with bortezomib in a patient with heavily pretreated refractory T-cell lymphoblastic lymphoma. Eur J Haematol; 2006 Nov;77(5):445-7
Hazardous Substances Data Bank. DEXAMETHASONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment with bortezomib in a patient with heavily pretreated refractory T-cell lymphoblastic lymphoma.
  • T-cell lymphoblastic lymphomas are highly aggressive non-Hodgkin's lymphoma (NHL) and account for approximately 3% of all adult NHL histologies, with poor prognosis.
  • We describe a 38-year-old patient with T-cell lymphoblastic lymphoma, who responds to bortezomib and doxorubincin combination, following a failure of conventional chemotherapy.
  • To our knowledge, this is the first case of T-cell lymphoblastic lymphoma treated with bortezomib.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Boronic Acids / administration & dosage. Lymphoma, T-Cell / drug therapy. Pyrazines / administration & dosage
  • [MeSH-minor] Adult. Bortezomib. Dexamethasone / administration & dosage. Doxorubicin / administration & dosage. Drug Synergism. Humans. Male. Remission Induction

  • Genetic Alliance. consumer health - Lymphoblastic lymphoma.
  • Hazardous Substances Data Bank. BORTEZOMIB .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16930138.001).
  • [ISSN] 0902-4441
  • [Journal-full-title] European journal of haematology
  • [ISO-abbreviation] Eur. J. Haematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Boronic Acids; 0 / Pyrazines; 69G8BD63PP / Bortezomib; 7S5I7G3JQL / Dexamethasone; 80168379AG / Doxorubicin
  •  go-up   go-down


6. Wang SS, Carreon JD, Hanchard B, Chanock S, Hisada M: Common genetic variants and risk for non-Hodgkin lymphoma and adult T-cell lymphoma/leukemia in Jamaica. Int J Cancer; 2009 Sep 15;125(6):1479-82
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Common genetic variants and risk for non-Hodgkin lymphoma and adult T-cell lymphoma/leukemia in Jamaica.
  • We evaluated whether risk of non-Hodgkin lymphoma (NHL), particularly adult T-cell leukemia/lymphoma (ATL) related to human T-lymphotropic virus (HTLV) infection was associated with 63 single nucleotide polymorphisms (SNPs) from 38 candidate genes.
  • The 395 NHL cases registered in Jamaica were matched by age, sex, calendar-year and HTLV serostatus to 309 controls from the same population.
  • Interleukin 13 (IL13) Ex4+98A>G SNP (rs20541) was associated with decreased NHL risk (OR(AG/AA) = 0.62,95% CI = 0.44-0.87, p = 0.006), as was vascular cell adhesion molecule-1, VCAM1 Ex9+149G>A SNP (rs1041163) (OR(CT) = 0.77, 95% CI = 0.54-1.10, OR(CC) = 0.35, 95% CI = 0.16-0.76, p-trend = 0.007).
  • [MeSH-major] HTLV-I Infections / genetics. Leukemia-Lymphoma, Adult T-Cell / genetics. Lymphoma, Non-Hodgkin / genetics. Polymorphism, Single Nucleotide / genetics
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Case-Control Studies. Female. Genetic Predisposition to Disease. Human T-lymphotropic virus 1 / immunology. Humans. Interleukin-13 / genetics. Interleukin-5 / genetics. Jamaica / epidemiology. Male. Middle Aged. Vascular Cell Adhesion Molecule-1 / genetics. Young Adult

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2009 UICC
  • (PMID = 19533685.001).
  • [ISSN] 1097-0215
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / IL5 protein, human; 0 / Interleukin-13; 0 / Interleukin-5; 0 / Vascular Cell Adhesion Molecule-1
  •  go-up   go-down


7. Gra OA, Glotov AS, Nikitin EA, Glotov OS, Kuznetsova VE, Chudinov AV, Sudarikov AB, Nasedkina TV: Polymorphisms in xenobiotic-metabolizing genes and the risk of chronic lymphocytic leukemia and non-Hodgkin's lymphoma in adult Russian patients. Am J Hematol; 2008 Apr;83(4):279-87
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Polymorphisms in xenobiotic-metabolizing genes and the risk of chronic lymphocytic leukemia and non-Hodgkin's lymphoma in adult Russian patients.
  • Using allele-specific hybridization on the biochip 76 T-cell non-Hodgkin's lymphoma (NHL) patients, 83 B-cell chronic lymphocytic leukemia (B-CLL) patients, and 177 healthy donors were tested.
  • The GSTM1 null genotype was more frequent in NHL patients relative to controls (OR = 1.82, 95% CI = 1.1-3.1).
  • Thus, our findings show the association between polymorphic alleles of CYP1A1, GSTM1, and CYP2C9 genes and the risk to develop NHL or B-CLL.
  • [MeSH-major] Biotransformation / genetics. Leukemia, Lymphocytic, Chronic, B-Cell / genetics. Lymphoma, T-Cell / genetics. Oligonucleotide Array Sequence Analysis. Xenobiotics / pharmacokinetics
  • [MeSH-minor] Adult. Alleles. Arylamine N-Acetyltransferase / genetics. Carcinogens, Environmental / pharmacokinetics. Cytochrome P-450 Enzyme System / genetics. Female. Ferredoxin-NADP Reductase / genetics. Genetic Predisposition to Disease. Glutathione Transferase / genetics. Humans. Male. Methylenetetrahydrofolate Reductase (NADPH2) / genetics. NAD(P)H Dehydrogenase (Quinone) / genetics. Nucleic Acid Hybridization. Risk Factors. Russia / epidemiology

  • Genetic Alliance. consumer health - Chronic Lymphocytic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2007 Wiley-Liss, Inc.
  • (PMID = 18061941.001).
  • [ISSN] 1096-8652
  • [Journal-full-title] American journal of hematology
  • [ISO-abbreviation] Am. J. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Carcinogens, Environmental; 0 / Xenobiotics; 9035-51-2 / Cytochrome P-450 Enzyme System; EC 1.18.1.- / methionine synthase reductase; EC 1.18.1.2 / Ferredoxin-NADP Reductase; EC 1.5.1.20 / Methylenetetrahydrofolate Reductase (NADPH2); EC 1.6.5.2 / NAD(P)H Dehydrogenase (Quinone); EC 1.6.5.2 / NQO1 protein, human; EC 2.3.1.5 / Arylamine N-Acetyltransferase; EC 2.3.1.5 / NAT2 protein, human; EC 2.5.1.- / glutathione S-transferase T1; EC 2.5.1.18 / Glutathione Transferase
  •  go-up   go-down


8. Gemmati D, Ongaro A, Tognazzo S, Catozzi L, Federici F, Mauro E, Della Porta M, Campioni D, Bardi A, Gilli G, Pellati A, Caruso A, Scapoli GL, De Mattei M: Methylenetetrahydrofolate reductase C677T and A1298C gene variants in adult non-Hodgkin's lymphoma patients: association with toxicity and survival. Haematologica; 2007 Apr;92(4):478-85
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Methylenetetrahydrofolate reductase C677T and A1298C gene variants in adult non-Hodgkin's lymphoma patients: association with toxicity and survival.
  • We analyzed 110 patients with high-grade non-Hodgkin's lymphoma (NHL), 68 of whom were eligible for a chemotherapy combination containing methotrexate (MACOP-B) and 42 for chemotherapy without methotrexate (CHOP).
  • INTERPRETATION AND CONCLUSIONS: Our data suggest that MTHFR gene variants play a critical role in NHL outcome, possibly by interfering with the action of methotrexate with significant effects on toxicity and survival.
  • [MeSH-major] Antimetabolites, Antineoplastic / pharmacokinetics. Lymphoma, Large B-Cell, Diffuse / genetics. Methotrexate / pharmacokinetics. Methylenetetrahydrofolate Reductase (NADPH2) / genetics. Neoplasm Proteins / genetics. Polymorphism, Single Nucleotide
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Amino Acid Substitution. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / adverse effects. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bleomycin / administration & dosage. Bleomycin / adverse effects. Cyclophosphamide / administration & dosage. Cyclophosphamide / adverse effects. Doxorubicin / administration & dosage. Doxorubicin / adverse effects. Drug-Induced Liver Injury / epidemiology. Drug-Induced Liver Injury / etiology. Female. Genotype. Hematologic Diseases / chemically induced. Hematologic Diseases / epidemiology. Humans. Kaplan-Meier Estimate. Leucovorin / administration & dosage. Leucovorin / adverse effects. Male. Middle Aged. Mucositis / chemically induced. Mucositis / epidemiology. Prednisone / administration & dosage. Prednisone / adverse effects. Risk. Survival Analysis. Treatment Outcome. Vincristine / administration & dosage. Vincristine / adverse effects

  • Pharmacogenomics Knowledge Base. meta-databases - Pharmacogenomic Annotation 827859137 for PMID:17488658 [PharmGKB] .
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. LEUCOVORIN .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17488658.001).
  • [ISSN] 1592-8721
  • [Journal-full-title] Haematologica
  • [ISO-abbreviation] Haematologica
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Neoplasm Proteins; 11056-06-7 / Bleomycin; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; EC 1.5.1.20 / Methylenetetrahydrofolate Reductase (NADPH2); Q573I9DVLP / Leucovorin; VB0R961HZT / Prednisone; YL5FZ2Y5U1 / Methotrexate; CHOP protocol; MACOP-B protocol
  •  go-up   go-down


9. Reiter A: Diagnosis and treatment of childhood non-hodgkin lymphoma. Hematology Am Soc Hematol Educ Program; 2007;:285-96
Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diagnosis and treatment of childhood non-hodgkin lymphoma.
  • Major advances have been made in the treatment of childhood non-Hodgkin lymphoma (NHL).
  • The recognition that different NHL subtypes require different treatment strategies was fundamental to developing successful therapy regimens.
  • Currently established therapy groups are lymphoblastic lymphoma (LBL) of precursor B- or T-cell type, mature B-cell neoplasms (B-NHL), and anaplastic large cell lymphoma (ALCL).
  • For children with B-NHL, a strategy of rapidly repeated short, dose-intense courses proved more efficacious, with EFS rates up to 90%.
  • A variety of new treatment options, some already established for treating adult NHL, await evaluation in childhood NHL.


10. Heerema NA, Bernheim A, Lim MS, Look AT, Pasqualucci L, Raetz E, Sanger WG, Cairo MS: State of the Art and Future Needs in Cytogenetic/Molecular Genetics/Arrays in childhood lymphoma: summary report of workshop at the First International Symposium on childhood and adolescent non-Hodgkin lymphoma, April 9, 2003, New York City, NY. Pediatr Blood Cancer; 2005 Oct 15;45(5):616-22
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] State of the Art and Future Needs in Cytogenetic/Molecular Genetics/Arrays in childhood lymphoma: summary report of workshop at the First International Symposium on childhood and adolescent non-Hodgkin lymphoma, April 9, 2003, New York City, NY.
  • BACKGROUND: A significant number of studies describe the cytogenetics and molecular genetics of adult non-Hodgkin lymphoma (NHL); however, similar knowledge is lacking regarding pediatric NHL.
  • METHODS: A workshop to discuss the "State of the Art and Future Needs in Cytogenetic/Molecular Genetics/Arrays" in pediatric NHL was held in conjunction with the First International Symposium on Childhood and Adolescent Non-Hodgkin Lymphoma on April 9, 2003 in New York City.
  • RESULTS: Cytogenetic characteristics of pediatric NHL include 14q11.2 rearrangements in T-cell lymphoblastic leukemia/lymphomas (LBL), ALK rearrangements in anaplastic large cell lymphomas (ALCL), and CMYC translocations in both Burkitt and Burkitt-like lymphomas (BL/BLL).
  • Pediatric diffuse large B-cell lymphoma (DLBCL) is cytogenetically different from DLBCL in adults, suggesting a different disease in children.
  • CONCLUSIONS: Additional cytogenetic, molecular and microarray investigations of NHL in children are vital to better understand these diseases, their etiology, and differences from adult NHL.
  • A greater understanding of pediatric NHL will lead to disease-specific and patient-individualized therapies of these diseases.
  • [MeSH-major] Lymphoma, Non-Hodgkin / genetics
  • [MeSH-minor] Adolescent. Basic Helix-Loop-Helix Transcription Factors. Burkitt Lymphoma / genetics. Child. Cytogenetic Analysis. DNA-Binding Proteins / genetics. Gene Rearrangement. Homeodomain Proteins / genetics. Humans. Intracellular Signaling Peptides and Proteins. Lymphoma, B-Cell / genetics. Lymphoma, Large B-Cell, Diffuse / genetics. Microarray Analysis. Molecular Biology. Neoplasm Proteins / genetics. Oncogene Proteins / genetics. Oncogene Proteins, Fusion / genetics

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Hodgkin lymphoma, childhood.
  • Genetic Alliance. consumer health - Non-Hodgkin lymphoma, childhood.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16127683.001).
  • [ISSN] 1545-5009
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R13-CA10195-01
  • [Publication-type] Congresses; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Basic Helix-Loop-Helix Transcription Factors; 0 / DNA-Binding Proteins; 0 / Homeodomain Proteins; 0 / Intracellular Signaling Peptides and Proteins; 0 / LYL1 protein, human; 0 / Neoplasm Proteins; 0 / Oncogene Proteins; 0 / Oncogene Proteins, Fusion; 0 / STIL protein, human; 0 / TLX3 protein, human
  •  go-up   go-down


11. Kuittinen T, Jantunen E, Vanninen E, Mussalo H, Vuolteenaho O, Ala-Kopsala M, Nousiainen T, Hartikainen J: Cardiac effects within 3 months of BEAC high-dose therapy in non-Hodgkin's lymphoma patients undergoing autologous stem cell transplantation. Eur J Haematol; 2006 Aug;77(2):120-7
Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cardiac effects within 3 months of BEAC high-dose therapy in non-Hodgkin's lymphoma patients undergoing autologous stem cell transplantation.
  • OBJECTIVES: Limited data are available on the cardiac effects of high-dose cyclophosphamide (CY) in patients with non-Hodgkin's lymphoma (NHL).
  • We prospectively assessed the cardiac effects of high-dose CY in 30 adult NHL patients receiving CY 6 g/m(2) as part of BEAC high-dose therapy (HDT).
  • CONCLUSIONS: Our findings suggest that high-dose CY results in acute, subclinical systolic dysfunction in NHL patients previously treated with anthracyclines.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / adverse effects. Cyclophosphamide / adverse effects. Heart / drug effects. Lymphoma, Non-Hodgkin / drug therapy. Peripheral Blood Stem Cell Transplantation. Postoperative Complications / chemically induced. Ventricular Dysfunction, Left / chemically induced
  • [MeSH-minor] Adult. Aged. Atrial Natriuretic Factor / blood. Biomarkers. Carmustine / administration & dosage. Carmustine / adverse effects. Cytarabine / administration & dosage. Cytarabine / adverse effects. Etoposide / administration & dosage. Etoposide / adverse effects. Female. Gated Blood-Pool Imaging. Humans. Male. Middle Aged. Natriuretic Peptide, Brain / blood. Peptide Fragments / blood. Postoperative Period. Prospective Studies. Protein Precursors / blood. Sensitivity and Specificity. Stroke Volume. Systole. Transplantation, Autologous

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - After Surgery.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. Carmustine .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16856907.001).
  • [ISSN] 0902-4441
  • [Journal-full-title] European journal of haematology
  • [ISO-abbreviation] Eur. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Biomarkers; 0 / N-terminal proatrial natriuretic peptide; 0 / Peptide Fragments; 0 / Protein Precursors; 0 / pro-brain natriuretic peptide (1-76); 04079A1RDZ / Cytarabine; 114471-18-0 / Natriuretic Peptide, Brain; 6PLQ3CP4P3 / Etoposide; 85637-73-6 / Atrial Natriuretic Factor; 8N3DW7272P / Cyclophosphamide; U68WG3173Y / Carmustine; BAEC protocol
  •  go-up   go-down


12. Goldman S, Coiffier B, Reiter A, Younes A, Cairo MS, International TLS Expert Panel: A medical decision tree for the prophylaxis (P) and treatment (T) of tumor lysis syndrome (TLS): An international TLS consensus panel. J Clin Oncol; 2009 May 20;27(15_suppl):e17575

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: We convened an international panel (N = 17) of experts in pediatric and adult hematological malignancies and solid tumors (ST) to develop a medical decision tree for the P and T of TLS based on the risk classification (low, medium, high) and management recommendations of Coiffier et al (J Clin Oncol.
  • MRD consisted of ALL ≤100K/mm<sup>3</sup>, AML 25-100K/mm<sup>3</sup>, BL/LL stage I/II and low LDH, childhood ALCL, DLBCL/PTCL/MCL/ATL non-bulky but elevated LDH, CLL treated with targeted therapy, and LRD with renal impairment/involvement.
  • LRD consisted of ST (except bulky sensitive to cytotoxic therapy [MRD]), CML, MM, HL, other NHL and AML <25K/mm<sup>3</sup>.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963935.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


13. Caces DD, Halaas J, Hamlin P, Noy A, Kewalramani T, Portlock CS, Zelenetz AD, O'Connor OA, Gerecitano JF: Therapeutic and palliative benefit from single-agent irinotecan in multiply treated and highly refractory cases of lymphoma. J Clin Oncol; 2009 May 20;27(15_suppl):e19554

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Therapeutic and palliative benefit from single-agent irinotecan in multiply treated and highly refractory cases of lymphoma.
  • : e19554 Background: Multiple reports corroborate a role for irinotecan in the treatment of lymphoma.
  • This study describes the Memorial Sloan Kettering experience with single-agent irinotecan in the management of heavily pretreated and highly refractory cases of lymphoma.
  • METHODS: Adult patients with histologically diagnosed relapsed or refractory lymphoma treated with irinotecan between 1/2001 and 8/2008 were identified.
  • Treatment responses were evaluated based on the Revised Response Criteria for Malignant Lymphoma.
  • 4 patients had Hodgkin Lymphoma (HL) and 26 had Non-Hodgkin lymphoma (NHL): 17 DLBCL, 6 transformed follicular lymphoma, 1 mantle cell lymphoma, 1 T-cell lymphoma and 1 Burkitt's. 25 patients were evaluable for response.
  • CONCLUSIONS: Irinotecan has utility even in multiply treated and highly refractory cases of lymphoma.
  • Strategies that limit adverse reactions may enhance the agent's effectiveness in refractory lymphoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961088.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


14. Asfour IA, Fayek M, Raouf S, Soliman M, Hegab HM, El-Desoky H, Saleh R, Moussa MA: The impact of high-dose sodium selenite therapy on Bcl-2 expression in adult non-Hodgkin's lymphoma patients: correlation with response and survival. Biol Trace Elem Res; 2007;120(1-3):1-10
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The impact of high-dose sodium selenite therapy on Bcl-2 expression in adult non-Hodgkin's lymphoma patients: correlation with response and survival.
  • The present study was undertaken to explore the effect of administration of high doses of sodium selenite on the expression of Bcl-2 in patients with non-Hodgkin's lymphoma (NHL).
  • Fifty patients with newly diagnosed NHL were randomly divided into two groups.
  • [MeSH-major] Lymphoma, Non-Hodgkin / metabolism. Proto-Oncogene Proteins c-bcl-2 / biosynthesis. Sodium Selenite / therapeutic use
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cyclophosphamide / therapeutic use. Down-Regulation. Doxorubicin / therapeutic use. Female. Gene Expression Regulation, Neoplastic / drug effects. Humans. Male. Middle Aged. Prednisone / therapeutic use. Vincristine / therapeutic use

  • Hazardous Substances Data Bank. SODIUM SELENITE .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17916949.001).
  • [ISSN] 0163-4984
  • [Journal-full-title] Biological trace element research
  • [ISO-abbreviation] Biol Trace Elem Res
  • [Language] eng
  • [Publication-type] Journal Article; Randomized Controlled Trial
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Proto-Oncogene Proteins c-bcl-2; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; HIW548RQ3W / Sodium Selenite; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


15. Lazarus HM, Carreras J, Boudreau C, Loberiza FR Jr, Armitage JO, Bolwell BJ, Freytes CO, Gale RP, Gibson J, Hale GA, Inwards DJ, LeMaistre CF, Maharaj D, Marks DI, Miller AM, Pavlovsky S, Schouten HC, van Besien K, Vose JM, Bitran JD, Khouri IF, McCarthy PL, Yu H, Rowlings P, Serna DS, Horowitz MM, Rizzo JD, Center For International Blood & Marrow Transplant Research (CIBMTR): Influence of age and histology on outcome in adult non-Hodgkin lymphoma patients undergoing autologous hematopoietic cell transplantation (HCT): a report from the Center For International Blood & Marrow Transplant Research (CIBMTR). Biol Blood Marrow Transplant; 2008 Dec;14(12):1323-33
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Influence of age and histology on outcome in adult non-Hodgkin lymphoma patients undergoing autologous hematopoietic cell transplantation (HCT): a report from the Center For International Blood & Marrow Transplant Research (CIBMTR).
  • To compare the clinical outcomes of older (age > or =55 years) non-Hodgkin lymphoma (NHL) patients with younger NHL patients (<55 years) receiving autologous hematopoietic cell transplantation (HCT) while adjusting for patient-, disease-, and treatment-related variables, we compared autologous HCT outcomes in 805 NHL patients aged > or =55 years to 1949 NHL patients <55 years during the years 1990-2000 using data reported to the Center for International Blood and Marrow Transplant Research (CIBMTR).
  • Autologous HCT in older NHL patients is feasible, but most disease-related outcomes are statistically inferior to younger patients.

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Transplantation.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 1999 Nov 15;94(10):3325-33 [10552941.001]
  • [Cites] Biol Blood Marrow Transplant. 2008 Jul;14(7):840-6 [18541205.001]
  • [Cites] Biol Blood Marrow Transplant. 2000;6(2A):204-10 [10816029.001]
  • [Cites] Bone Marrow Transplant. 2000 Oct;26(7):737-41 [11042654.001]
  • [Cites] Blood. 2000 Nov 1;96(9):2934-42 [11049969.001]
  • [Cites] Bone Marrow Transplant. 2001 Mar;27(6):593-9 [11319588.001]
  • [Cites] Blood. 2002 May 1;99(9):3158-62 [11964278.001]
  • [Cites] Biol Blood Marrow Transplant. 2003 Jun;9(6):383-8 [12813446.001]
  • [Cites] Blood. 2003 Jul 1;102(1):31-5 [12595317.001]
  • [Cites] Biol Blood Marrow Transplant. 2004 Feb;10(2):116-27 [14750077.001]
  • [Cites] Blood. 2004 Sep 1;104(5):1258-65 [15126323.001]
  • [Cites] Vital Health Stat 13. 1991 Sep;(108):1-236 [1720910.001]
  • [Cites] Cancer Res. 1992 Oct 1;52(19 Suppl):5432s-5440s [1394149.001]
  • [Cites] N Engl J Med. 1993 Sep 30;329(14):987-94 [8141877.001]
  • [Cites] N Engl J Med. 1994 Oct 20;331(16):1063-7 [8090167.001]
  • [Cites] Bone Marrow Transplant. 1994 Dec;14(6):981-7 [7711677.001]
  • [Cites] N Engl J Med. 1995 Dec 7;333(23):1540-5 [7477169.001]
  • [Cites] Lancet. 1996 Feb 10;347(8998):353-7 [8598700.001]
  • [Cites] J Clin Oncol. 1996 Apr;14(4):1327-32 [8648391.001]
  • [Cites] J Clin Oncol. 1997 Jan;15(1):18-25 [8996120.001]
  • [Cites] Bone Marrow Transplant. 1997 Jan;19(1):31-5 [9012928.001]
  • [Cites] J Clin Oncol. 1997 Feb;15(2):445-50 [9053464.001]
  • [Cites] N Engl J Med. 1997 Mar 27;336(13):897-904 [9070469.001]
  • [Cites] Clin Geriatr Med. 1997 May;13(2):251-63 [9115450.001]
  • [Cites] Bone Marrow Transplant. 1997 Apr;19(7):671-8 [9156243.001]
  • [Cites] J Clin Oncol. 1998 Jan;16(1):48-55 [9440722.001]
  • [Cites] Bone Marrow Transplant. 1998 Jun;21(12):1193-6 [9674850.001]
  • [Cites] Stat Med. 1999 Jun 30;18(12):1489-500 [10398287.001]
  • [Cites] Bone Marrow Transplant. 1999 Jun;23(12):1273-8 [10414915.001]
  • [Cites] Bone Marrow Transplant. 2006 Jun;37(11):1017-22 [16633361.001]
  • [Cites] Ann Oncol. 2008 Jun;19(6):1166-71 [18272911.001]
  • [Cites] Blood. 2000 Mar 1;95(5):1588-93 [10688812.001]
  • (PMID = 19041053.001).
  • [ISSN] 1523-6536
  • [Journal-full-title] Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
  • [ISO-abbreviation] Biol. Blood Marrow Transplant.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / U24 CA076518; United States / NCI NIH HHS / CA / U24 CA076518-11; United States / NCI NIH HHS / CA / U24-CA76518
  • [Publication-type] Comparative Study; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS83336; NLM/ PMC2638759
  •  go-up   go-down


16. Claviez A, Meyer U, Dominick C, Beck JF, Rister M, Tiemann M: MALT lymphoma in children: a report from the NHL-BFM Study Group. Pediatr Blood Cancer; 2006 Aug;47(2):210-4
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] MALT lymphoma in children: a report from the NHL-BFM Study Group.
  • Marginal zone lymphomas of MALT type comprise a considerable group of indolent B-cell non-Hodgkin lymphoma (NHL) in adult patients.
  • In childhood, however, these tumors are extremely rare, as nearly all pediatric patients have aggressive NHL.
  • Among 2,703 children and adolescents registered into the prospective multicenter NHL-BFM treatment studies since 1986, only 4 patients (0.1%) displayed features of MALT lymphoma.
  • All children are alive but long-term follow-up will be mandatory to assess the behavior of MALT lymphoma in this age group.
  • [MeSH-major] Lymphoma, B-Cell, Marginal Zone / pathology. Lymphoma, B-Cell, Marginal Zone / therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16123999.001).
  • [ISSN] 1545-5009
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


17. Abid MB, Nasim F, Anwar K, Pervez S: Diffuse large B cell lymphoma (DLBCL) in Pakistan: an emerging epidemic? Asian Pac J Cancer Prev; 2005 Oct-Dec;6(4):531-4
Genetic Alliance. consumer health - Large B cell diffuse lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diffuse large B cell lymphoma (DLBCL) in Pakistan: an emerging epidemic?
  • There has been a recent concern among oncological clinicians and pathologists of our region regarding the disproportionate increase in the number of patients presenting with diffuse large B cell lymphoma (DLBCL).
  • A total of 780 specimens were collected over last half decade from cases classified as adult Non Hodgkin's lymphoma (NHL).
  • Nodal-NHLs constituted 42.2 % of all adult NHLs, with the cervical lymph nodes as the most frequent nodal site of presentation.
  • [MeSH-major] Disease Outbreaks. Lymphoma, B-Cell / epidemiology. Lymphoma, Large B-Cell, Diffuse / epidemiology
  • [MeSH-minor] Adolescent. Adult. Age Distribution. Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged. Pakistan / epidemiology. Prevalence. Sex Distribution

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16436006.001).
  • [ISSN] 1513-7368
  • [Journal-full-title] Asian Pacific journal of cancer prevention : APJCP
  • [ISO-abbreviation] Asian Pac. J. Cancer Prev.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Thailand
  •  go-up   go-down


18. Smith SK, Crespi CM, Petersen L, Zimmerman S, Ganz PA: The impact of cancer and quality of life for post-treatment non-Hodgkin lymphoma survivors. Psychooncology; 2010 Dec;19(12):1259-67
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The impact of cancer and quality of life for post-treatment non-Hodgkin lymphoma survivors.
  • This study examines the association between the Impact of Cancer Version 2 Scales (IOCv2) and these outcomes in a large sample of survivors of adult non-Hodgkin lymphoma (NHL).
  • RESULTS: A total of 652 post-treatment NHL survivors participated.

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 John Wiley & Sons, Ltd.
  • [Cites] J Natl Cancer Inst. 2002 Jan 2;94(1):39-49 [11773281.001]
  • [Cites] J Cancer Surviv. 2010 Mar;4(1):45-58 [19967410.001]
  • [Cites] Arthritis Rheum. 2003 Apr 15;49(2):156-63 [12687505.001]
  • [Cites] Cancer. 2003 Aug 15;98(4):679-89 [12910510.001]
  • [Cites] Soc Sci Med. 1991;32(6):705-14 [2035047.001]
  • [Cites] Med Care. 1992 Jun;30(6):473-83 [1593914.001]
  • [Cites] Cancer. 1992 Oct 15;70(8):2214-24 [1394054.001]
  • [Cites] J Clin Oncol. 1993 Mar;11(3):570-9 [8445433.001]
  • [Cites] J Consult Clin Psychol. 1995 Dec;63(6):981-6 [8543720.001]
  • [Cites] Psychosomatics. 1996 May-Jun;37(3):254-61 [8849502.001]
  • [Cites] BMJ. 2005 Mar 26;330(7493):702 [15695497.001]
  • [Cites] J Clin Oncol. 2005 Jul 1;23(19):4399-405 [15994149.001]
  • [Cites] Psychooncology. 2006 May;15(5):407-21 [16097041.001]
  • [Cites] Psychooncology. 2006 Sep;15(9):749-58 [16304622.001]
  • [Cites] Psychooncology. 2007 Oct;16(10):895-903 [17245695.001]
  • [Cites] J Clin Oncol. 2008 Feb 20;26(6):934-41 [18281667.001]
  • [Cites] Psychooncology. 2008 Sep;17(9):891-900 [18050153.001]
  • [Cites] J Natl Cancer Inst. 2008 Nov 5;100(21):1530-41 [18957678.001]
  • [Cites] Am J Gastroenterol. 2002 May;97(5):1228-34 [12017152.001]
  • (PMID = 20099255.001).
  • [ISSN] 1099-1611
  • [Journal-full-title] Psycho-oncology
  • [ISO-abbreviation] Psychooncology
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA101492; United States / NCI NIH HHS / CA / CA116339; United States / NCI NIH HHS / CA / CA016042; United States / AHRQ HHS / HS / T32-HS000032; United States / NCI NIH HHS / CA / R03 CA101492; United States / NCI NIH HHS / CA / P30 CA016042; United States / NCI NIH HHS / CA / R03 CA101492-02; United States / NCI NIH HHS / CA / R25 CA116339; United States / AHRQ HHS / HS / T32 HS000032
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Other-IDs] NLM/ NIHMS166749; NLM/ PMC2889206
  •  go-up   go-down


19. Ganti AK, Bociek RG, Bierman PJ, Enke CA, Vose JM, Armitage JO: Follicular lymphoma: expanding therapeutic options. Oncology (Williston Park); 2005 Feb;19(2):213-28; discussion 228, 233-6, 239
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Follicular lymphoma: expanding therapeutic options.
  • The most common indolent lymphoma, follicular lymphoma comprises 35% of adult non-Hodgkin's lymphoma (NHL) in the United States and 22% worldwide.
  • Long-term disease-free survival is possible in select patient subgroups after treatment, but very late relapses suggest that quiescent lymphoma cells might be harbored for long periods of time.
  • Radiation therapy is the mainstay of treatment for limited-stage follicular lymphoma, but there is some experience with chemotherapy and combined chemoradiation.
  • Future directions in the treatment of follicular lymphoma include vaccines, antisense therapy, and proteasome inhibitors.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, Follicular / drug therapy. Lymphoma, Follicular / radiotherapy

  • Genetic Alliance. consumer health - Follicular Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15770890.001).
  • [ISSN] 0890-9091
  • [Journal-full-title] Oncology (Williston Park, N.Y.)
  • [ISO-abbreviation] Oncology (Williston Park, N.Y.)
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Cancer Vaccines; 0 / Oligonucleotides, Antisense; 0 / Proteasome Inhibitors
  • [Number-of-references] 148
  •  go-up   go-down


20. Ling JY, Sun XF, Zhang X, Zhen ZJ, Xia Y, Luo WB, Lin H, Zheng L: [Dynamic changes of serum proteomic spectra in patients with non-Hodgkin's lymphoma (NHL) before and after chemotherapy and screening of candidate biomarkers for NHL]. Ai Zheng; 2008 Oct;27(10):1065-9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Dynamic changes of serum proteomic spectra in patients with non-Hodgkin's lymphoma (NHL) before and after chemotherapy and screening of candidate biomarkers for NHL].
  • BACKGROUND & OBJECTIVE: Although the complete response rate of non-Hodgkin's lymphoma (NHL) is 70%-80% using modern comprehensive treatments, its relapse rate is about 40%-50%.
  • This study was to detect dynamic changes of serum proteomic spectra in NHL patients before and after chemotherapy, thus to screen candidate markers for NHL.
  • METHODS: The proteomic spectra from serum of 44 NHL patients before chemotherapy, 44 NHL patients who achieved complete remission (CR) after chemotherapy, and 51 healthy individuals were analyzed by surface-enhanced laser desorption/ ionization time of flight mass spectrometry (SELDI-TOF-MS) and Ciphergen ProteinChip 3.1 software.
  • RESULTS: Compared with the normal group, one protein peak (M11710) was up-regulated in untreated NHL group, while was close to the normal level in CR group (P < 0.05); nine other protein peaks (M3322, M4355, M6445, M6646, M8581, M8708, M8918, M13959, M15149) were down-regulated in untreated NHL group, while were close to normal levels in CR group(P < 0.05).
  • Five candidate biomarkers for NHL were screened using the decision tree model.
  • CONCLUSIONS: Expressions of serum proteomic spectra are different before and after chemotherapy in NHL patients.
  • Protein signatures of NHL may be screened using SELDI mass spectrometry combined with ProteinChip software.
  • [MeSH-major] Biomarkers, Tumor / blood. Gene Expression Profiling. Lymphoma, Non-Hodgkin / blood. Proteome / analysis
  • [MeSH-minor] Adolescent. Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Child. Child, Preschool. Decision Trees. Female. Humans. Infant. Male. Middle Aged. Neoplasm Recurrence, Local. Neoplasm, Residual / blood. Protein Array Analysis. Remission Induction. Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18851786.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Proteome
  •  go-up   go-down


21. Sandlund JT: Should adolescents with NHL be treated as old children or young adults? Hematology Am Soc Hematol Educ Program; 2007;:297-303
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Should adolescents with NHL be treated as old children or young adults?
  • The SEER (Surveillance, Epidemiology, and End Results) data for the years 1975-1998 show that children with non-Hodgkin lymphoma (NHL) have a better treatment outcome than do adults.
  • The spectrum of NHL subtypes is well known to differ in children and adults.
  • From ages 5 through 14 years, Burkitt lymphoma is the predominant histologic subtype, whereas diffuse large B-cell lymphoma is most common in the 15- to 29-year age range.
  • Because different treatment strategies are often used in children and adults with NHL, the choice of therapy for adolescents and young adults (ages 15 through 29 years) is challenging and somewhat controversial.
  • It is reasonable to consider pediatric strategies for some adolescents and very young adults with NHL, and pediatric strategies are currently used to treat adults with certain subtypes of NHL (Burkitt lymphoma, lymphoblastic lymphoma).
  • However, the use of pediatric strategies in adults does not guarantee a comparable outcome, as illustrated by trials for adult lymphoblastic lymphoma.
  • There is clearly a need for further biologic study of NHL in children, adolescents, and young adults.
  • Age-related differences in tumor biology have been demonstrated in anaplastic large-cell lymphoma (ALCL) and diffuse large B-cell lymphoma (DLBCL).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18024643.001).
  • [ISSN] 1520-4391
  • [Journal-full-title] Hematology. American Society of Hematology. Education Program
  • [ISO-abbreviation] Hematology Am Soc Hematol Educ Program
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA 21765
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 62
  •  go-up   go-down


22. King JK, Costenbader KH: Characteristics of patients with systemic lupus erythematosus (SLE) and non-Hodgkin's lymphoma (NHL). Clin Rheumatol; 2007 Sep;26(9):1491-4
MedlinePlus Health Information. consumer health - Lupus.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Characteristics of patients with systemic lupus erythematosus (SLE) and non-Hodgkin's lymphoma (NHL).
  • Patients with systemic lupus erythematosus (SLE) are at increased risk of developing non-Hodgkin's lymphoma (NHL), but features of SLE associated with NHL are not well described.
  • The objective of this study was to describe SLE characteristics, laboratory serologies, and medication histories in patients who subsequently develop NHL.
  • We confirmed the diagnoses of SLE and NHL and sought details of medical history and treatment by medical record review.
  • Eleven patients with NHL without coexisting rheumatoid arthritis, Sjögren's, or HIV were identified; seven of these (64%) had a diffuse large B cell lymphoma subtype, and 83% of those stained were Epstein-Barr virus (EBV) negative.
  • The mean duration of SLE at NHL diagnosis was 17.8 years (range 1.6-41.8), and the mean Systemic Lupus International Collaborative Clinics/American College of Rheumatology damage index was 1.9.
  • Diffuse large B cell lymphoma was the most common subtype of NHL, and most were EBV negative.
  • Although disease duration was fairly long and end organ damage moderately severe in this group of patients, renal disease and the use of immunosuppressive chemotherapeutic agents were rare and did not appear to confer an increased risk of NHL development.
  • [MeSH-major] Lupus Erythematosus, Systemic / complications. Lymphoma, Non-Hodgkin / complications
  • [MeSH-minor] Adolescent. Adult. Female. Humans. Immunosuppressive Agents / adverse effects. Kidney Diseases / complications. Kidney Diseases / etiology. Male. Middle Aged. Retrospective Studies. Risk Factors

  • Genetic Alliance. consumer health - Lupus.
  • Genetic Alliance. consumer health - Systemic lupus erythematosus.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Arthritis Rheum. 1997 Sep;40(9):1725 [9324032.001]
  • [Cites] Ann Intern Med. 1990 May 1;112(9):682-98 [2110431.001]
  • [Cites] Rheum Dis Clin North Am. 2005 May;31(2):387-402, viii-ix [15922152.001]
  • [Cites] Q J Med. 1991 Jul;80(291):605-12 [1946940.001]
  • [Cites] Oncogene. 2004 Aug 23;23(38):6524-34 [15322522.001]
  • [Cites] Arthritis Rheum. 1997 Apr;40(4):761-8 [9125261.001]
  • [Cites] Lupus. 2002;11(3):152-60 [12004788.001]
  • [Cites] Ann Rheum Dis. 1992 Apr;51(4):437-9 [1586239.001]
  • [Cites] Rheumatology (Oxford). 2004 Feb;43(2):202-5 [12923289.001]
  • [Cites] Scand J Rheumatol. 2002;31(2):66-71 [12109649.001]
  • [Cites] Rheumatology (Oxford). 2004 Aug;43(8):1039-44 [15161983.001]
  • [Cites] J Natl Cancer Inst. 2006 Jan 4;98(1):51-60 [16391371.001]
  • [Cites] Arthritis Rheum. 2001 Apr;45(2):191-202 [11324784.001]
  • [Cites] Arthritis Rheum. 2003 Jun;48(6):1543-50 [12794821.001]
  • [Cites] Ann Intern Med. 1987 Apr;106(4):524-31 [3103510.001]
  • [Cites] Br J Haematol. 1976 Jan;32(1):41-6 [1259924.001]
  • [Cites] Singapore Med J. 2000 Jun;41(6):279-85 [11109344.001]
  • [Cites] Ann Rheum Dis. 2005 Oct;64(10):1507-9 [16162903.001]
  • [Cites] Br J Rheumatol. 1996 Mar;35(3):248-54 [8620300.001]
  • [Cites] Arch Intern Med. 2005 Nov 14;165(20):2337-44 [16287762.001]
  • [Cites] Q J Med. 1990 Mar;74(275):319-30 [2385739.001]
  • [Cites] Arthritis Rheum. 1982 Nov;25(11):1271-7 [7138600.001]
  • [Cites] Rheumatology (Oxford). 2002 Nov;41(11):1308-12 [12422005.001]
  • [Cites] Lupus. 2001;10(6):394-400 [11434573.001]
  • [Cites] Arthritis Rheum. 2005 May;52(5):1481-90 [15880596.001]
  • [Cites] Arthritis Rheum. 2001 Dec;44(12):2797-806 [11762940.001]
  • [Cites] Blood Rev. 1993 Dec;7(4):199-207 [8130682.001]
  • (PMID = 17297594.001).
  • [ISSN] 0770-3198
  • [Journal-full-title] Clinical rheumatology
  • [ISO-abbreviation] Clin. Rheumatol.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Immunosuppressive Agents
  •  go-up   go-down


23. Choi MK, Jun HJ, Lee SY, Kim KH, Lim DH, Kim K, Ko YH, Kim WS, Kim SJ: Treatment outcome of adult patients with Burkitt lymphoma: results using the LMB protocol in Korea. Ann Hematol; 2009 Nov;88(11):1099-106
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment outcome of adult patients with Burkitt lymphoma: results using the LMB protocol in Korea.
  • Burkitt lymphoma (BL) is a rare subtype of adult non-Hodgkin lymphoma, so studies on the outcome of adult BL, especially in Asian patients, are scarce.
  • We report our results using the LMB protocol on Korean adult BL patients.
  • All of the non-CR patients died, including five PR and one with progressive disease.
  • In conclusion, the LMB protocol was effective for Korean adult BL patients.
  • However, considering the high incidence of treatment-related deaths and the poor outcome of non-CR patients, risk-adapted modification of the induction phase is warranted.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Burkitt Lymphoma / drug therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Cyclophosphamide / administration & dosage. Cyclophosphamide / adverse effects. Cytarabine / administration & dosage. Cytarabine / adverse effects. Disease-Free Survival. Doxorubicin / administration & dosage. Doxorubicin / adverse effects. Drug Evaluation. Etoposide / administration & dosage. Etoposide / adverse effects. Female. Hematologic Diseases / chemically induced. Hematologic Diseases / epidemiology. Humans. Kaplan-Meier Estimate. Korea / epidemiology. Male. Methotrexate / administration & dosage. Methotrexate / adverse effects. Middle Aged. Prednisone / administration & dosage. Prednisone / adverse effects. Prognosis. Proportional Hazards Models. Retrospective Studies. Risk Factors. Sepsis / epidemiology. Sepsis / etiology. Treatment Outcome. Vincristine / administration & dosage. Vincristine / adverse effects. Young Adult

  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19288103.001).
  • [ISSN] 1432-0584
  • [Journal-full-title] Annals of hematology
  • [ISO-abbreviation] Ann. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 04079A1RDZ / Cytarabine; 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


24. Cillessen SA, Meijer CJ, Notoya M, Ossenkoppele GJ, Oudejans JJ: Molecular targeted therapies for diffuse large B-cell lymphoma based on apoptosis profiles. J Pathol; 2010 Apr;220(5):509-20
Genetic Alliance. consumer health - Large B cell diffuse lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Molecular targeted therapies for diffuse large B-cell lymphoma based on apoptosis profiles.
  • Diffuse large B-cell lymphoma (DLBCL) is the most common type of adult non-Hodgkin lymphoma and is treated with chemotherapy in combination with rituximab.
  • In order to survive, lymphoma cells depend on disruption of the apoptosis pathway by mutations in apoptosis inducing genes or by continuous expression of anti-apoptotic proteins.
  • The development of molecules targeting these apoptosis inhibitors provides a very promising opportunity to specifically target tumour cells without toxicity to non-malignant cells in DLBCL patients.
  • [MeSH-major] Apoptosis / physiology. Apoptosis Regulatory Proteins / antagonists & inhibitors. Lymphoma, Large B-Cell, Diffuse / therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20087881.001).
  • [ISSN] 1096-9896
  • [Journal-full-title] The Journal of pathology
  • [ISO-abbreviation] J. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Apoptosis Regulatory Proteins; 0 / Neoplasm Proteins
  • [Number-of-references] 119
  •  go-up   go-down


25. Zvonkov EE, Krasil'nikova BB, Makhinia VA, Kaplanskaia IB, Kravchenko SK, Karagiulian SR, Grzhimolovskiĭ AV, Kuznetsov AN, Magomedova AU, Shukhman IM, Bariakh EA, Giliazitdinova EA, Gubkin AV, Lorie IuIu, Kremenetskaia AM, Vorob'ev AI: [First experience with the modified program NHL-BFM-90 application in adult patients with primary diffuse large B-cell gastric lymphosarcoma with unfavourable prognosis]. Ter Arkh; 2006;78(7):38-46
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [First experience with the modified program NHL-BFM-90 application in adult patients with primary diffuse large B-cell gastric lymphosarcoma with unfavourable prognosis].
  • AIM: To assess efficacy of a modified program NHL-BFM-90 in adult patients with primary diffuse large B-cell gastric lymphosarcoms (PDLBGL) with unfavourable prognosis.
  • MATERIAL AND METHODS: Modified courses of NHL-BFM-90 were conducted in 5 patients aged 27-67 years from January 2004 to September 2005.
  • The program NHL-BFM-90 was modified because of the patients' age.
  • Chemotherapy was conducted according to the middle arm of the original program NHL-BFM-90, but methotrexate was introduced in a dose 1 g/m2 for 12 hours, while leukovorin was given 18 hours after the start of methotrexate injection.
  • A total of 23 modified blocks NHL-BFM-90 were performed: one patient was given 6 blocks, two patients--5, one patient--4 blocks and one patient--3 blocks.
  • RESULTS: Four patients after block 2 and one patient after block 3 of polychemotherapy NHL-BFM-90 achieved remission of the disease of 6 to 22 months duration which still continues.
  • CONCLUSION: Treatment according to the modified program NHL-BFM-90 in adult patients with PDLBGL and unfavourable prognosis is highly effective.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, B-Cell / drug therapy. Lymphoma, Large B-Cell, Diffuse / drug therapy. Stomach Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Disease Progression. Drug Administration Schedule. Endoscopy, Gastrointestinal. Female. Humans. Middle Aged. Prognosis. Remission Induction

  • Genetic Alliance. consumer health - Lymphosarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16944749.001).
  • [ISSN] 0040-3660
  • [Journal-full-title] Terapevticheskiĭ arkhiv
  • [ISO-abbreviation] Ter. Arkh.
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Russia (Federation)
  •  go-up   go-down


26. Wennberg RA, Tator CH: Concussion incidence and time lost from play in the NHL during the past ten years. Can J Neurol Sci; 2008 Nov;35(5):647-51
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Concussion incidence and time lost from play in the NHL during the past ten years.
  • To evaluate the current state of this injury in the National Hockey League (NHL), we analyzed the concussion incidence and time lost from play due to concussions during the past ten NHL seasons.
  • METHODS: Data were obtained from a complete review of injury reports in two different sports media sources covering the NHL seasons 1997-98 through 2007-08.
  • CONCLUSIONS: Possibly related to injury reduction efforts, the number of concussions reported per season in the NHL has trended downward in recent years.
  • [MeSH-minor] Adult. Guidelines as Topic / standards. Humans. Incidence. Regression Analysis. Risk Factors. Safety Management / trends. Sick Leave / statistics & numerical data. Sick Leave / trends. Sports Equipment / adverse effects. Time Factors. Young Adult

  • Genetic Alliance. consumer health - TEN.
  • MedlinePlus Health Information. consumer health - Concussion.
  • MedlinePlus Health Information. consumer health - Sports Injuries.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19235451.001).
  • [ISSN] 0317-1671
  • [Journal-full-title] The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques
  • [ISO-abbreviation] Can J Neurol Sci
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Canada
  •  go-up   go-down


27. Juranić ZD, Besu I, Jelić S, Konić-Ristić A, Matković S, Janković L, Gavrilović D, Radojcić B, Minić I: Some patients with NHL possessed immunoreactivity to gliadin and to cow's milk proteins. Int J Hematol; 2009 Sep;90(2):212-6
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Some patients with NHL possessed immunoreactivity to gliadin and to cow's milk proteins.
  • Non-Hodgkin lymphoma (NHL) represents heterogeneous group of diseases either B, or T cell origin.
  • In order to assess whether food antigens contribute to the imbalance of immune response, the aim of this work was screening the sera of patients with (mostly) B cell NHL, and of people with non-malignant health disorders (NMD), as well as of healthy people for their immunoreactivity to food constituent gliadin, and to cow's milk proteins.
  • Data obtained by ELISA tests show the existence of the enhanced immunoreactivity to food antigens in some NHL patients, as well as in some people with NMD.
  • The high degree of coincidence in the presence of enhanced levels of immune complexes in circulation (CIC) and of immunoreactivity with gliadin in immunofixation (after the serum protein electrophoresis in agarose gel in veronal buffer, at pH 8.6) especially in NHL patients points that some antigliadin immunoreactivity unrevealed in ELISA tests could be hidden in CIC.
  • This, only in the presence of malignant genotype, as well as the enhanced levels of CIC in some of NHL patients could both, at least partially contribute to the persistent non-specific support of disease.
  • [MeSH-major] Food Hypersensitivity / immunology. Gliadin / immunology. Lymphoma, Non-Hodgkin / immunology. Milk Proteins / immunology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Animals. Antigen-Antibody Complex / blood. Cattle. Female. Humans. Immunoglobulin A / blood. Immunoglobulin G / blood. Male. Middle Aged. Seroepidemiologic Studies. Young Adult

  • MedlinePlus Health Information. consumer health - Food Allergy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Mol Immunol. 1979 Jul;16(7):489-93 [40871.001]
  • [Cites] J BUON. 2006 Oct-Dec;11(4):485-9 [17309182.001]
  • [Cites] Eur J Cancer Prev. 2000 Feb;9(1):59-64 [10777011.001]
  • [Cites] Br J Cancer. 2007 May 7;96(9):1324-8 [17406363.001]
  • [Cites] Oncogene. 2004 Aug 23;23(38):6524-34 [15322522.001]
  • [Cites] Cutis. 2005 Sep;76(3):186-8 [16268262.001]
  • [Cites] Haematologia (Budap). 1999;29(4):301-4 [10438070.001]
  • [Cites] Rev Rhum Engl Ed. 1997 May;64(5):287-92 [9190001.001]
  • [Cites] Semin Oncol. 1986 Sep;13(3):350-65 [3094150.001]
  • [Cites] J Clin Gastroenterol. 2004 Apr;38(4):360-3 [15087696.001]
  • [Cites] J Clin Microbiol. 2001 Sep;39(9):3213-21 [11526153.001]
  • [Cites] Br J Dermatol. 1996 Sep;135(3):363-7 [8949426.001]
  • [Cites] Dig Liver Dis. 2006 Jun;38(6):374-80 [16627018.001]
  • [Cites] J Natl Cancer Inst. 2006 Jan 4;98(1):51-60 [16391371.001]
  • [Cites] Acta Clin Belg. 2004 May-Jun;59(3):143-51 [15462511.001]
  • [Cites] Hematology. 2006 Feb;11(1):15-23 [16522544.001]
  • [Cites] Nutr Rev. 2002 Apr;60(4):116-8 [12002682.001]
  • [Cites] Gut. 1989 Mar;30(3):333-8 [2707633.001]
  • [Cites] J Pathol. 2006 Jul;209(3):344-51 [16583361.001]
  • [Cites] JAMA. 2000 Aug 9;284(6):695-6 [10927775.001]
  • [Cites] Haematologica. 2000 Feb;85(2):147-53 [10681721.001]
  • [Cites] Int J Hematol. 2006 Jan;83(1):63-5 [16443555.001]
  • [Cites] Gut. 2005 Jan;54(1):54-9 [15591504.001]
  • [Cites] Lancet. 2003 Jun 21;361(9375):2152-4 [12826451.001]
  • [Cites] J Egypt Natl Canc Inst. 2004 Jun;16(2):114-22 [15912152.001]
  • [Cites] Leuk Res. 2006 Dec;30(12):1585-6 [16516966.001]
  • [Cites] Hepatology. 2000 Jan;31(1):182-9 [10613744.001]
  • [Cites] BMC Gastroenterol. 2007 Mar 09;7:8 [17349035.001]
  • [Cites] J Clin Gastroenterol. 2007 Jul;41(6):548-58 [17577110.001]
  • [Cites] Cancer Immunol Immunother. 1985;20(1):80-4 [3877562.001]
  • (PMID = 19609644.001).
  • [ISSN] 1865-3774
  • [Journal-full-title] International journal of hematology
  • [ISO-abbreviation] Int. J. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antigen-Antibody Complex; 0 / Immunoglobulin A; 0 / Immunoglobulin G; 0 / Milk Proteins; 9007-90-3 / Gliadin
  •  go-up   go-down


28. Smith SK, Zimmerman S, Williams CS, Preisser JS, Clipp EC: Post-traumatic stress outcomes in non-Hodgkin's lymphoma survivors. J Clin Oncol; 2008 Feb 20;26(6):934-41
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Post-traumatic stress outcomes in non-Hodgkin's lymphoma survivors.
  • Therefore, this study aims to estimate the prevalence of post-traumatic stress disorder (PTSD) symptoms in survivors of adult non-Hodgkin's lymphoma (NHL) who are at least 2 years postdiagnosis and identify the risk factors associated with PTSD symptoms, with a focus on those that are amenable for screening and modifiable.
  • PATIENTS AND METHODS: A total of 886 NHL survivors identified from the cancer registries of two hospitals in North Carolina participated, ranging in age from 25 to 92 years old and ranging from 2 to 44 years postdiagnosis.

  • MedlinePlus Health Information. consumer health - Post-Traumatic Stress Disorder.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Fam Psychol. 2004 Sep;18(3):493-504 [15382974.001]
  • [Cites] Cancer. 2003 Aug 15;98(4):679-89 [12910510.001]
  • [Cites] Cancer. 1992 Oct 15;70(8):2214-24 [1394054.001]
  • [Cites] J Consult Clin Psychol. 1995 Dec;63(6):981-6 [8543720.001]
  • [Cites] Psychosomatics. 1996 May-Jun;37(3):254-61 [8849502.001]
  • [Cites] Behav Res Ther. 1996 Aug;34(8):669-73 [8870294.001]
  • [Cites] Annu Rev Psychol. 1997;48:449-80 [9046566.001]
  • [Cites] J Trauma Stress. 1998 Apr;11(2):189-203 [9565911.001]
  • [Cites] Pediatr Blood Cancer. 2007 Aug;49(2):177-82 [16862538.001]
  • [Cites] Psychooncology. 2007 Oct;16(10):895-903 [17245695.001]
  • [Cites] Psychosomatics. 2001 Mar-Apr;42(2):133-40 [11239126.001]
  • [Cites] J Natl Cancer Inst. 2002 Jan 2;94(1):39-49 [11773281.001]
  • [Cites] Psychooncology. 2002 Nov-Dec;11(6):479-94 [12476430.001]
  • [Cites] Arthritis Rheum. 2003 Apr 15;49(2):156-63 [12687505.001]
  • [Cites] Soc Sci Med. 1991;32(6):705-14 [2035047.001]
  • (PMID = 18281667.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA101492-01A2; United States / NCI NIH HHS / CA / R03 CA101492; United States / NCI NIH HHS / CA / R03 CA101492-01A2; United States / NCI NIH HHS / CA / R03-CA-101492
  • [Publication-type] Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS261515; NLM/ PMC3025533
  •  go-up   go-down


29. Dembowska-Baginska B, Perek D, Brozyna A, Wakulinska A, Olczak-Kowalczyk D, Gladkowska-Dura M, Grajkowska W, Chrzanowska KH: Non-Hodgkin lymphoma (NHL) in children with Nijmegen Breakage syndrome (NBS). Pediatr Blood Cancer; 2009 Feb;52(2):186-90
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Non-Hodgkin lymphoma (NHL) in children with Nijmegen Breakage syndrome (NBS).
  • BACKGROUND: Due to small number of patients with Nijmegen Breakage Syndrome (NBS) and Non-Hodgkin lymphoma (NHL) experience in their treatment is limited.
  • PROCEDURE: Since 1996, 17 patients with a median age of 9.5 years who had NBS, were treated for NHL.
  • NHL type, stage, chemotherapy, dose modifications, chemotherapy delays, response to chemotherapy, toxicity, outcome and correlation of drug reduction with response to treatment and outcome were analyzed.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Lymphoma, Non-Hodgkin / drug therapy. Nijmegen Breakage Syndrome / complications
  • [MeSH-minor] Adolescent. Child. Child, Preschool. Dose-Response Relationship, Drug. Female. Humans. Male. Remission Induction. Retrospective Studies. Treatment Outcome. Young Adult


30. Morris E, Mackinnon S: Outcome following alemtuzumab (CAMPATH-1H)-containing reduced intensity allogeneic transplant regimen for relapsed and refractory non-Hodgkin's lymphoma (NHL). Transfus Apher Sci; 2005 Feb;32(1):73-83
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcome following alemtuzumab (CAMPATH-1H)-containing reduced intensity allogeneic transplant regimen for relapsed and refractory non-Hodgkin's lymphoma (NHL).
  • We report the outcome following RIT for NHL in 88 patients (LG-NHL n = 41, HG-NHL n = 37, MCL n = 10).
  • With a median follow-up of 36 months (range 18-60), the actuarial overall survival (OS) at 3 years was 34% for HG-NHL, 60% for MCL and 73% for LG-NHL (p < or = 0.001).
  • The 100-day and 3-year TRM for patients with LG-NHL were 2% and 11%, respectively, and were better (p = 0.01) than for patients with HG-NHL (27% and 38%, respectively).
  • The actuarial current progression free survival (PFS) at 3 years, including those who achieved remission following DLI for progression, was 65% for LG-NHL 50% for MCL and 34% for HG-NHL (p = 0.002).
  • Patients with relapsed LG-NHL and CLL achieve excellent PFS with extremely low TRM and GVHD, even when matched family donors are unavailable.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antibodies, Neoplasm / therapeutic use. Lymphoma, Non-Hodgkin / drug therapy. Lymphoma, Non-Hodgkin / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Antibodies, Monoclonal, Humanized. Disease-Free Survival. Drug Resistance, Neoplasm. Female. Graft vs Host Disease. Humans. Male. Middle Aged. Recurrence. Time Factors. Transplantation Chimera. Transplantation Conditioning. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15737876.001).
  • [ISSN] 1473-0502
  • [Journal-full-title] Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis
  • [ISO-abbreviation] Transfus. Apher. Sci.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antibodies, Neoplasm; 3A189DH42V / alemtuzumab
  •  go-up   go-down


31. Handa U, Mohan H, Punia RS, Nada R: FNAC in a case of NHL presenting initially as nodal infarction. Indian J Pathol Microbiol; 2005 Oct;48(4):510-2

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] FNAC in a case of NHL presenting initially as nodal infarction.
  • Fine needle aspiration cytology (FNAC) of infarction preceding lymphoma has not been described earlier.
  • A cytologic diagnosis of infarction in a case of non-Hodgkin's lymphoma (NHL) was made and subsequently confirmed by histopathologic examination.
  • Our case indicates that such cases should be followed up closely and repeated aspirations should be done to prevent a delayed diagnosis of lymphoma.
  • [MeSH-major] Lymphoma, Non-Hodgkin / pathology
  • [MeSH-minor] Adult. Biopsy, Fine-Needle. Diagnosis, Differential. Humans. Infarction / diagnosis. Infarction / pathology. Lymph Nodes / blood supply. Lymph Nodes / pathology. Male

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16366114.001).
  • [ISSN] 0377-4929
  • [Journal-full-title] Indian journal of pathology & microbiology
  • [ISO-abbreviation] Indian J Pathol Microbiol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] India
  •  go-up   go-down


32. Magomedova AU, Kravchenko SK, Kremenetskaia AM, Zvonkov EE, Bariakh EA, Margolin OV, Kaplanskaia IB, Vorob'ev IA, Samoĭlova RS, Obukhova TN, Moiseeva TN, Zybunova EE, Gemdzhian EG, Vorob'ev AI: [The modified program NHL-BFM-90 in the treatment of patients with diffuse large B-cell lymphosarcoma]. Ter Arkh; 2006;78(10):44-7
Genetic Alliance. consumer health - Lymphosarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [The modified program NHL-BFM-90 in the treatment of patients with diffuse large B-cell lymphosarcoma].
  • AIM: To investigate efficacy of the modified protocol NHL-BFM-90 in patients with diffuse large B-cell lymphosarcoma (DLBCLS).
  • MATERIAL AND METHODS: A total of 13 DLBCLS patients with stage II-IV of the disease with affection of lymph nodes at the disease onset (nodal lesion) and stage II with tumor size more than 10 cm (bulky disease) received first-line treatment according to the modified program NHL-BFM-90 from 2002 to 2005.
  • CONCLUSION: The efficacy of the modified protocol NHL-BFM-90 in DLBCLS patients with stage III-IV of the "nodal" disease and stage II of the "bulky" disease was high.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, B-Cell / complications. Lymphoma, B-Cell / drug therapy. Lymphoma, Large B-Cell, Diffuse / complications. Lymphoma, Large B-Cell, Diffuse / drug therapy
  • [MeSH-minor] Adult. Dose-Response Relationship, Drug. Female. Humans. Male. Middle Aged. Survival Rate

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17180937.001).
  • [ISSN] 0040-3660
  • [Journal-full-title] Terapevticheskiĭ arkhiv
  • [ISO-abbreviation] Ter. Arkh.
  • [Language] rus
  • [Publication-type] Clinical Trial; English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  •  go-up   go-down


33. Smith SK, Zimmerman S, Williams CS, Zebrack BJ: Health status and quality of life among non-Hodgkin lymphoma survivors. Cancer; 2009 Jul 15;115(14):3312-23
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Health status and quality of life among non-Hodgkin lymphoma survivors.
  • BACKGROUND: : A growing body of evidence suggests that long-term survivors with 1 of the more common forms of adult cancer report a quality of life (QOL) similar to that in the general population.
  • Also, less is known concerning survivors of adult non-Hodgkin lymphoma (NHL), a disease often marked by alternating periods of disease and remission.
  • Therefore, in the current study, the authors compared the QOL status of individuals who reported having active NHL with the QOL status of individuals who were disease-free short-term survivors (STS) (2-4 years postdiagnosis) and long-term survivors (LTS) (> or =5 years postdiagnosis).
  • METHODS: Eligible survivors completed a mailed survey with validated measures, including physical and mental health status measured with the Medical Outcomes Study 36-item Short Form, cancer-related QOL, the Functional Assessment of Cancer Therapy-Lymphoma module, and self-reported impact of cancer.
  • CONCLUSIONS: Although survivors with NHL who had active disease reported more negative outcomes compared with off-treatment survivors, the length of time after diagnosis did not appear to matter with regard to outcomes for STS or LTS.

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gynecol Oncol. 2001 Dec;83(3):537-42 [11733968.001]
  • [Cites] J Clin Oncol. 2002 Jul 1;20(13):2920-9 [12089220.001]
  • [Cites] J Anxiety Disord. 2002;16(2):195-206 [12194544.001]
  • [Cites] Arthritis Rheum. 2003 Apr 15;49(2):156-63 [12687505.001]
  • [Cites] Oncologist. 2003;8(4):342-9 [12897331.001]
  • [Cites] Cancer. 2003 Aug 15;98(4):679-89 [12910510.001]
  • [Cites] Soc Sci Med. 1991;32(6):705-14 [2035047.001]
  • [Cites] Med Care. 1992 Jun;30(6):473-83 [1593914.001]
  • [Cites] Cancer. 1992 Oct 15;70(8):2214-24 [1394054.001]
  • [Cites] J Clin Oncol. 1993 Mar;11(3):570-9 [8445433.001]
  • [Cites] Oncol Nurs Forum. 1995 Jul;22(6):915-22 [7567610.001]
  • [Cites] J Consult Clin Psychol. 1995 Dec;63(6):981-6 [8543720.001]
  • [Cites] Psychosomatics. 1996 May-Jun;37(3):254-61 [8849502.001]
  • [Cites] Psychooncology. 2005 Apr;14(4):307-17 [15386765.001]
  • [Cites] J Clin Oncol. 2005 Jul 1;23(19):4399-405 [15994149.001]
  • [Cites] Psychooncology. 2006 May;15(5):407-21 [16097041.001]
  • [Cites] Cancer. 2006 Jun 1;106(11):2355-62 [16649218.001]
  • [Cites] Psychooncology. 2006 Sep;15(9):749-58 [16304622.001]
  • [Cites] Cancer. 2006 Nov 1;107(9):2186-96 [17013914.001]
  • [Cites] J Clin Oncol. 2008 Feb 20;26(6):934-41 [18281667.001]
  • [Cites] Psychooncology. 2008 Sep;17(9):891-900 [18050153.001]
  • [Cites] Psychooncology. 2008 Sep;17(9):948-53 [18213677.001]
  • [Cites] J Natl Cancer Inst. 2002 Jan 2;94(1):39-49 [11773281.001]
  • (PMID = 19452546.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R03 CA101492; United States / NCI NIH HHS / CA / R03 CA101492-02; United States / NCI NIH HHS / CA / R03-CA-101492
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS124430; NLM/ PMC2718726
  •  go-up   go-down


34. Steffens M, Beauloye V, Brichard B, Robert A, Alexopoulou O, Vermylen Ch, Maiter D: Endocrine and metabolic disorders in young adult survivors of childhood acute lymphoblastic leukaemia (ALL) or non-Hodgkin lymphoma (NHL). Clin Endocrinol (Oxf); 2008 Nov;69(5):819-27
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endocrine and metabolic disorders in young adult survivors of childhood acute lymphoblastic leukaemia (ALL) or non-Hodgkin lymphoma (NHL).
  • BACKGROUND: Treatments of acute lymphoblastic leukaemia (ALL) and non-Hodgkin lymphoma (NHL), involving various combinations of chemotherapy (chemo), cranial irradiation (CI) and/or bone marrow transplantation after total body irradiation (BMT/TBI), are often successful but may have several long-term harmful effects.
  • OBJECTIVE: To evaluate late endocrine and metabolic complications in adult survivors of childhood ALL and NHL, in relation with the different therapeutic schemes received.
  • DESIGN: Endocrine and metabolic parameters were determined in 94 patients (48 men, mean age: 24 +/- 5 years) with a former childhood ALL (n = 78) or NHL (n = 16) and subgrouped according to their previous treatment: chemo only (group I; n = 44), chemo + CI (group II; n = 32) and chemo + BMT/TBI (group III; n = 18).
  • CONCLUSIONS: This study reveals a high prevalence of endocrine and metabolic disorders in young adult survivors of childhood ALL or NHL, this frequency mainly depending on the treatment received.
  • [MeSH-major] Endocrine System Diseases / epidemiology. Lymphoma, Non-Hodgkin / epidemiology. Metabolic Diseases / epidemiology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / epidemiology. Survivors / statistics & numerical data
  • [MeSH-minor] Adolescent. Adult. Age of Onset. Female. Gonads / physiology. Human Growth Hormone / blood. Human Growth Hormone / metabolism. Humans. Insulin-Like Growth Factor I / metabolism. Male. Prevalence. Signal Transduction / physiology. Thyroid Gland / physiology. Young Adult


35. Epeldegui M, Breen EC, Hung YP, Boscardin WJ, Detels R, Martínez-Maza O: Elevated expression of activation induced cytidine deaminase in peripheral blood mononuclear cells precedes AIDS-NHL diagnosis. AIDS; 2007 Nov 12;21(17):2265-70
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Elevated expression of activation induced cytidine deaminase in peripheral blood mononuclear cells precedes AIDS-NHL diagnosis.
  • Non-Hodgkin's B cell lymphoma (NHL) is a common cancer in HIV infection.
  • Many NHL are thought to result from errors in class switch recombination and/or somatic hypermutation, processes that occur in germinal center B cells, and require the activity of activation induced cytidine deaminase (AID).
  • Since NHL is a common cancer in HIV infection, and expression of AID could contribute to the development of NHL, we hypothesized that AID expression would be elevated in those who went on to develop AIDS-associated NHL (AIDS-NHL).
  • AID mRNA levels were measured by TaqMan RT-PCR in peripheral blood mononuclear cells, obtained prior to AIDS-NHL diagnosis, from 16 HIV-infected subjects who developed AIDS-NHL, and from control subjects (AIDS but no NHL, and HIV-negative subjects).
  • PBMC AID expression was markedly elevated in those who developed AIDS-NHL, when compared to AIDS and HIV-negative controls.
  • Additionally, AID expression was seen to differ depending on NHL subtype, with the highest levels of expression seen in those who developed Burkitt's lymphoma.
  • [MeSH-major] B-Lymphocytes / enzymology. Cytidine Deaminase / genetics. Gene Expression Regulation, Viral. Lymphoma, AIDS-Related / enzymology. Lymphoma, B-Cell / enzymology
  • [MeSH-minor] Adult. California. Case-Control Studies. Cell Transformation, Viral. Cohort Studies. Enzyme Induction. Humans. Lymphocyte Activation. Male. RNA, Viral / blood. Reverse Transcriptase Polymerase Chain Reaction. Statistics, Nonparametric

  • Genetic Alliance. consumer health - AIDS-HIV.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18090274.001).
  • [ISSN] 0269-9370
  • [Journal-full-title] AIDS (London, England)
  • [ISO-abbreviation] AIDS
  • [Language] eng
  • [Grant] United States / NIAID NIH HHS / AI / AI28697; United States / NCI NIH HHS / CA / CA57152; United States / NCI NIH HHS / CA / CA73475; United States / NCI NIH HHS / CA / CA96888
  • [Publication-type] Journal Article; Multicenter Study; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Chemical-registry-number] 0 / RNA, Viral; EC 3.5.4.5 / Cytidine Deaminase
  •  go-up   go-down


36. Paz S, Linn S, Portnov BA, Lazimi A, Futerman B, Barchana M: Non-Hodgkin Lymphoma (NHL) linkage with residence near heavy roads--a case study from Haifa Bay, Israel. Health Place; 2009 Jun;15(2):636-41
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Non-Hodgkin Lymphoma (NHL) linkage with residence near heavy roads--a case study from Haifa Bay, Israel.
  • The linkage between NHL morbidity and residence near heavy roads is analyzed among the Jewish population of the Haifa Metropolis, Israel.
  • The geographic distribution of NHL patients was adjusted by the overall density of population in the study area.
  • The much higher occurrence of NHL in areas near main roads may be indicative of disease risks.
  • [MeSH-major] Lymphoma, Non-Hodgkin / epidemiology. Residence Characteristics. Vehicle Emissions / analysis
  • [MeSH-minor] Adult. Aged. Environmental Exposure / adverse effects. Female. Humans. Israel / epidemiology. Male. Middle Aged. Urban Health

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19081284.001).
  • [ISSN] 1353-8292
  • [Journal-full-title] Health & place
  • [ISO-abbreviation] Health Place
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Vehicle Emissions
  •  go-up   go-down


37. Montella M, Maso LD, Crispo A, Talamini R, Bidoli E, Grimaldi M, Giudice A, Pinto A, Franceschi S: Do childhood diseases affect NHL and HL risk? A case-control study from northern and southern Italy. Leuk Res; 2006 Aug;30(8):917-22
MedlinePlus Health Information. consumer health - Hodgkin Disease.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Do childhood diseases affect NHL and HL risk? A case-control study from northern and southern Italy.
  • To investigate the association between non-Hodgkin lymphoma (NHL), Hodgkin lymphoma (HL), and exposure to childhood diseases, we analyzed an Italian case-control study that included 225 histologically-confirmed incident cases of NHL, 62 HL cases, and 504 controls.
  • Measles was negatively associated with NHL, particularly follicular B-cell NHL.
  • In addition, our study shows that measles may provide a protective effect against NHL.
  • [MeSH-major] Bacterial Infections / epidemiology. Chickenpox / epidemiology. Hodgkin Disease / epidemiology. Lymphoma, Non-Hodgkin / epidemiology. Paramyxoviridae Infections / epidemiology
  • [MeSH-minor] Adolescent. Adult. Aged. Case-Control Studies. Causality. Female. Humans. Italy / epidemiology. Male. Middle Aged. Risk Factors

  • MedlinePlus Health Information. consumer health - Bacterial Infections.
  • MedlinePlus Health Information. consumer health - Chickenpox.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16406019.001).
  • [ISSN] 0145-2126
  • [Journal-full-title] Leukemia research
  • [ISO-abbreviation] Leuk. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


38. Krishnan A, Palmer JM, Zaia JA, Tsai NC, Alvarnas J, Forman SJ: HIV status does not affect the outcome of autologous stem cell transplantation (ASCT) for non-Hodgkin lymphoma (NHL). Biol Blood Marrow Transplant; 2010 Sep;16(9):1302-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] HIV status does not affect the outcome of autologous stem cell transplantation (ASCT) for non-Hodgkin lymphoma (NHL).
  • Randomized trials comparing autologous stem cell transplant (ASCT) to conventional chemotherapy have demonstrated superior survival among HIV-negative ASCT patients with relapsed non-Hodgkin lymphoma (NHL).
  • Although these studies have shown that ASCT in HIV-positive NHL patients (HIVpos-NHL) is well tolerated, the impact of HIV infection on long-term transplant outcome is not well characterized.
  • Ongoing comparison of long-term survival following ASCT in HIVpos-NHL patients and HIVneg-NHL patients will allow investigators to explore whether there should be inclusion of HIVpos-NHL patients in ASCT trials.
  • To study long-term outcome we conducted a single-institution matched case-controlled study in HIVpos-NHL patients (cases) and HIVneg-NHL patients (controls).
  • Twenty-nine patients with HIVpos-NHL were matched with HIVneg-NHL controls on sex, time to ASCT, year of transplant, histology, age, disease status, number prior regimens, and conditioning regimen.
  • Nonrelapse mortality (NRM) was similar: 11% (95% confidence interval [CI]: 4%-28%) in HIVpos-NHL patients and 4% (95% CI: 1%-25%) in HIVneg-NHL controls (P = .18).
  • Two-year disease-free survival (DFS) for the HIVpos-NHL patients was 76% (95% CI: 62%-85%) and 56% (95% CI: 45%-66%) for the HIVneg-NHL controls (P = .33).
  • Overall survival was also similar; the 2-year point estimates were 75% (95% CI: 61%-85%) and 75% (95% CI: 60%-85%), respectively (P = .93), despite inclusion of more poor risk HIVpos-NHL patients.
  • These results provide further evidence that HIV status does not affect the long-term outcome of ASCT for NHL, and therefore HIV status alone should no longer exclude these patients from transplant clinical trials.

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Transplantation.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - HIV/AIDS in Women.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2010 American Society for Blood and Marrow Transplantation. Published by Elsevier Inc. All rights reserved.
  • [Cites] J Clin Oncol. 2008 Mar 1;26(7):1027-32 [18309938.001]
  • [Cites] Biol Blood Marrow Transplant. 2008 Jan;14(1):59-66 [18158962.001]
  • [Cites] Blood. 2009 Jun 4;113(23):6011-4 [19307667.001]
  • [Cites] Blood. 2009 Aug 13;114(7):1306-13 [19451551.001]
  • [Cites] J Clin Oncol. 1999 Apr;17(4):1244 [10561185.001]
  • [Cites] N Engl J Med. 2002 Jan 24;346(4):235-42 [11807147.001]
  • [Cites] N Engl J Med. 2002 Jul 25;347(4):284-7 [12140307.001]
  • [Cites] Cancer. 2004 Jul 15;101(2):317-24 [15241829.001]
  • [Cites] Cancer. 1991 Dec 1;68(11):2466-72 [1933784.001]
  • [Cites] Blood. 1992 Jul 1;80(1):8-20 [1319239.001]
  • [Cites] N Engl J Med. 1995 Dec 7;333(23):1540-5 [7477169.001]
  • [Cites] Bone Marrow Transplant. 1996 Dec;18(6):1195-7 [8971396.001]
  • [Cites] N Engl J Med. 1997 Jun 5;336(23):1641-8 [9171066.001]
  • [Cites] N Engl J Med. 1998 Mar 26;338(13):853-60 [9516219.001]
  • [Cites] Blood. 2005 Jan 15;105(2):874-8 [15388574.001]
  • [Cites] Transplantation. 2006 Jun 27;81(12):1658-61 [16794531.001]
  • [Cites] J Clin Oncol. 2006 Sep 1;24(25):4123-8 [16896005.001]
  • [Cites] J Clin Oncol. 2009 May 1;27(13):2192-8 [19332732.001]
  • (PMID = 20353830.001).
  • [ISSN] 1523-6536
  • [Journal-full-title] Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
  • [ISO-abbreviation] Biol. Blood Marrow Transplant.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P30CA033572; United States / NCI NIH HHS / CA / P01 CA030206-260020; United States / NCI NIH HHS / CA / CA030206-250020; United States / NCI NIH HHS / CA / CA030206-260020; United States / NCI NIH HHS / CA / CA107399-04; United States / NCI NIH HHS / CA / P50 CA107399-04; United States / NCI NIH HHS / CA / P30 CA033572; United States / NCI NIH HHS / CA / P01 CA030206-250020; United States / NCI NIH HHS / CA / P01 CA030206; United States / NCI NIH HHS / CA / P50 CA107399
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS192932; NLM/ PMC2916976
  •  go-up   go-down


39. Kato I, Koenig KL, Watanabe-Meserve H, Baptiste MS, Lillquist PP, Frizzera G, Burke JS, Moseson M, Shore RE: Personal and occupational exposure to organic solvents and risk of non-Hodgkin's lymphoma (NHL) in women (United States). Cancer Causes Control; 2005 Dec;16(10):1215-24
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Personal and occupational exposure to organic solvents and risk of non-Hodgkin's lymphoma (NHL) in women (United States).
  • OBJECTIVES: The authors assessed whether home and occupational exposure to organic solvents is associated with risk of NHL in women.
  • METHODS: A population-based, incidence case-control study was conducted in upstate New York, involving 376 NHL cases and 463 population controls selected from the Medicare beneficiary files and State driver's license records.
  • Odds ratios (OR) and 95% confidence intervals (CI) were estimated using an unconditional logistic regression model, adjusting for a number of risk factors for NHL.
  • RESULTS: Overall, history of exposure to organic solvents was not associated with the risk of NHL.
  • When occupational and home exposures to paint thinners/turpentine were combined and analyzed together, the risk of NHL associated with any exposure, compared to no exposure at either job or home, was a statistically significantly increased (OR=1.46, 95% CI: 1.05-2.03).
  • This observation was more pronounced for B-cell lymphoma and for low-grade lymphoma with ORs of 1.52 (95 CI: 1.08-2.14) and 2.20 (95% CI; 1.42-3.41), respectively.
  • CONCLUSIONS: The results of this case-control study do support of a major role of organic solvents in the development of NHL among women currently living in the US.
  • [MeSH-major] Environmental Exposure / adverse effects. Lymphoma, Non-Hodgkin / epidemiology. Occupational Diseases / epidemiology. Occupational Exposure / adverse effects. Solvents / adverse effects
  • [MeSH-minor] Adult. Aged. Case-Control Studies. Female. Humans. Middle Aged. New York / epidemiology. Risk Factors. Turpentine / adverse effects

  • MedlinePlus Health Information. consumer health - Occupational Health.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. TURPENTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16215872.001).
  • [ISSN] 0957-5243
  • [Journal-full-title] Cancer causes & control : CCC
  • [ISO-abbreviation] Cancer Causes Control
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / 5P30CA16087; United States / NCI NIH HHS / CA / CA 63550; United States / NIEHS NIH HHS / ES / ES00260
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Solvents; 8006-64-2 / Turpentine
  •  go-up   go-down


40. Wang W, Gao L, Wang LL, Li MY, Li YY, Zhao W, Xu YY, Ding Y, Yu L: [Detection of bone marrow involvement by lymphoma cells in patients with B-NHL by using flow cytometry analysis]. Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2010 Oct;18(5):1204-7

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Detection of bone marrow involvement by lymphoma cells in patients with B-NHL by using flow cytometry analysis].
  • This study was purposed to investigate the significance of using (FCM) flow cytometry for detection bone marrow involvement by lymphoma cells in untreated patients with B cell non-Hodgkin's lymphoma (B-NHL).
  • Bone marrow samples of 54 patients with B-NHL were analyzed by flow cytometry, morphological method and molecular biology technique.
  • Even in patients with early stage, lymphoma cells still could be detected by FCM in involved bone marrow.
  • It is concluded that the detection of monoclonal B lymphocytes by using FCM has high sensitivity and accuracy in patients with B-NHL.
  • Evaluation whether the bone marrow has been involved by lymphoma cells should be recommend to every patient with B-NHL before chemotherapy and every disease stages.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21129261.001).
  • [ISSN] 1009-2137
  • [Journal-full-title] Zhongguo shi yan xue ye xue za zhi
  • [ISO-abbreviation] Zhongguo Shi Yan Xue Ye Xue Za Zhi
  • [Language] CHI
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


41. Ruben I, Dighe S, Ajit D, Gujral S, Jambhekar NA, Rekhi B: Pulmonary non-Hodgkin's lymphoma (NHL) of diffuse large B-cell type with simultaneous humeral involvement in a young lady: an uncommon presentation with cytologic implications. Diagn Cytopathol; 2010 Mar;38(3):217-20
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pulmonary non-Hodgkin's lymphoma (NHL) of diffuse large B-cell type with simultaneous humeral involvement in a young lady: an uncommon presentation with cytologic implications.
  • We report an unusual case of a pulmonary non-Hodgkin's lymphoma (NHL) with simultaneous involvement of the right humerus in a 37 year old lady.
  • Diagnosis of a pulmonary NHL of diffuse large B-cell type with involvement of the humerus was formed.
  • The case is presented to create an index of suspicion for the possibility of a NHL on respiratory samples, while dealing with small round cells with irregular nuclear membranes.
  • [MeSH-major] Bone Neoplasms / pathology. Humerus / pathology. Lung Neoplasms / pathology. Lymphoma, Large B-Cell, Diffuse / pathology
  • [MeSH-minor] Adult. Antineoplastic Agents / therapeutic use. Apoptosis. Biomarkers, Tumor / metabolism. Carcinoma, Small Cell / diagnosis. Diagnosis, Differential. Fatal Outcome. Female. Humans. Immunohistochemistry. Magnetic Resonance Imaging. Tomography, X-Ray Computed


42. Djavanmardi L, Oprean N, Alantar A, Bousetta K, Princ G: Malignant non-Hodgkin's lymphoma (NHL) of the jaws: a review of 16 cases. J Craniomaxillofac Surg; 2008 Oct;36(7):410-4

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant non-Hodgkin's lymphoma (NHL) of the jaws: a review of 16 cases.
  • Non-Hodgkin's lymphoma (NHL) is rarely found in the jaw.
  • The therapy of this rare, diffuse, large cell lymphoma was very variable from one case to another but the majority of the patients were treated with a combination of chemotherapy and radiotherapy.
  • [MeSH-major] Lymphoma, Non-Hodgkin / diagnosis. Mandibular Neoplasms / diagnosis. Maxillary Neoplasms / diagnosis
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Biopsy. Burkitt Lymphoma / diagnosis. Chemotherapy, Adjuvant. Child. Diagnosis, Differential. Female. Humans. Lymphoma, Large B-Cell, Diffuse / diagnosis. Male. Middle Aged. Neoadjuvant Therapy. Radiotherapy, Adjuvant. Time Factors. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18562205.001).
  • [ISSN] 1010-5182
  • [Journal-full-title] Journal of cranio-maxillo-facial surgery : official publication of the European Association for Cranio-Maxillo-Facial Surgery
  • [ISO-abbreviation] J Craniomaxillofac Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Scotland
  •  go-up   go-down


43. Sun XF, Zhen ZJ, Liu DG, Xia Y, Xiang XJ, Chen XQ, Ling JY, Zheng L, Luo WB, Lin H, He YJ, Guan ZZ: [Efficacy of modified B-NHL-BFM-90 protocol on Burkitt's lymphoma in Chinese children and adolescents]. Ai Zheng; 2007 Dec;26(12):1339-43
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Efficacy of modified B-NHL-BFM-90 protocol on Burkitt's lymphoma in Chinese children and adolescents].
  • BACKGROUND & OBJECTIVE: Burkitt's lymphoma is an aggressive non-Hodgkin's lymphoma (NHL) and often involves bone marrow and central nerve system.
  • The efficacy of CHOP regimen on Burkitt's lymphoma is poor.
  • This study was to evaluate the efficacy of modified B-NHL-BFM-90 protocol on Burkitt's lymphoma in children and adolescents, and observe the survival status.
  • 2006, 31 untreated Burkitt's lymphoma patients aged less than 20 were enrolled.
  • They received modified B-NHL-BFM-90 protocol: cytotoxic drugs such as cyclophosphamide, vincristine, ifosfamide, etoposide, adriamycin, HD-methotrexate, vindesin, dexamethasone, cytarabinec/HD-cytarabine and intrathecal injection.
  • CONCLUSIONS: Modified B-NHL-BFM-90 protocol can improve the responses and survival of Burkitt's lymphoma in Chinese children and adolescents, with tolerable toxicity.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Burkitt Lymphoma / drug therapy
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Cyclophosphamide / administration & dosage. Dexamethasone / administration & dosage. Female. Follow-Up Studies. Humans. Ifosfamide / administration & dosage. Infant. L-Lactate Dehydrogenase / blood. Leukopenia / chemically induced. Lymphatic Metastasis. Male. Neoplasm Invasiveness. Neoplasm Staging. Remission Induction. Vincristine / administration & dosage. Young Adult

  • Genetic Alliance. consumer health - Burkitt's Lymphoma.
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18076797.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 7S5I7G3JQL / Dexamethasone; 8N3DW7272P / Cyclophosphamide; EC 1.1.1.27 / L-Lactate Dehydrogenase; UM20QQM95Y / Ifosfamide
  •  go-up   go-down


44. Siegel CA, Marden SM, Persing SM, Larson RJ, Sands BE: Risk of lymphoma associated with combination anti-tumor necrosis factor and immunomodulator therapy for the treatment of Crohn's disease: a meta-analysis. Clin Gastroenterol Hepatol; 2009 Aug;7(8):874-81
PubMed Health. DARE review .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Risk of lymphoma associated with combination anti-tumor necrosis factor and immunomodulator therapy for the treatment of Crohn's disease: a meta-analysis.
  • BACKGROUND & AIMS: Although anti-tumor necrosis factor (TNF) therapy can effectively treat Crohn's disease (CD), there is concern that it might increase the risk of non-Hodgkin's lymphoma (NHL).
  • A meta-analysis was performed to determine the rate of NHL in adult CD patients who have received anti-TNF therapy and to compare this rate with that of a population-based registry and a population of CD patients treated with immunomodulators.
  • Inclusion criteria included randomized controlled trials, cohort studies, or case series reporting on anti-TNF therapy in adult CD patients.
  • Standardized incidence ratios (SIR) were calculated by comparing the pooled rate of NHL with the expected rate of NHL derived from the Surveillance Epidemiology & End Results (SEER) database and a meta-analysis of CD patients treated with immunomodulators.
  • Among anti-TNF treated subjects, 13 cases of NHL were reported (6.1 per 10,000 patient-years).
  • Compared with the expected rate of NHL in the SEER database (1.9 per 10,000 patient-years), anti-TNF treated subjects had a significantly elevated risk (SIR, 3.23; 95% confidence interval, 1.5-6.9).
  • When compared with the NHL rate in CD patients treated with immunomodulators alone (4 per 10,000 patient-years), the SIR was 1.7 (95% confidence interval, 0.5-7.1).
  • CONCLUSIONS: The use of anti-TNF agents with immunomodulators is associated with an increased risk of NHL in adult CD patients, but the absolute rate of these events remains low and should be weighed against the substantial benefits associated with treatment.

  • Genetic Alliance. consumer health - Crohn Disease.
  • MedlinePlus Health Information. consumer health - Crohn's Disease.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Aliment Pharmacol Ther. 2004 Feb 1;19(3):295-301 [14984376.001]
  • [Cites] Risk Anal. 2009 Jan;29(1):121-36 [18826414.001]
  • [Cites] Gut. 2004 Jun;53(6):849-53 [15138212.001]
  • [Cites] Inflamm Bowel Dis. 2004 Mar;10(2):91-6 [15168807.001]
  • [Cites] Digestion. 2004;70(1):3-9 [15297773.001]
  • [Cites] N Engl J Med. 2004 Feb 26;350(9):876-85 [14985485.001]
  • [Cites] Am J Gastroenterol. 2000 Sep;95(9):2308-12 [11007233.001]
  • [Cites] Cancer. 2001 Feb 15;91(4):854-62 [11241255.001]
  • [Cites] Inflamm Bowel Dis. 2001 May;7 Suppl 1:S17-22 [11380038.001]
  • [Cites] Gastroenterology. 2001 Nov;121(5):1080-7 [11677199.001]
  • [Cites] Lancet. 2002 May 4;359(9317):1541-9 [12047962.001]
  • [Cites] Am J Gastroenterol. 2003 Mar;98(3):608-12 [12650795.001]
  • [Cites] Gastroenterology. 2004 Jan;126(1):19-31 [14699483.001]
  • [Cites] Gastroenterology. 2004 Feb;126(2):402-13 [14762776.001]
  • [Cites] Rev Esp Enferm Dig. 2004 Aug;96(8):548-54; 554-8 [15449986.001]
  • [Cites] Clin Gastroenterol Hepatol. 2004 Oct;2(10):912-20 [15476155.001]
  • [Cites] Inflamm Bowel Dis. 1999 May;5(2):119-33 [10338381.001]
  • [Cites] Gastroenterology. 1999 Oct;117(4):761-9 [10500056.001]
  • [Cites] Colorectal Dis. 2005 Mar;7(2):164-8 [15720356.001]
  • [Cites] Gastroenterology. 2005 Apr;128(4):862-9 [15825070.001]
  • [Cites] Gut. 2005 Aug;54(8):1121-5 [16009685.001]
  • [Cites] Korean J Gastroenterol. 2005 Jul;46(1):48-55 [16030404.001]
  • [Cites] Eur J Gastroenterol Hepatol. 2006 Jan;18(1):11-6 [16357613.001]
  • [Cites] Gut. 2006 Feb;55(2):228-33 [16120759.001]
  • [Cites] Gastroenterology. 2006 Apr;130(4):1054-61 [16618399.001]
  • [Cites] Dis Colon Rectum. 2006 Dec;49(12):1837-41 [17041753.001]
  • [Cites] Aliment Pharmacol Ther. 2007 Mar 15;25(6):675-80 [17311600.001]
  • [Cites] Gut. 2007 Sep;56(9):1232-9 [17299059.001]
  • [Cites] Ann N Y Acad Sci. 2007 Jun;1107:346-55 [17804562.001]
  • [Cites] Gastroenterology. 2007 Sep;133(3):769-79 [17628557.001]
  • [Cites] N Engl J Med. 2007 Nov 29;357(22):2277-84 [18046031.001]
  • [Cites] Clin Gastroenterol Hepatol. 2007 Dec;5(12):1424-9 [17904915.001]
  • [Cites] Jpn J Clin Oncol. 2008 May;38(5):391-3 [18490372.001]
  • [Cites] Clin Gastroenterol Hepatol. 2008 Jun;6(6):644-53 [18550004.001]
  • [Cites] Am J Gastroenterol. 2008 Aug;103(8):2015-22 [18564113.001]
  • [CommentIn] Clin Gastroenterol Hepatol. 2009 Oct;7(10):1139 [19465159.001]
  • (PMID = 19558997.001).
  • [ISSN] 1542-7714
  • [Journal-full-title] Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association
  • [ISO-abbreviation] Clin. Gastroenterol. Hepatol.
  • [Language] ENG
  • [Grant] United States / NIDDK NIH HHS / DK / DK078678-02; United States / NIDDK NIH HHS / DK / K23 DK078678; United States / NIDDK NIH HHS / DK / K23 DK078678-02; United States / NIDDK NIH HHS / DK / K23DK078678
  • [Publication-type] Journal Article; Meta-Analysis; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Immunologic Factors; 0 / TNF protein, human; 0 / Tumor Necrosis Factor-alpha
  • [Other-IDs] NLM/ NIHMS184443; NLM/ PMC2846413
  •  go-up   go-down


45. Bilić E, Femenić R, Konja J, Simat M, Dubravcić K, Batinić D, Ries S, Rajić L: CD20 positive childhood B-non Hodgkin lymphoma (B-NHL): morphology, immunophenotype and a novel treatment approach: a single center experience. Coll Antropol; 2010 Mar;34(1):171-5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CD20 positive childhood B-non Hodgkin lymphoma (B-NHL): morphology, immunophenotype and a novel treatment approach: a single center experience.
  • Lymphomas represent the third most common group of cancers in childhood and adolescence, mature B non Hodgkin's lymphoma (B-NHL) accounting for up to 60% of newly diagnosed patients.
  • The diagnosis of specific entities of B-NHL is based on well-defined morphologic analysis, immunophenotyping, cytogenetics and molecular genetics, which determine the optimal treatment strategy.
  • In adult population a major turning point in treatment of B-NHL has been achieved since rituximab, in combination with CHOP has improved the survival rate up to 19%.
  • Based on morphology and immunophenotype of malignant cells, seven children with B-NHL in our institution were eligible for treatment with modified B-NHL-Berlin-Frankfurt-Münster (BFM)-95-based protocol with rituximab administered on day -5.
  • Rituximab in combination with B-NHL-BFM-95 protocol was otherwise well tolerated and proved to be effective in children and adolescents with B-NHL.
  • The number of our patients is too small and the follow-up of a larger group of patients will help in defining the role of rituximab in the treatment of childhood B-NHL.
  • [MeSH-major] Antibodies, Monoclonal / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Burkitt Lymphoma / drug therapy. Burkitt Lymphoma / pathology. Lymphoma, Large B-Cell, Diffuse / drug therapy. Lymphoma, Large B-Cell, Diffuse / pathology


46. Morozova AK, Zvonkov EE, Kremenetskaia AM, Magomedova AU, Obukhova TN, Mamonov VE, Bariakh EA, Gubkin AV, Lukina AI, Iliushkina EA, Fink OS, Perestoronina TN, Kravchenko SK: [First experience of using modified program NHL-BFM-90 for the treatment of primary diffuse large-B-cell lymphosarcoma of the bones and soft tissues with poor-prognosis]. Ter Arkh; 2009;81(7):61-5
MedlinePlus Health Information. consumer health - Bone Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [First experience of using modified program NHL-BFM-90 for the treatment of primary diffuse large-B-cell lymphosarcoma of the bones and soft tissues with poor-prognosis].
  • AIM: To evaluate efficacy of intensive modified program NHL-BFM-90 (mNHL-BFM-90) in adult poor-prognosis patients with diffuse large B-cell lymphosarcoma (DLBCL) of the bones and soft tissues.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bone Neoplasms / drug therapy. Lymphoma, Large B-Cell, Diffuse / drug therapy. Soft Tissue Neoplasms / drug therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Dose-Response Relationship, Drug. Female. Humans. L-Lactate Dehydrogenase / blood. Male. Middle Aged. Neoplasm Staging. Prognosis. Remission Induction. Young Adult

  • Genetic Alliance. consumer health - Lymphosarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19708576.001).
  • [ISSN] 0040-3660
  • [Journal-full-title] Terapevticheskiĭ arkhiv
  • [ISO-abbreviation] Ter. Arkh.
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] EC 1.1.1.27 / L-Lactate Dehydrogenase
  •  go-up   go-down


47. Shi YX, Zhang XS, Xia JC, Li YQ, Xu RH, Han WJ, Zhang JH, Guan ZZ, Jiang WQ: [Expression of CD16zeta in NK cells of B-cell non-Hodgkin's lymphoma patients and in vitro killing effect of rituximab combined lymphokine-activated killer cells on B-NHL cells]. Ai Zheng; 2007 Aug;26(8):837-42
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Expression of CD16zeta in NK cells of B-cell non-Hodgkin's lymphoma patients and in vitro killing effect of rituximab combined lymphokine-activated killer cells on B-NHL cells].
  • This study was to find out whether the activation disorder of NK cells exist in B-cell non-Hodgkin's lymphoma (B-NHL) patients, whether interleukin-2 (IL-2) can reverse the activation disorder in vitro, and whether the combination of rituximab and LAK cells can produce synergistic antitumor effect.
  • METHODS: Peripheral blood mononuclear cells (PBMCs) were isolated from 69 B-NHL patients and 30 healthy donors by density gradient centrifugation method, and cultured with IL-2 (1 000 U/ml) to prepare LAK cells.
  • RESULTS: The positive rate and MFI value of CD16zeta chain on CD56+ cells were significantly lower in B-NHL group than in control group [(63.3+/-16.4)% vs. (97.8+/-3.1)%, P<0.001; 1.3+/-1.3 vs. 3.6+/-1.7, P<0.001].
  • CONCLUSIONS: The down-regulation of CD16zeta chain expression widely exists in B-NHL patients, while high dose of IL-2 could enhance the expression of CD16zeta chain greatly in vitro.
  • [MeSH-major] Antibodies, Monoclonal / pharmacology. Killer Cells, Lymphokine-Activated / metabolism. Killer Cells, Natural / metabolism. Lymphoma, B-Cell. Receptors, IgG / metabolism
  • [MeSH-minor] Adult. Aged. Antibodies, Monoclonal, Murine-Derived. Antibody-Dependent Cell Cytotoxicity / drug effects. Antigens, CD20 / metabolism. Antineoplastic Agents / pharmacology. Apoptosis / drug effects. Cell Line, Tumor. Female. Humans. Male. Middle Aged. Rituximab. Young Adult

  • Hazardous Substances Data Bank. RITUXIMAB .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17697543.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antigens, CD20; 0 / Antineoplastic Agents; 0 / Receptors, IgG; 4F4X42SYQ6 / Rituximab
  •  go-up   go-down


48. Saberi Hosnijeh F, Krop EJ, Scoccianti C, Krogh V, Palli D, Panico S, Tumino R, Sacredote C, Nawroly N, Portengen L, Linseisen J, Vineis P, Vermeulen R: Plasma cytokines and future risk of non-Hodgkin lymphoma (NHL): a case-control study nested in the Italian European Prospective Investigation into Cancer and Nutrition. Cancer Epidemiol Biomarkers Prev; 2010 Jun;19(6):1577-84
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Plasma cytokines and future risk of non-Hodgkin lymphoma (NHL): a case-control study nested in the Italian European Prospective Investigation into Cancer and Nutrition.
  • BACKGROUND: Recently, biological markers related to the immune system such as cytokines have been studied to further understand the etiology of non-Hodgkin Lymphoma (NHL).
  • However, to date, there are no studies that have studied cytokine levels prospectively in relation to NHL risk in the general population.
  • METHODS: Using bead-based immunoassays, plasma levels of 11 cytokines, 4 chemokines, and 1 adhesion molecules were measured in prediagnostic blood samples of 86 NHL cases and 86 matched controls (average time between blood collection and diagnosis, 4.5 y).
  • Conditional logistic regression adjusted for body mass index and alcohol consumption was used to analyze the association between individual plasma cytokine levels and the risk of developing NHL.
  • Subanalyses of B-cell NHL patients showed a significant association with IL2 (P trend = 0.003), tumor necrosis factor-alpha (TNF-alpha; P trend = 0.03), and ICAM (P trend = 0.04) and a borderline association with IL5 (P trend = 0.07) and IFN-gamma (P trend = 0.08).
  • CONCLUSIONS: The results of this study suggest, in a prospective setting, a possible association between plasma levels of IL2, ICAM, IFN-gamma, and TNF-alpha with NHL risk and provide some evidence that risk of NHL might be related to a downregulation of T helper 1 cytokines.
  • IMPACT: Identification of subtle changes in immune response regulation quantified by plasma cytokine levels possibly provides new insights in the etiology of NHL.
  • [MeSH-major] Cytokines / blood. Lymphoma, Non-Hodgkin / immunology
  • [MeSH-minor] Adult. Aged. Biomarkers. Case-Control Studies. Down-Regulation. Female. Humans. Italy / epidemiology. Male. Middle Aged. Prospective Studies. Risk Factors

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 AACR.
  • (PMID = 20501772.001).
  • [ISSN] 1538-7755
  • [Journal-full-title] Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
  • [ISO-abbreviation] Cancer Epidemiol. Biomarkers Prev.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers; 0 / Cytokines
  •  go-up   go-down


49. Foroutan B, Ali Ruf A, Jerwood D, Anderson D: In vitro studies of DNA damage and its repair in cells from NHL patients with different p53 mutant protein status, resistant (p53(+)) and sensitive (p53(-)) to cancer chemotherapy. J Pharmacol Toxicol Methods; 2007 Jan-Feb;55(1):58-64
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] In vitro studies of DNA damage and its repair in cells from NHL patients with different p53 mutant protein status, resistant (p53(+)) and sensitive (p53(-)) to cancer chemotherapy.
  • INTRODUCTION: Resistance to an anthracycline-based regimen, such as CHOP, constitutes a problem for curing non-Hodgkin's lymphoma (NHL) patients.
  • METHODS: In this study, lymphocytes from NHL patients were treated with hydrogen peroxide (H(2)O(2)), a free radical generating model agent, and ethyl methanesulfonate (EMS), a model alkylating agent, to induce DNA damage which was evaluated by SCGE.
  • An NHL cell line model [Raji TK(+) (mex(+)) and TK(-) (mex(-))] with p53 over-expression was also investigated.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. DNA Damage. DNA Repair. Drug Resistance, Neoplasm / genetics. Lymphoma, Non-Hodgkin / genetics. Lymphoma, Non-Hodgkin / physiopathology. Tumor Suppressor Protein p53 / genetics
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Cyclophosphamide / administration & dosage. Cyclophosphamide / therapeutic use. Doxorubicin / administration & dosage. Doxorubicin / therapeutic use. Ethyl Methanesulfonate / pharmacology. Female. Humans. Hydrogen Peroxide / pharmacology. Male. Middle Aged. Prednisone / administration & dosage. Prednisone / therapeutic use. Tumor Cells, Cultured. Vincristine / administration & dosage. Vincristine / therapeutic use

  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. ETHYL METHANESULFONATE .
  • Hazardous Substances Data Bank. HYDROGEN PEROXIDE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16624596.001).
  • [ISSN] 1056-8719
  • [Journal-full-title] Journal of pharmacological and toxicological methods
  • [ISO-abbreviation] J Pharmacol Toxicol Methods
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / TP53 protein, human; 0 / Tumor Suppressor Protein p53; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; 9H154DI0UP / Ethyl Methanesulfonate; BBX060AN9V / Hydrogen Peroxide; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


50. Woessmann W, Seidemann K, Mann G, Zimmermann M, Burkhardt B, Oschlies I, Ludwig WD, Klingebiel T, Graf N, Gruhn B, Juergens H, Niggli F, Parwaresch R, Gadner H, Riehm H, Schrappe M, Reiter A, BFM Group: The impact of the methotrexate administration schedule and dose in the treatment of children and adolescents with B-cell neoplasms: a report of the BFM Group Study NHL-BFM95. Blood; 2005 Feb 1;105(3):948-58
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The impact of the methotrexate administration schedule and dose in the treatment of children and adolescents with B-cell neoplasms: a report of the BFM Group Study NHL-BFM95.
  • In the Non-Hodgkin Lymphoma-Berlin-Frankfurt-Münster 95 (NHL-BFM95) study, we tested by randomization whether for patients with B-cell neoplasms methotrexate as intravenous infusion over 4 hours (MTX-4h) is not inferior to, but less toxic than, a 24-hour intravenous infusion (MTX-24h).
  • Second, we investigated against the historical control of study NHL-BFM90, whether for patients with moderate tumor mass MTX can be reduced from 5 g/m(2) to 1 g/m(2).
  • For patients in R2, event-free survival (pEFS) was 95% +/- 2% (n = 222) in NHL-BFM95 (MTX 1 g/m(2)) and 97% +/- 1% (n = 154) in NHL-BFM90 (MTX 5 g/m(2)).
  • MTX-4h was noninferior to MTX-24h for limited stage B-cell non-Hodgkin lymphoma (B-NHL) but not for advanced disease.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, B-Cell / drug therapy. Methotrexate / administration & dosage. Methotrexate / therapeutic use
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Disease-Free Survival. Drug Administration Schedule. Female. Follow-Up Studies. Humans. Infant. Male. Survival Analysis. Time Factors

  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15486066.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


51. Greb A, Bohlius J, Schiefer D, Schwarzer G, Schulz H, Engert A: High-dose chemotherapy with autologous stem cell transplantation in the first line treatment of aggressive non-Hodgkin lymphoma (NHL) in adults. Cochrane Database Syst Rev; 2008;(1):CD004024
Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High-dose chemotherapy with autologous stem cell transplantation in the first line treatment of aggressive non-Hodgkin lymphoma (NHL) in adults.
  • BACKGROUND: High-dose chemotherapy with autologous stem cell support (HDT) has been proven effective in relapsed aggressive non-Hodgkin lymphoma (NHL).
  • OBJECTIVES: To determine whether high-dose chemotherapy with autologous stem cell transplantation as part of first-line treatment improves survival in patients with aggressive non-Hodgkin lymphoma.
  • SELECTION CRITERIA: Randomised controlled trials comparing conventional chemotherapy versus high-dose chemotherapy in the first-line treatment of adults with aggressive non-Hodgkin lymphoma were included in this review.
  • Other possible risk factors such as the proportion of patient with diffuse large cell lymphoma, protocol adherence, HDT strategy, response status before HDT, conditioning regimens and methodological issues were analysed in sensitivity analyses.
  • Despite higher CR rates, there is no benefit for high-dose chemotherapy with stem cell transplantation as a first line treatment in patients with aggressive NHL.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Lymphoma, Non-Hodgkin / drug therapy. Lymphoma, Non-Hodgkin / surgery. Stem Cell Transplantation
  • [MeSH-minor] Adult. Combined Modality Therapy / methods. Humans. Randomized Controlled Trials as Topic. Transplantation, Autologous

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18254036.001).
  • [ISSN] 1469-493X
  • [Journal-full-title] The Cochrane database of systematic reviews
  • [ISO-abbreviation] Cochrane Database Syst Rev
  • [Language] eng
  • [Publication-type] Journal Article; Meta-Analysis; Review
  • [Publication-country] England
  • [Number-of-references] 75
  •  go-up   go-down


52. Imai Y, Chou T, Tobinai K, Tanosaki R, Morishima Y, Ogura M, Shimazaki C, Taniwaki M, Hiraoka A, Tanimoto M, Koike T, Kogawa K, Hirai H, Yoshida T, Tamura K, Kishi K, Hotta T, CliniMACS Study Group: Isolation and transplantation of highly purified autologous peripheral CD34+ progenitor cells: purging efficacy, hematopoietic reconstitution in non-Hodgkin's lymphoma (NHL): results of Japanese phase II study. Bone Marrow Transplant; 2005 Mar;35(5):479-87
Genetic Alliance. consumer health - Transplantation.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Isolation and transplantation of highly purified autologous peripheral CD34+ progenitor cells: purging efficacy, hematopoietic reconstitution in non-Hodgkin's lymphoma (NHL): results of Japanese phase II study.
  • The purging efficacy of positive selection of autologous CD34+ PBSC with a clinical scale method of magnetic-activated cell sorting system (CliniMACS) was investigated in 48 patients with non-Hodgkin's lymphoma (NHL).
  • MRT) and CD19 and CD20 positivities were used for the detection of contaminating NHL cells before and after CD34+ selection.
  • The present study demonstrated that CliniMACS is a highly effective positive selection method and a high purging efficacy could be obtained without compromising the hematopoietic reconstitution capacity of the graft in NHL patients undergoing high-dose chemotherapy.
  • [MeSH-major] Antigens, CD34. Graft Survival. Immunomagnetic Separation. Lymphoma, Non-Hodgkin / therapy. Neoplastic Cells, Circulating / pathology. Peripheral Blood Stem Cell Transplantation / methods
  • [MeSH-minor] Adult. Antineoplastic Agents / therapeutic use. Clone Cells. Female. Gene Rearrangement. Humans. Immunoglobulin Heavy Chains / genetics. Immunophenotyping. Male. Middle Aged. Polymerase Chain Reaction. Transplantation, Autologous

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15654349.001).
  • [ISSN] 0268-3369
  • [Journal-full-title] Bone marrow transplantation
  • [ISO-abbreviation] Bone Marrow Transplant.
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article; Multicenter Study
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, CD34; 0 / Antineoplastic Agents; 0 / Immunoglobulin Heavy Chains
  •  go-up   go-down


53. McDuffie HH, Pahwa P, Karunanayake CP, Spinelli JJ, Dosman JA: Clustering of cancer among families of cases with Hodgkin Lymphoma (HL), Multiple Myeloma (MM), Non-Hodgkin's Lymphoma (NHL), Soft Tissue Sarcoma (STS) and control subjects. BMC Cancer; 2009;9:70
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clustering of cancer among families of cases with Hodgkin Lymphoma (HL), Multiple Myeloma (MM), Non-Hodgkin's Lymphoma (NHL), Soft Tissue Sarcoma (STS) and control subjects.
  • METHODS: We conducted population-based studies of Hodgkin lymphoma (HL), Multiple Myeloma (MM), non-Hodgkin's Lymphoma (NHL), and Soft Tissue Sarcoma (STS) among male incident case and control subjects in six Canadian provinces.
  • The information was collected on 1528 cases (HL (n = 316), MM (n = 342), NHL (n = 513), STS (n = 357)) and 1506 age +/- 2 years and province of residence matched control subjects.
  • HL [(OR(adj) (95% CI) 1.79 (1.33, 2.42)], MM (1.38(1.07, 1.78)), NHL (1.43 (1.15, 1.77)), and STS cases (1.30(1.00, 1.68)) had higher incidence of cancer if any first degree relative was affected with cancer compared to control families.
  • Also, a positive family history of cancer both with (1.72 (1.21, 2.45)) and without pesticide exposure (1.43(1.12, 1.83)) increased risk of NHL.
  • CONCLUSION: HL, MM, NHL, and STS cases had higher incidence of cancer if any first degree relative affected with cancer compared to control families.
  • [MeSH-major] Hodgkin Disease / genetics. Lymphoma, Non-Hodgkin / genetics. Multiple Myeloma / genetics. Sarcoma / genetics
  • [MeSH-minor] Adult. Aged. Canada / epidemiology. Case-Control Studies. Cluster Analysis. Family Health. Female. Humans. Incidence. Male. Middle Aged. Surveys and Questionnaires


54. Akutsu M, Tsunoda S, Izumi T, Tanaka M, Katano S, Inoue K, Igarashi S, Hirabayashi K, Furukawa Y, Ohmine K, Sato K, Kobayashi H, Ozawa K, Kirito K, Nagashima T, Teramukai S, Fukushima M, Kano Y: Long-term results of dose-intensive chemotherapy with G-CSF support (TCC-NHL-91) for advanced intermediate-grade non-Hodgkin's lymphoma: a review of 59 consecutive cases treated at a single institute. Oncol Res; 2008;17(3):137-49
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term results of dose-intensive chemotherapy with G-CSF support (TCC-NHL-91) for advanced intermediate-grade non-Hodgkin's lymphoma: a review of 59 consecutive cases treated at a single institute.
  • We evaluated the long-term outcome of very dose-intensive chemotherapy (TCC-NHL-91) for advanced intermediate-grade lymphoma, in which an eight-cycle regimen with 11 drugs was given with granulocyte colony-stimulating factor (G-CSF) support (total 18 weeks).
  • This retrospective study suggests that the TCC-NHL-91 regimen achieves high CR, OS, and PFS in patients with advanced intermediate-grade lymphoma up to 60 years old and may be a valuable asset in the management of this disease.
  • Further evaluation and prospective studies of the TCC-NHL-91 are warranted.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, Non-Hodgkin / drug therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Cyclophosphamide / administration & dosage. Doxorubicin / administration & dosage. Female. Granulocyte Colony-Stimulating Factor / administration & dosage. Humans. Kaplan-Meier Estimate. Male. Middle Aged. Prednisone / administration & dosage. Remission Induction. Retrospective Studies. Treatment Outcome. Vincristine / administration & dosage

  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18669165.001).
  • [ISSN] 0965-0407
  • [Journal-full-title] Oncology research
  • [ISO-abbreviation] Oncol. Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 143011-72-7 / Granulocyte Colony-Stimulating Factor; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone
  •  go-up   go-down


55. Vellenga E, van Putten WL, van 't Veer MB, Zijlstra JM, Fibbe WE, van Oers MH, Verdonck LF, Wijermans PW, van Imhoff GW, Lugtenburg PJ, Huijgens PC: Rituximab improves the treatment results of DHAP-VIM-DHAP and ASCT in relapsed/progressive aggressive CD20+ NHL: a prospective randomized HOVON trial. Blood; 2008 Jan 15;111(2):537-43
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Rituximab improves the treatment results of DHAP-VIM-DHAP and ASCT in relapsed/progressive aggressive CD20+ NHL: a prospective randomized HOVON trial.
  • We evaluated the role of rituximab during remission induction chemotherapy in relapsed aggressive CD20+ non-Hodgkin lymphoma.
  • These results demonstrate improved FFS and PFS for relapsed aggressive B-cell NHL if rituximab is added to the re-induction chemotherapy regimen.
  • [MeSH-major] Antibodies, Monoclonal / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Lymphoma, B-Cell / therapy. Stem Cell Transplantation
  • [MeSH-minor] Adolescent. Adult. Aged. Antibodies, Monoclonal, Murine-Derived. Cisplatin / administration & dosage. Cytarabine / administration & dosage. Dexamethasone / administration & dosage. Disease-Free Survival. Etoposide / administration & dosage. Female. Follow-Up Studies. Humans. Ifosfamide / administration & dosage. Male. Methotrexate / administration & dosage. Middle Aged. Prospective Studies. Recurrence. Remission Induction. Rituximab. Survival Rate. Transplantation, Autologous


56. Oschlies I, Salaverria I, Mahn F, Meinhardt A, Zimmermann M, Woessmann W, Burkhardt B, Gesk S, Krams M, Reiter A, Siebert R, Klapper W: Pediatric follicular lymphoma--a clinico-pathological study of a population-based series of patients treated within the Non-Hodgkin's Lymphoma--Berlin-Frankfurt-Munster (NHL-BFM) multicenter trials. Haematologica; 2010 Feb;95(2):253-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pediatric follicular lymphoma--a clinico-pathological study of a population-based series of patients treated within the Non-Hodgkin's Lymphoma--Berlin-Frankfurt-Munster (NHL-BFM) multicenter trials.
  • Background Pediatric follicular lymphoma has recently been recognized as a novel variant of follicular lymphoma in the World Health Organization classification of lymphomas.
  • Given the rarity of the disease, histopathological and genetic data on this type of lymphoma are still scarce.
  • DESIGN AND METHODS: We analyzed 25 cases of pediatric follicular lymphoma (patients aged <or=18 years) by morphology, immunohistochemistry and interphase fluorescence in situ hybridization.
  • All patients analyzed were treated within Non-Hodgkin's Lymphoma--Berlin-Frankfurt-Münster (NHL-BFM) multicenter trials, and the cohort was representative of the German population.
  • RESULTS: The genetic hallmark of adult follicular lymphoma, t(14;18)(q32;q21), was not detectable in any of the pediatric cases, although BCL2 protein was expressed in 55% of the latter cases.
  • Patients with pediatric follicular lymphoma had long event-free survival and, in contrast to adult follicular lymphoma, the clinical course was not dominated by relapses.
  • A simultaneous diffuse large B-cell lymphoma was frequently detected at initial diagnosis in children but did not indicate an aggressive clinical course.
  • Conclusions Our data suggest that pediatric follicular lymphoma is a disease that differs from its adult counterpart both genetically and clinically.
  • [MeSH-major] Lymphoma, Follicular / genetics. Lymphoma, Follicular / pathology
  • [MeSH-minor] Adolescent. Child. Child, Preschool. Cohort Studies. Cytogenetic Analysis. Female. Gene Expression. Humans. Immunohistochemistry. Infant. Lymphoma, Large B-Cell, Diffuse / diagnosis. Male. Proto-Oncogene Proteins c-bcl-2 / genetics. Treatment Outcome

  • Genetic Alliance. consumer health - Follicular Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 1999 Nov 15;94(10):3294-306 [10552938.001]
  • [Cites] Br J Haematol. 2008 Jun;142(2):166-78 [18492111.001]
  • [Cites] Leukemia. 2003 Dec;17(12):2257-317 [14671650.001]
  • [Cites] Blood. 2004 Aug 1;104(3):626-33 [14982884.001]
  • [Cites] Blood. 2004 Aug 1;104(3):634-41 [15016643.001]
  • [Cites] Blood. 2004 Nov 1;104(9):2667-74 [15238420.001]
  • [Cites] Cancer. 1979 Apr;43(4):1216-24 [376087.001]
  • [Cites] Semin Oncol. 1980 Sep;7(3):332-9 [7414342.001]
  • [Cites] Cancer. 1981 Nov 15;48(10):2223-35 [7028244.001]
  • [Cites] Mod Pathol. 1990 May;3(3):308-13 [2194214.001]
  • [Cites] Leukemia. 1992 Aug;6(8):761-5 [1640726.001]
  • [Cites] J Clin Oncol. 1995 Feb;13(2):359-72 [7844597.001]
  • [Cites] Br J Haematol. 1998 Oct;103(1):220-3 [9792312.001]
  • [Cites] Cancer. 1999 Apr 1;85(7):1626-35 [10193956.001]
  • [Cites] Blood. 2005 Feb 1;105(3):948-58 [15486066.001]
  • [Cites] Am J Clin Pathol. 2004 Dec;122 Suppl:S98-109 [15690646.001]
  • [Cites] J Mol Diagn. 2006 May;8(2):141-51 [16645199.001]
  • [Cites] Blood. 2006 May 15;107(10):4047-52 [16424389.001]
  • [Cites] J Clin Oncol. 2007 Jun 10;25(17):2426-33 [17485708.001]
  • [Cites] Blood. 2008 Aug 15;112(4):1374-81 [18509088.001]
  • [Cites] J Clin Oncol. 2008 Nov 10;26(32):5165-9 [18838711.001]
  • [Cites] Int J Cancer. 2009 Feb 15;124(4):958-63 [19030176.001]
  • [Cites] Arch Pathol Lab Med. 2009 Jan;133(1):142-6 [19123728.001]
  • [Cites] Br J Haematol. 2008 Jul;142(3):329-47 [18537979.001]
  • [Cites] Blood. 2002 Mar 15;99(6):1959-64 [11877266.001]
  • (PMID = 19679882.001).
  • [ISSN] 1592-8721
  • [Journal-full-title] Haematologica
  • [ISO-abbreviation] Haematologica
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Proto-Oncogene Proteins c-bcl-2
  • [Other-IDs] NLM/ PMC2817028
  •  go-up   go-down


57. Gouda I, Nada O, Ezzat S, Eldaly M, Loffredo C, Taylor C, Abdel-Hamid M: Immunohistochemical detection of hepatitis C virus (genotype 4) in B-cell NHL in an Egyptian population: correlation with serum HCV-RNA. Appl Immunohistochem Mol Morphol; 2010 Jan;18(1):29-34
Genetic Alliance. consumer health - Hepatitis C (HCV).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunohistochemical detection of hepatitis C virus (genotype 4) in B-cell NHL in an Egyptian population: correlation with serum HCV-RNA.
  • BACKGROUND AND AIM: Retrospective evaluation of hepatitis C virus (HCV) prevalence in lymphoma tissues has important applications in clarifying the contribution of viral factors to the pathogenesis.
  • Trials for detection of HCV at the cellular level in lymphoma tissues are, so far, minimal with unsatisfactory results.
  • We aimed to study the detection and localization of HCV in the tissues of B-cell non-Hodgkin lymphoma (NHL) patients.
  • DESIGN: We performed immunohistochemistry to detect the HCV nonstructural 3 protein in paraffin-embedded tissue specimens of B-cell NHL patients, in 39 serum HCV-RNA positive samples and 35 serum HCV-RNA negative samples as controls.
  • CONCLUSIONS: Immunohistochemical detection of HCV proteins in lymphoma tissues supports a potential role of viral replication in lymphomagenesis.
  • The low number of cases showing expression of viral proteins may represent a low viral load in lymphoid tissue and/or restriction of HCV protein expression to certain subtypes of B-cell NHL.
  • Immunohistochemistry can be used as a complementary tool for specific HCV detection in the paraffin-embedded material of lymphoma tissues not suitable for RNA analysis.

  • Genetic Alliance. consumer health - Hepatitis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Lupus. 2000;9(2):83-91 [10787003.001]
  • [Cites] Aliment Pharmacol Ther. 2005 Mar 15;21(6):653-62 [15771751.001]
  • [Cites] Hepatology. 2001 Jan;33(1):248-53 [11124843.001]
  • [Cites] N Engl J Med. 2002 Jul 11;347(2):89-94 [12110736.001]
  • [Cites] Am J Gastroenterol. 2002 Jul;97(7):1802-6 [12135039.001]
  • [Cites] Tumori. 2002 Sep-Oct;88(5):400-6 [12487559.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Mar 23;101(12):4262-7 [14999097.001]
  • [Cites] Am J Hematol. 2004 Jul;76(3):252-7 [15224361.001]
  • [Cites] Int J Epidemiol. 2004 Oct;33(5):1034-9 [15155696.001]
  • [Cites] Nature. 1970 Dec 12;228(5276):1056-8 [4320657.001]
  • [Cites] Proc Natl Acad Sci U S A. 1982 Mar;79(6):2031-5 [6979048.001]
  • [Cites] Jpn J Exp Med. 1990 Aug;60(4):215-22 [1963453.001]
  • [Cites] Hepatology. 1991 Aug;14(2):381-8 [1650328.001]
  • [Cites] Blood. 1993 Aug 1;82(3):872-6 [8393354.001]
  • [Cites] N Engl J Med. 1995 May 4;332(18):1186-91 [7700311.001]
  • [Cites] Blood. 1995 Sep 1;86(5):1887-92 [7655017.001]
  • [Cites] Blood. 1996 Jul 15;88(2):645-56 [8695812.001]
  • [Cites] Blood. 1996 Dec 15;88(12):4638-45 [8977256.001]
  • [Cites] Blood. 1997 Apr 15;89(8):3066-8 [9108432.001]
  • [Cites] J Hum Virol. 1997 Nov-Dec;1(1):58-65 [10195232.001]
  • [Cites] Hepatology. 2005 Mar;41(3):652-9 [15723449.001]
  • [Cites] Leuk Lymphoma. 2005 Sep;46(9):1365-8 [16109616.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2006 Nov;15(11):2078-85 [17119031.001]
  • [Cites] Gastroenterology. 2006 Dec;131(6):1879-86 [17087949.001]
  • [Cites] J Vet Diagn Invest. 2007 Jan;19(1):35-42 [17459830.001]
  • [Cites] World J Gastroenterol. 2007 May 7;13(17):2467-78 [17552031.001]
  • [Cites] Egypt J Immunol. 2006;13(1):105-14 [17974155.001]
  • [Cites] Int J Cancer. 2008 Feb 1;122(3):630-3 [17935132.001]
  • [Cites] Int J Cancer. 2008 Apr 15;122(8):x-xii [18271007.001]
  • [Cites] Clin Gastroenterol Hepatol. 2008 Apr;6(4):451-8 [18387498.001]
  • [Cites] Lancet. 2000 Mar 11;355(9207):887-91 [10752705.001]
  • [Cites] Am J Clin Pathol. 2000 Mar;113(3):391-8 [10705820.001]
  • [Cites] Semin Liver Dis. 2000;20(1):85-102 [10895434.001]
  • (PMID = 19644357.001).
  • [ISSN] 1533-4058
  • [Journal-full-title] Applied immunohistochemistry & molecular morphology : AIMM
  • [ISO-abbreviation] Appl. Immunohistochem. Mol. Morphol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA085888
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Hepatitis C Antibodies; 0 / RNA, Viral
  • [Other-IDs] NLM/ NIHMS461675; NLM/ PMC3663591
  •  go-up   go-down


58. Nachbaur D, Greinix HT, Koller E, Krieger O, Linkesch W, Kasparu H, Pober M, Hinterberger W, Hausmaninger H, Heistinger M, Ulsperger E, Karlhuber S, Schwinger W, Lindner B: Long-term results of autologous stem cell transplantation for Hodgkin's disease (HD) and low-/intermediate-grade B non-Hodgkin's lymphoma (NHL): a report from the Austrian Stem Cell Transplantation Registry (ASCTR). Ann Hematol; 2005 Jul;84(7):462-73
MedlinePlus Health Information. consumer health - Hodgkin Disease.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term results of autologous stem cell transplantation for Hodgkin's disease (HD) and low-/intermediate-grade B non-Hodgkin's lymphoma (NHL): a report from the Austrian Stem Cell Transplantation Registry (ASCTR).
  • Between 1990 and 2001, 68 patients with advanced Hodgkin's disease (HD) and 86 patients classified as low-/intermediate-grade B non-Hodgkin's lymphoma (NHL) were reported to the Austrian Stem Cell Transplantation Registry (ASCTR).
  • Overall survival for NHL patients was 45% (95% CI: 26-64%) with a disease-/progression-free survival of 26% at 7 years.
  • Mantle cell lymphoma, greater than or equal to three lines of previous therapy, and a conditioning regimen other than BEAM were also predictive for death.
  • [MeSH-major] Hematopoietic Stem Cell Transplantation. Hodgkin Disease / mortality. Hodgkin Disease / therapy. Transplantation, Autologous
  • [MeSH-minor] Adolescent. Adult. Austria. Child. Disease-Free Survival. Female. Humans. Longitudinal Studies. Male. Middle Aged. Recurrence. Registries. Remission Induction. Retrospective Studies. Treatment Outcome

  • Genetic Alliance. consumer health - Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15726362.001).
  • [ISSN] 0939-5555
  • [Journal-full-title] Annals of hematology
  • [ISO-abbreviation] Ann. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


59. Di Renzo N, Brugiatelli M, Montanini A, Vigliotti ML, Cervetti G, Liberati AM, Luminari S, Spedini P, Giglio G, Federico M: Vinorelbine, gemcitabine, procarbazine and prednisone (ViGePP) as salvage therapy in relapsed or refractory aggressive non-Hodgkin's lymphoma (NHL): results of a phase II study conducted by the Gruppo Italiano per lo Studio dei Linfomi. Leuk Lymphoma; 2006 Mar;47(3):473-9
Hazardous Substances Data Bank. VINBLASTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Vinorelbine, gemcitabine, procarbazine and prednisone (ViGePP) as salvage therapy in relapsed or refractory aggressive non-Hodgkin's lymphoma (NHL): results of a phase II study conducted by the Gruppo Italiano per lo Studio dei Linfomi.
  • Patients with aggressive NHL who fail initial treatment or subsequently relapse have a very poor outcome and less than 20-25% achieve a prolonged disease-free interval with salvage therapies.
  • To improve the outcome of patients with refractory aggressive NHL not suitable for High Dose Therapy (HDT) and Autologous Stem Cell Transplant (ASCT), the efficacy of a combination of gemcitabine, vinorelbine, procarbazine and prednisone (ViGePP) were tested.
  • Between November 1999 and September 2002, 69 patients with relapsed or refractory aggressive NHL were treated with ViGePP regimen, every 4 weeks up to six courses.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Deoxycytidine / analogs & derivatives. Lymphoma, Non-Hodgkin / therapy. Prednisone / administration & dosage. Procarbazine / administration & dosage. Salvage Therapy. Vinblastine / analogs & derivatives
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Combined Modality Therapy. Dose-Response Relationship, Drug. Female. Humans. Male. Middle Aged. Recurrence. Remission Induction. Stem Cell Transplantation. Survival Analysis. Transplantation, Autologous. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Steroids.
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. PROCARBAZINE .
  • Hazardous Substances Data Bank. VINORELBINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Leuk Lymphoma. 2006 Apr;47(4):576-7 [16886269.001]
  • (PMID = 16396771.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Comparative Study; Journal Article; Randomized Controlled Trial
  • [Publication-country] England
  • [Chemical-registry-number] 0W860991D6 / Deoxycytidine; 35S93Y190K / Procarbazine; 5V9KLZ54CY / Vinblastine; B76N6SBZ8R / gemcitabine; Q6C979R91Y / vinorelbine; VB0R961HZT / Prednisone
  •  go-up   go-down


60. Taylor PR, White JM, Prescott RJ, Angus B, Galloway MJ, Jackson GH, Lessells AM, Lucraft HH, Summerfield GP, Proctor SJ, Scotland And Newcastle Lymphoma Group: The addition of oral idarubicin to a chlorambucil/dexamethasone combination has a significant impact on time to treatment failure but none on overall survival in patients with low grade non-Hodgkin's lymphoma: Results of the Scotland and Newcastle Lymphoma Group randomized NHL VIII trial. Leuk Lymphoma; 2006 Nov;47(11):2321-30
Hazardous Substances Data Bank. DEXAMETHASONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The addition of oral idarubicin to a chlorambucil/dexamethasone combination has a significant impact on time to treatment failure but none on overall survival in patients with low grade non-Hodgkin's lymphoma: Results of the Scotland and Newcastle Lymphoma Group randomized NHL VIII trial.
  • Two hundred untreated patients with low grade NHL (KIEL), including 155 follicular NHL, were randomized to six courses of treatment with chlorambucil 20 mg m-2 for 3 days and dexamethasone 4 mg bd for 5 days (CD) vs the same regimen plus oral idarubicin 10 mg m-2 for 3 days (CID).
  • The Follicular Lymphoma International Prognostic Index (FLIPI) is confirmed as a good predictor of risk groups including a group of 23% with shorter survival.
  • [MeSH-major] Chlorambucil / therapeutic use. Dexamethasone / therapeutic use. Idarubicin / administration & dosage. Idarubicin / therapeutic use. Lymphoma, Non-Hodgkin / drug therapy. Lymphoma, Non-Hodgkin / pathology
  • [MeSH-minor] Administration, Oral. Adolescent. Adult. Aged. Disease Progression. Drug Therapy, Combination. England. Female. Humans. Male. Middle Aged. Neoplasm Staging. Survival Rate. Time Factors. Treatment Failure

  • Hazardous Substances Data Bank. CHLORAMBUCIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Leuk Lymphoma. 2006 Nov;47(11):2267-8 [17107893.001]
  • (PMID = 17107904.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 18D0SL7309 / Chlorambucil; 7S5I7G3JQL / Dexamethasone; ZRP63D75JW / Idarubicin
  •  go-up   go-down


61. Koch P, Probst A, Berdel WE, Willich NA, Reinartz G, Brockmann J, Liersch R, del Valle F, Clasen H, Hirt C, Breitsprecher R, Schmits R, Freund M, Fietkau R, Ketterer P, Freitag EM, Hinkelbein M, Heinecke A, Parwaresch R, Tiemann M: Treatment results in localized primary gastric lymphoma: data of patients registered within the German multicenter study (GIT NHL 02/96). J Clin Oncol; 2005 Oct 1;23(28):7050-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment results in localized primary gastric lymphoma: data of patients registered within the German multicenter study (GIT NHL 02/96).
  • PURPOSE: In the prospective study 02/96 on primary GI lymphoma, we have collected data on histology, clinical features, and treatment results.
  • In particular, in stages I and II localized primary gastric lymphoma (PGL), our objectives were to reduce treatment intensity and to confirm our hypothesis from study 01/92, which maintained that an organ-preserving approach is not inferior to primary surgery.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma / drug therapy. Lymphoma / radiotherapy. Stomach Neoplasms / drug therapy. Stomach Neoplasms / radiotherapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Combined Modality Therapy. Cyclophosphamide / administration & dosage. Dose Fractionation. Doxorubicin / administration & dosage. Female. Humans. Male. Middle Aged. Neoplasm Staging. Prednisone / administration & dosage. Prospective Studies. Survival Analysis. Treatment Outcome. Vincristine / administration & dosage

  • Genetic Alliance. consumer health - Gastric Lymphoma.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Clin Oncol. 2006 Jun 10;24(17):2682; author reply 2682-3 [16763284.001]
  • (PMID = 16129843.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


62. Linch DC, Yung L, Smith P, Maclennan K, Jack A, Hancock B, Cunningham D, Hoskin P, Qian W, Holte H, Boesen AM, Grigg A, Browett P, Trneny M: Final analysis of the UKLG LY02 trial comparing 6-8 cycles of CHOP with 3 cycles of CHOP followed by a BEAM autograft in patients &lt;65 years with poor prognosis histologically aggressive NHL. Br J Haematol; 2010 Apr;149(2):237-43
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Final analysis of the UKLG LY02 trial comparing 6-8 cycles of CHOP with 3 cycles of CHOP followed by a BEAM autograft in patients <65 years with poor prognosis histologically aggressive NHL.
  • This trial involved 457 patients and sought to assess the value of early intensification with autologous transplantation in patients with poor prognosis histologically aggressive non-Hodgkin lymphoma (NHL) showing a response to initial CHOP (cyclophosphamide, doxorubicin, vincristine, prednisolone) chemotherapy.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Hematopoietic Stem Cell Transplantation. Lymphoma, Large B-Cell, Diffuse / drug therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Carmustine / therapeutic use. Cyclophosphamide / administration & dosage. Cyclophosphamide / therapeutic use. Cytarabine / therapeutic use. Doxorubicin / administration & dosage. Doxorubicin / therapeutic use. Drug Administration Schedule. Etoposide / therapeutic use. Female. Humans. Male. Melphalan / therapeutic use. Middle Aged. Neoplasm Staging. Prednisolone / administration & dosage. Prednisolone / therapeutic use. Prognosis. Recurrence. Survival Analysis. Transplantation Conditioning / methods. Treatment Outcome. Vincristine / administration & dosage. Vincristine / therapeutic use. Young Adult

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. MELPHALAN .
  • Hazardous Substances Data Bank. Carmustine .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20201949.001).
  • [ISSN] 1365-2141
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Randomized Controlled Trial
  • [Publication-country] England
  • [Chemical-registry-number] 04079A1RDZ / Cytarabine; 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; 9PHQ9Y1OLM / Prednisolone; Q41OR9510P / Melphalan; U68WG3173Y / Carmustine; BEAM regimen; VAP-cyclo protocol
  •  go-up   go-down


63. Mones JV, Coleman M, Kostakoglu L, Furman RR, Chadburn A, Shore TB, Muss D, Stewart P, Kroll S, Vallabhajosula S, Goldsmith SJ, Leonard JP: Dose-attenuated radioimmunotherapy with tositumomab and iodine 131 tositumomab in patients with recurrent non-Hodgkin's lymphoma (NHL) and extensive bone marrow involvement. Leuk Lymphoma; 2007 Feb;48(2):342-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dose-attenuated radioimmunotherapy with tositumomab and iodine 131 tositumomab in patients with recurrent non-Hodgkin's lymphoma (NHL) and extensive bone marrow involvement.
  • Radioimmunotherapy (RIT) with tositumomab and iodine 131 tositumomab can produce durable and complete responses in relapsed/refractory low-grade Non-Hodgkin's lymphoma.
  • Three patients received 55 cGy, one had hematologic DLT concurrent with lymphoma progression and extensive BMI at relapse.
  • RIT with attenuated dose iodine 131 tositumomab for patients with >25% BMI has acceptable toxicity and can result in lymphoma responses.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antineoplastic Agents / therapeutic use. Bone Marrow / immunology. Lymphoma, Non-Hodgkin / radiotherapy. Neoplasm Recurrence, Local / radiotherapy. Radioimmunotherapy
  • [MeSH-minor] Adult. Aged. Antigens, CD20 / immunology. Dose-Response Relationship, Radiation. Feasibility Studies. Female. Humans. Iodine Radioisotopes. Lymphoma, B-Cell / radiotherapy. Lymphoma, Follicular / radiotherapy. Male. Middle Aged. Remission Induction

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17325895.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Grant] United States / NCRR NIH HHS / RR / K23 RR16814
  • [Publication-type] Clinical Trial, Phase I; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antigens, CD20; 0 / Antineoplastic Agents; 0 / Iodine Radioisotopes; 0 / iodine-131 anti-B1 antibody
  •  go-up   go-down


64. von der Weid NX: Adult life after surviving lymphoma in childhood. Support Care Cancer; 2008 Apr;16(4):339-45
MedlinePlus Health Information. consumer health - Radiation Therapy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adult life after surviving lymphoma in childhood.
  • The combined incidence of Hodgkin's disease (HD) and non-Hodgkin lymphoma (NHL) reaches 10 to 12 new cases a year per million children under the age of 16 years, representing about 10% of all pediatric cancers.
  • HD makes up to 40% and NHL 60% of pediatric lymphomas.
  • During the last 20 years, cure rates raised dramatically so that currently over 90% of children and adolescents with HD and about 80% of those with NHL can be cured.
  • DISCUSSION: Like survivors from acute lymphoblastic leukemia, young adults cured from NHL may present with neurocognitive deficits, especially if treated at a young age and with cranial irradiation.
  • A well functioning network of pediatric oncologists, GP's, adult oncologists and other specialists of adult medicine must be developed in order to prevent, early detect and treat expected long-term toxicities.
  • [MeSH-major] Lymphoma. Radiotherapy / adverse effects. Survivors
  • [MeSH-minor] Adult. Child. Cognition Disorders / etiology. Endocrine System / physiopathology. Follow-Up Studies. Humans. Neoplasms, Radiation-Induced. Neoplasms, Second Primary

  • MedlinePlus Health Information. consumer health - Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Leukemia. 1995 Dec;9(12):1990-6 [8609707.001]
  • [Cites] Cancer. 1976 Dec;38(6):2263-8 [826312.001]
  • [Cites] Lancet. 1999 Jul 3;354(9172):34-9 [10406363.001]
  • [Cites] N Engl J Med. 1981 Jun 4;304(23):1377-82 [7231460.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Oct 27;95(22):13176-81 [9789061.001]
  • [Cites] Cancer Treat Rep. 1982 Apr;66(4):977-89 [7074658.001]
  • [Cites] Pediatrics. 2002 Jul;110(1 Pt 1):42-52 [12093945.001]
  • [Cites] Med Pediatr Oncol. 2002 Apr;38(4):229-39 [11920786.001]
  • [Cites] J Natl Cancer Inst. 2001 Apr 18;93(8):618-29 [11309438.001]
  • [Cites] J Pediatr Hematol Oncol. 2005 Jan;27(1):28-36 [15654275.001]
  • [Cites] Med Pediatr Oncol. 1996 Aug;27(2):74-8 [8649323.001]
  • [Cites] J Clin Oncol. 2001 Jan 1;19(1):191-6 [11134212.001]
  • [Cites] J Clin Oncol. 2003 Apr 1;21(7):1359-65 [12663727.001]
  • [Cites] J Pediatr. 1993 Jul;123(1):59-64 [8320626.001]
  • [Cites] J Clin Oncol. 1991 Jan;9(1):145-51 [1985164.001]
  • [Cites] Med Pediatr Oncol. 1997 Jun;28(6):387-400 [9143382.001]
  • [Cites] Clin Cancer Res. 2000 Oct;6(10):4091-5 [11051261.001]
  • [Cites] Ann Neurol. 1999 Dec;46(6):834-41 [10589535.001]
  • [Cites] Pharmacogenetics. 2002 Nov;12(8):605-11 [12439220.001]
  • [Cites] Ann Oncol. 2002 Jun;13(6):819-29 [12123328.001]
  • [Cites] Blood. 1996 Apr 1;87(7):3045-52 [8639928.001]
  • [Cites] J Clin Oncol. 2006 Dec 20;24(36):5735-41 [17179107.001]
  • [Cites] N Engl J Med. 1988 Jan 14;318(2):76-81 [3336397.001]
  • [Cites] Cancer. 1981 May 15;47(10):2368-74 [6791800.001]
  • [Cites] J Clin Oncol. 1984 Jun;2(6):571-7 [6547167.001]
  • [Cites] Am J Obstet Gynecol. 1992 Mar;166(3):788-93 [1550144.001]
  • [Cites] J Clin Oncol. 1993 Jul;11(7):1208-15 [8315419.001]
  • [Cites] J Clin Oncol. 1999 Feb;17(2):569-77 [10080601.001]
  • [Cites] Swiss Med Wkly. 2001 Apr 7;131(13-14):180-7 [11345808.001]
  • [Cites] J Clin Oncol. 2000 Jun;18(12):2435-43 [10856104.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1990 Oct;19(4):873-80 [2211255.001]
  • [Cites] J Clin Endocrinol Metab. 2000 Sep;85(9):3227-32 [10999813.001]
  • [Cites] Br J Haematol. 2003 Aug;122(3):345-59 [12877662.001]
  • [Cites] Eur J Cancer. 2003 Feb;39(3):359-65 [12565989.001]
  • [Cites] J Pediatr. 1993 Oct;123(4):546-52 [8410505.001]
  • [Cites] JAMA. 1979 Oct 26;242(17):1877-81 [480620.001]
  • [Cites] Biochim Biophys Acta. 1998 Oct 1;1400(1-3):233-55 [9748598.001]
  • (PMID = 18196290.001).
  • [ISSN] 0941-4355
  • [Journal-full-title] Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer
  • [ISO-abbreviation] Support Care Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 41
  •  go-up   go-down


65. Bariakh EA, Zvonkov EE, Kremenetskaia AM, Kravchenko SK, Magomedova AU, Obukhova TN, Samoĭlova RS, Vorob'ev IA, Kaplanskaia IB, Moiseeva TN, Zybunova EE, Lorie IuIu, Chernova NG, Mar'in DS, Egorova EK, Krasil'nikova BB, Gabeeva NG, Vorob'ev AI: [Treatment of adult Berkitt-like lymphoma]. Ter Arkh; 2005;77(7):53-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Treatment of adult Berkitt-like lymphoma].
  • AIM: To compare programs of chemotherapy used in adult Berkitt-like lymphoma (ABLL); to assess efficacy and toxicity of the protocol AblL-M-04.
  • 10 patients had diffuse large B-cell lymphoma.
  • 9 patients received 2 to 6 courses of CHOP, 1 patient--6 courses of Pro-Mace-Cytabom, 11 patients with newly diagnosed ABLL and 5 pretreated with CHOP--NHL-BFM-90.
  • 5 patients on the protocol NHL-BFM-90 died after short-term improvement.
  • Of 10 patients with newly diagnosed ABLL treated according to NHL-BFM-90 protocol, remission was achieved in 4 patients, follow-up median--34 months (2-56).
  • CONCLUSION: The protocol ABLL-M-04 seems to be more effective than a classic NHL-BFM-90, but this must be supported by more cases.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Burkitt Lymphoma / drug therapy
  • [MeSH-minor] 6-Mercaptopurine / therapeutic use. Adolescent. Adult. Asparaginase / therapeutic use. Cyclophosphamide / therapeutic use. Daunorubicin / therapeutic use. Disease Progression. Dose-Response Relationship, Drug. Doxorubicin / therapeutic use. Female. Follow-Up Studies. Humans. Male. Methotrexate / therapeutic use. Middle Aged. Prednisolone / therapeutic use. Prednisone / therapeutic use. Retrospective Studies. Severity of Illness Index. Time Factors. Treatment Outcome. Trimethoprim, Sulfamethoxazole Drug Combination / therapeutic use. Vincristine / therapeutic use

  • Hazardous Substances Data Bank. DAUNORUBICIN .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • Hazardous Substances Data Bank. MERCAPTOPURINE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • Hazardous Substances Data Bank. TRIMETHOPRIM/SULFAMETHOXAZOLE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16116910.001).
  • [ISSN] 0040-3660
  • [Journal-full-title] Terapevticheskiĭ arkhiv
  • [ISO-abbreviation] Ter. Arkh.
  • [Language] rus
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8064-90-2 / Trimethoprim, Sulfamethoxazole Drug Combination; 8N3DW7272P / Cyclophosphamide; 9PHQ9Y1OLM / Prednisolone; E7WED276I5 / 6-Mercaptopurine; EC 3.5.1.1 / Asparaginase; VB0R961HZT / Prednisone; YL5FZ2Y5U1 / Methotrexate; ZS7284E0ZP / Daunorubicin; CHOP protocol; PVDA protocol; non-Hodgkin's lymphoma protocol 8503
  •  go-up   go-down


66. Cheung MC, Imrie KR, Friedlich J, Buckstein R, Lathia N, Mittmann N: The impact of follicular (FL) and other indolent non-Hodgkin's lymphomas (NHL) on work productivity-a preliminary analysis. Psychooncology; 2009 May;18(5):554-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The impact of follicular (FL) and other indolent non-Hodgkin's lymphomas (NHL) on work productivity-a preliminary analysis.
  • INTRODUCTION: Although much is known about the efficacy, toxicity, and direct costs of treatment for follicular lymphoma (FL), there is no data assessing the impact of this diagnosis on the work productivity of affected individuals.
  • Patients with a diagnosis of FL or other indolent non-Hodgkin's lymphoma completed questionnaires assessing health status, work productivity, and activity impairment.
  • Prior to lymphoma diagnosis, over 71% of patients were working while 14% were retired.
  • CONCLUSIONS: Although few patients with indolent lymphoma identified significant impairment in productivity, many were unable to continue employment following diagnosis, needed to miss days from work, or imposed a significant burden on caregivers.
  • [MeSH-major] Burnout, Professional / epidemiology. Burnout, Professional / psychology. Efficiency, Organizational / statistics & numerical data. Lymphoma, Follicular / epidemiology. Lymphoma, Follicular / psychology. Lymphoma, Non-Hodgkin / epidemiology. Lymphoma, Non-Hodgkin / psychology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Caregivers / psychology. Cross-Sectional Studies. Female. Health Status. Humans. Male. Middle Aged. Quality of Life / psychology. Surveys and Questionnaires. Unemployment / psychology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2008 John Wiley & Sons, Ltd.
  • (PMID = 18942670.001).
  • [ISSN] 1099-1611
  • [Journal-full-title] Psycho-oncology
  • [ISO-abbreviation] Psychooncology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


67. Burmeister T, Schwartz S, Hummel M, Hoelzer D, Thiel E: No genetic evidence for involvement of Deltaretroviruses in adult patients with precursor and mature T-cell neoplasms. Retrovirology; 2007;4:11
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] No genetic evidence for involvement of Deltaretroviruses in adult patients with precursor and mature T-cell neoplasms.
  • HTLV-I is the main causative agent in adult T-cell leukemia in endemic areas and some of the simian T-cell lymphotropic viruses have been implicated in the induction of malignant lymphomas in their hosts.
  • We used this PCR to detect Deltaretroviruses in samples from adult patients with a variety of rare T-cell neoplasms in Germany.
  • Fifty acute T-cell lymphoblastic leukemia (T-ALL) samples and 33 samples from patients with various rare mature T-cell neoplasms (T-PLL, Sézary syndrome and other T-NHL) were subsequently investigated.
  • [MeSH-major] Deltaretrovirus / genetics. Precursor T-Cell Lymphoblastic Leukemia-Lymphoma / virology
  • [MeSH-minor] Adult. Base Sequence. DNA Primers. Humans. Molecular Sequence Data

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Virol. 2001 Feb;75(3):1095-103 [11152482.001]
  • [Cites] Blood. 2006 Nov 15;108(10):3556-9 [16873673.001]
  • [Cites] J Gen Virol. 2001 Sep;82(Pt 9):2205-13 [11514731.001]
  • [Cites] Blood. 2004 Jul 15;104(2):328-35 [15044256.001]
  • [Cites] J Infect Dis. 2004 Aug 1;190(3):504-10 [15243924.001]
  • [Cites] J Natl Cancer Inst. 1969 Dec;43(6):1297-305 [5408805.001]
  • [Cites] J Immunol. 1978 Mar;120(3):777-82 [344797.001]
  • [Cites] Nature. 1981 Nov 19;294(5838):268-71 [6272125.001]
  • [Cites] Lancet. 1982 Sep 18;2(8299):658 [6125790.001]
  • [Cites] Science. 1982 Nov 5;218(4572):571-3 [6981847.001]
  • [Cites] Science. 1983 Feb 18;219(4586):856-9 [6600519.001]
  • [Cites] Lancet. 1983 Dec 24-31;2(8365-66):1495 [6140580.001]
  • [Cites] Proc Natl Acad Sci U S A. 1985 Feb;82(3):677-81 [2983308.001]
  • [Cites] Immunogenetics. 1992;35(1):1-8 [1345904.001]
  • [Cites] J Virol. 1994 Feb;68(2):1149-57 [7507178.001]
  • [Cites] Proc Natl Acad Sci U S A. 1994 Mar 29;91(7):2848-52 [7908445.001]
  • [Cites] J Gen Virol. 1996 Feb;77 ( Pt 2 ):347-58 [8627239.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Jun 10;94(12):6403-7 [9177230.001]
  • [Cites] Nucleic Acids Res. 1997 Dec 15;25(24):4876-82 [9396791.001]
  • [Cites] Nucleic Acids Res. 1998 Jan 1;26(1):148-53 [9399820.001]
  • [Cites] Am J Hematol. 1998 Feb;57(2):184-5 [9462561.001]
  • [Cites] Virology. 1998 Apr 10;243(2):366-79 [9568035.001]
  • [Cites] AIDS Res Hum Retroviruses. 1998 Sep 1;14(13):1199-203 [9737591.001]
  • [Cites] J Virol Methods. 1998 Nov;75(2):123-40 [9870588.001]
  • [Cites] Br J Haematol. 1999 May;105(2):376-81 [10233407.001]
  • [Cites] Br J Dermatol. 1999 Jul;141(1):44-9 [10417514.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 May 31;102(22):7994-9 [15911757.001]
  • [Cites] Intervirology. 2005;48(6):362-71 [16024940.001]
  • [Cites] Retrovirology. 2005;2:17 [15743526.001]
  • [Cites] Retrovirology. 2005;2:30 [15882466.001]
  • [Cites] Leukemia. 2006 Mar;20(3):451-7 [16424875.001]
  • [Cites] Int J Dermatol. 2006 Apr;45(4):447-9 [16650175.001]
  • [Cites] Cancer Invest. 2001;19(4):383-95 [11405178.001]
  • (PMID = 17284327.001).
  • [ISSN] 1742-4690
  • [Journal-full-title] Retrovirology
  • [ISO-abbreviation] Retrovirology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / DNA Primers
  • [Other-IDs] NLM/ PMC1802090
  •  go-up   go-down


68. Omoti CE: Socio-demographic factors of adult malignant lymphomas in Benin City, Nigeria. Niger Postgrad Med J; 2006 Sep;13(3):256-60
MedlinePlus Health Information. consumer health - Lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Socio-demographic factors of adult malignant lymphomas in Benin City, Nigeria.
  • AIM: The aim of this study is to determine the incidence and sociodemographic factors associated with adult malignant lymphoma in Benin City, Niger Delta region of Nigeria.
  • METHOD: A retrospective study of 205 patients with a diagnosis of lymphoma seen over a 13-year period (1990-2003) at the University of Benin Teaching Hospital, Nigeria.
  • Non-Hodgkin's lymphoma (NHL) was more frequent (83%) while Hodgkin's lymphoma had incidence of 17%.
  • Marital status (P = 0.0002), geographical abode (p = 0.0046), educational (P = 0.0045) and occupational status (p = 0.0001) were significantly associated with the malignant lymphoma at presentation.
  • All the lymphoma subtypes were most common in patients who resided in Delta state, a major oil producer.
  • The majority of the lymphoma patients (46.3%) had tertiary form of education.
  • The highest and lowest social classes were most likely to have lymphoma, which may have been related to age and industrial exposure.
  • Living in Delta State where the petrochemical industries and gas flare sites are located may be a risk factor for the development of lymphoma.
  • [MeSH-major] Lymphoma / epidemiology
  • [MeSH-minor] Adolescent. Adult. Aged. Demography. Educational Status. Female. Hodgkin Disease / epidemiology. Humans. Lymphoma, Non-Hodgkin / epidemiology. Male. Marital Status. Middle Aged. Nigeria / epidemiology. Occupations. Residence Characteristics. Sex Factors. Social Class

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17278323.001).
  • [ISSN] 1117-1936
  • [Journal-full-title] The Nigerian postgraduate medical journal
  • [ISO-abbreviation] Niger Postgrad Med J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Nigeria
  •  go-up   go-down


69. Karanes C, Nelson GO, Chitphakdithai P, Agura E, Ballen KK, Bolan CD, Porter DL, Uberti JP, King RJ, Confer DL: Twenty years of unrelated donor hematopoietic cell transplantation for adult recipients facilitated by the National Marrow Donor Program. Biol Blood Marrow Transplant; 2008 Sep;14(9 Suppl):8-15
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Twenty years of unrelated donor hematopoietic cell transplantation for adult recipients facilitated by the National Marrow Donor Program.
  • For more than 20 years the National Marrow Donor Program has facilitated unrelated donor hematopoietic cell transplants for adult recipients.
  • In this time period, the volunteer donor pool has expanded to nearly 12 million adult donors worldwide, improvements have occurred in the understanding and technology of HLA matching, there have been many changes in clinical practice and supportive care, and the more common graft source has shifted from bone marrow (BM) to peripheral blood stem cells (PBSCs).
  • The percentage of older patients who are receiving unrelated donor transplants is increasing; currently over 1 in 10 adult transplant recipients is over the age of 60 years.
  • Chronic myelogenous leukemia (CML) was previously the most common diagnosis for unrelated donor transplantation, but it now comprises less than 10% of transplants for adult recipients.
  • Transplants for acute myelogenous leukemia (AML), acute lymphoblastic leukemia (ALL), non-Hodgkin lymphoma (NHL), and myelodysplastic syndromes (MDS) all outnumber CML.
  • [MeSH-minor] Adult. Aged. Hematologic Neoplasms / therapy. History, 20th Century. History, 21st Century. Humans. Middle Aged. Registries. Survival Rate. Tissue Donors. Transplantation, Homologous. United States

  • Genetic Alliance. consumer health - Transplantation.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18721775.001).
  • [ISSN] 1523-6536
  • [Journal-full-title] Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
  • [ISO-abbreviation] Biol. Blood Marrow Transplant.
  • [Language] eng
  • [Publication-type] Historical Article; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 16
  •  go-up   go-down


70. Shimizu D, Taki T, Utsunomiya A, Nakagawa H, Nomura K, Matsumoto Y, Nishida K, Horiike S, Taniwaki M: Detection of NOTCH1 mutations in adult T-cell leukemia/lymphoma and peripheral T-cell lymphoma. Int J Hematol; 2007 Apr;85(3):212-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Detection of NOTCH1 mutations in adult T-cell leukemia/lymphoma and peripheral T-cell lymphoma.
  • We analyzed NOTCH1 gene mutation in 53 adults with mature T-cell leukemia/lymphoma: 21 patients with adult T-cell leukemia (ATL), 25 with T-cell non-Hodgkin's lymphoma (T-NHL), and 7 with T-cell prolymphocytic leukemia.
  • We detected a nonsense mutation, C7249T (resulting in Q2417X, where X is a termination codon) in the PEST domain of NOTCH1 in an ATL patient and detected a 3-bp deletion (positions 7234-7236) that resulted in deletion of a proline codon at codon 2412 in the PEST domain of NOTCH1 in a patient with a T-NHL, peripheral T-cell lymphoma-unspecified (PTCL-u).
  • Although NOTCH1 mutation occurs infrequently in mature T-cell leukemia/lymphoma, NOTCH1 may be involved in leukemogenesis associated with various forms of T-cell leukemia/lymphoma rather than only with T-ALL.
  • [MeSH-major] Codon, Nonsense. Leukemia-Lymphoma, Adult T-Cell / genetics. Lymphoma, T-Cell, Peripheral / genetics. Receptor, Notch1 / genetics
  • [MeSH-minor] Adult. DNA Mutational Analysis. Humans

  • Genetic Alliance. consumer health - Peripheral T-cell lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 2004 Sep 15;104(6):1696-702 [15187027.001]
  • [Cites] Blood. 2002 May 1;99(9):3398-403 [11964309.001]
  • [Cites] Cell. 1991 Aug 23;66(4):649-61 [1831692.001]
  • [Cites] J Biol Chem. 2001 Sep 14;276(37):34371-8 [11425854.001]
  • [Cites] Mol Cell Biol. 2000 Oct;20(20):7505-15 [11003647.001]
  • [Cites] Virchows Arch. 2005 Apr;446(4):416-20 [15756589.001]
  • [Cites] Int J Hematol. 2005 Nov;82(4):277-84 [16298815.001]
  • [Cites] Ann Oncol. 2004 Jul;15(7):1091-6 [15205204.001]
  • [Cites] Int J Hematol. 2005 Nov;82(4):295-301 [16298817.001]
  • [Cites] Science. 2004 Oct 8;306(5694):269-71 [15472075.001]
  • [Cites] Mol Cell Biol. 2003 Jan;23(2):655-64 [12509463.001]
  • [Cites] Leukemia. 2006 Mar;20(3):537-9 [16424867.001]
  • [Cites] Blood. 2006 Feb 15;107(4):1255-64 [16210342.001]
  • [Cites] Leukemia. 2005 Oct;19(10):1841-3 [16079893.001]
  • [Cites] Blood. 2000 Sep 1;96(5):1906-13 [10961893.001]
  • [Cites] Blood. 2006 Mar 15;107(6):2540-3 [16282337.001]
  • [Cites] Immunity. 1999 Sep;11(3):299-308 [10514008.001]
  • [Cites] Blood. 2006 Jan 15;107(2):781-5 [16166587.001]
  • [Cites] Science. 1999 Apr 30;284(5415):770-6 [10221902.001]
  • [Cites] Br J Haematol. 1999 Sep;106(3):702-5 [10468859.001]
  • [Cites] Blood. 2004 Dec 1;104(12 ):3697-704 [15292061.001]
  • [Cites] Nat Immunol. 2005 Jul;6(7):680-8 [15991363.001]
  • [Cites] Nature. 2005 Sep 8;437(7056):270-4 [16025100.001]
  • [Cites] Blood. 1994 Jan 15;83(2):505-11 [8286748.001]
  • [Cites] Blood. 2004 Nov 15;104(10):3097-105 [15251982.001]
  • [Cites] Electrophoresis. 2001 Oct;22(18):4016-22 [11700735.001]
  • [Cites] Pathol Int. 2000 Sep;50(9):696-702 [11012982.001]
  • [Cites] Mol Cell Biol. 2006 Jun;26(12):4642-51 [16738328.001]
  • [Cites] Cell. 1997 Mar 21;88(6):833-43 [9118226.001]
  • [Cites] Blood. 2004 Jul 15;104(2):328-35 [15044256.001]
  • [Cites] Mol Cell Biol. 2000 Jun;20(11):3928-41 [10805736.001]
  • [Cites] Cancer Genet Cytogenet. 2000 Feb;117(1):71-9 [10700871.001]
  • [Cites] Blood. 2005 Dec 1;106(12):3898-906 [16118316.001]
  • [Cites] Trends Biochem Sci. 1996 Jul;21(7):267-71 [8755249.001]
  • [Cites] Cell. 2004 May 14;117(4):515-26 [15137944.001]
  • [Cites] Blood. 2006 Aug 15;108(4):1151-7 [16614245.001]
  • [Cites] Blood. 1997 Jun 1;89(11):3909-18 [9166827.001]
  • [Cites] Clin Cancer Res. 2006 May 15;12(10):3043-9 [16707600.001]
  • [Cites] Leukemia. 2003 Apr;17(4):738-45 [12682631.001]
  • [Cites] Cell. 1996 Nov 1;87(3):483-92 [8898201.001]
  • [Cites] Leukemia. 2001 Oct;15(10):1627-32 [11587222.001]
  • [Cites] Mol Cell Biol. 2004 Nov;24(21):9265-73 [15485896.001]
  • [Cites] Blood. 2001 Dec 15;98(13):3793-9 [11739188.001]
  • (PMID = 17483057.001).
  • [ISSN] 0925-5710
  • [Journal-full-title] International journal of hematology
  • [ISO-abbreviation] Int. J. Hematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Codon, Nonsense; 0 / NOTCH1 protein, human; 0 / Receptor, Notch1
  •  go-up   go-down


71. Anunobi CC, Banjo AA, Abdulkareem FB, Daramola AO, Akinde RO, Abudu EK: Adult lymphomas in Lagos Nigeria: a fourteen year study. Nig Q J Hosp Med; 2007 Apr-Jun;17(2):63-6
MedlinePlus Health Information. consumer health - Lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adult lymphomas in Lagos Nigeria: a fourteen year study.
  • OBJECTIVE: we present a 14 year retrospective histopathological study of 92 cases of adult lymphomas in Lagos.
  • MATERIALS AND METHOD: The materials consisted of slides and paraffin embedded blocks of all cases of lymphoma in adults above the age of 16 years seen between 1991 and 2004 at the Morbid Anatomy Department of Lagos University Teaching Hospital Idi-Araba Lagos.
  • RESULTS: Of ninety two cases of lymphoma studied, male and female patients accounted for 59(64%) and 33(36%) cases respectively, giving a M: F ratio of 1.8:1.
  • Non-Hodgkin's lymphoma (NHL) which accounted for 60 cases occurred most frequently in the 46-55 years age group and gives a male: female ratio of 2:1.
  • Hodgkin's lymphoma mostly affected patients of younger age group, 25-35 years with a M:F ratio of 1.7:1.
  • Mixed cellularity 17 (55%) was the commonest subtype of Hodgkin's lymphoma.
  • CONCLUSION: Non-Hodgkin's lymphoma is commoner than Hodgkin's lymphoma.
  • [MeSH-major] Lymphoma / epidemiology. Lymphoma / pathology
  • [MeSH-minor] Adolescent. Adult. Age Distribution. Female. Humans. Male. Middle Aged. Nigeria / epidemiology. Retrospective Studies. Sex Distribution

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18318094.001).
  • [ISSN] 0189-2657
  • [Journal-full-title] Nigerian quarterly journal of hospital medicine
  • [ISO-abbreviation] Nig Q J Hosp Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Nigeria
  •  go-up   go-down


72. Bellizzi KM, Rowland JH, Arora NK, Hamilton AS, Miller MF, Aziz NM: Physical activity and quality of life in adult survivors of non-Hodgkin's lymphoma. J Clin Oncol; 2009 Feb 20;27(6):960-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Physical activity and quality of life in adult survivors of non-Hodgkin's lymphoma.
  • PURPOSE: To examine the prevalence and correlates of physical activity in adult survivors of aggressive non-Hodgkin's Lymphoma (NHL) and to explore the association between physical activity level and health-related quality of life (HRQOL).
  • PATIENTS AND METHODS: Physical activity and HRQOL data from 319 survivors of NHL (mean age, 59.8 years, standard deviation, +/-14.8) who were diagnosed in Los Angeles County approximately 2 to 5 years before the study was analyzed.
  • RESULTS: One quarter of survivors of NHL met public health guidelines of 150 minutes or more of moderate to vigorous exercise per week.
  • As NHL, similar to other cancers, becomes a disease that people live with as opposed to one that people die as a result of, oncologists and primary care physicians will be increasingly challenged to provide evidence-based guidance for the long-term management of the patient's health.

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Med Sci Sports Exerc. 2000 Jan;32(1):149-56 [10647542.001]
  • [Cites] Compr Ther. 1997 Sep;23(9):605-11 [9285161.001]
  • [Cites] Psychooncology. 2000 Mar-Apr;9(2):127-36 [10767750.001]
  • [Cites] Ann Behav Med. 2001 Fall;23(4):229-46 [11761340.001]
  • [Cites] Semin Oncol Nurs. 2001 Nov;17(4):241-8 [11764707.001]
  • [Cites] Med Oncol. 2001;18(1):85-94 [11778974.001]
  • [Cites] J Clin Oncol. 2003 May 1;21(9):1660-8 [12721239.001]
  • [Cites] Blood. 1997 Nov 1;90(9):3390-4 [9345021.001]
  • [Cites] Cancer Nurs. 1997 Dec;20(6):430-9 [9409065.001]
  • [Cites] Oncol Nurs Forum. 1998 Jan-Feb;25(1):107-13 [9460778.001]
  • [Cites] Semin Oncol Nurs. 1998 Nov;14(4):321-8 [9839345.001]
  • [Cites] J Clin Oncol. 2005 May 20;23(15):3577-87 [15908668.001]
  • [Cites] JAMA. 2005 May 25;293(20):2479-86 [15914748.001]
  • [Cites] Oncology (Williston Park). 2005 Apr;19(4 Suppl 1):26-34 [15934515.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2005 Jul;14(7):1588-95 [16030088.001]
  • [Cites] J Med Libr Assoc. 2005 Jul;93(3):353-62 [16059425.001]
  • [Cites] Psychooncology. 2005 Nov;14(11):979-91 [15744764.001]
  • [Cites] J Clin Oncol. 2005 Dec 1;23(34):8884-93 [16314649.001]
  • [Cites] CMAJ. 2006 Jul 4;175(1):34-41 [16818906.001]
  • [Cites] J Clin Oncol. 2006 Aug 1;24(22):3527-34 [16822844.001]
  • [Cites] Support Care Cancer. 2006 Oct;14(10):1012-9 [16538497.001]
  • [Cites] Nurs Res. 2007 Jan-Feb;56(1):18-27 [17179870.001]
  • [Cites] Breast Cancer Res Treat. 2007 Jan;101(2):225-32 [17028988.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2007 Mar;16(3):566-71 [17372253.001]
  • [Cites] J Aging Phys Act. 2007 Jan;15(1):103-18 [17387232.001]
  • [Cites] Acta Oncol. 2007;46(4):417-32 [17497308.001]
  • [Cites] Gynecol Oncol. 2007 Jul;106(1):244-50 [17493671.001]
  • [Cites] Ann Behav Med. 2007 Oct;34(2):188-99 [17927557.001]
  • [Cites] J Cancer Surviv. 2007 Mar;1(1):49-63 [18648945.001]
  • [Cites] Med Sci Sports Exerc. 2003 Nov;35(11):1846-52 [14600549.001]
  • [Cites] Med Sci Sports Exerc. 2004 Feb;36(2):253-60 [14767248.001]
  • [Cites] J Clin Epidemiol. 2004 Jun;57(6):571-9 [15246125.001]
  • [Cites] Oncogene. 2004 Aug 23;23(38):6524-34 [15322522.001]
  • [Cites] Crit Rev Oncol Hematol. 2004 Sep;51(3):249-61 [15331082.001]
  • [Cites] Acta Psychiatr Scand. 1983 Jun;67(6):361-70 [6880820.001]
  • [Cites] Can J Appl Sport Sci. 1985 Sep;10(3):141-6 [4053261.001]
  • [Cites] J Pers Soc Psychol. 1987 Aug;53(2):273-9 [3625467.001]
  • [Cites] J Natl Cancer Inst. 1993 Jun 16;85(12):979-87 [8496983.001]
  • [Cites] Med Sci Sports Exerc. 1994 Jun;26(6):649-60 [8052103.001]
  • [Cites] J Natl Cancer Inst Monogr. 1994;(16):101-12 [7999452.001]
  • [Cites] JAMA. 1995 Feb 1;273(5):402-7 [7823386.001]
  • [Cites] Am J Epidemiol. 1995 Jul 15;142(2):191-201 [7598119.001]
  • [Cites] Health Educ Res. 1995 Mar;10(1):51-64 [10150421.001]
  • [Cites] Br J Soc Psychol. 1995 Jun;34 ( Pt 2):199-220 [7620846.001]
  • [Cites] Health Psychol. 2000 Mar;19(2):155-64 [10762099.001]
  • (PMID = 19139438.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] ENG
  • [Grant] United States / PHS HHS / / U55/CCR921930-02; United States / NCI NIH HHS / PC / N02-PC-15105; United States / NCI NIH HHS / PC / N01-PC-35139; United States / NCI NIH HHS / PC / N02 PC015105; United States / NCI NIH HHS / CA / N01PC35139
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2668638
  •  go-up   go-down


73. Lopes da Silva R, Fernandes T, Lopes A, Santos S, Mafra M, Rodrigues AS, de Sousa AB: B lymphoblastic lymphoma presenting as a tumor of the nasopharynx in an adult patient. Head Neck Pathol; 2010 Dec;4(4):318-23
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] B lymphoblastic lymphoma presenting as a tumor of the nasopharynx in an adult patient.
  • In adults, non-Hodgkin's lymphoma (NHL) is the second most common neoplasm found in the head and neck region after squamous cell carcinoma.
  • Within this region, primary NHL of the nasopharynx is rare.
  • We report the case of a 28-year-old male diagnosed with a B lymphoblastic lymphoma (CD20-; CD79a+; CD3-; CD10+; PAX5+, CyclinD1-; TdT+) of the nasopharynx extending to the deep and superficial structures of the right hemiface, to the skull base with an intracranial component and a small but detectable bone marrow involvement, who was started on chemotherapy with a complete response.
  • To the best of our knowledge, this is the first case of a primary nasopharynx B-LBL in an adult patient with such aggressive regional spread to be reported in the literature.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Nasopharyngeal Neoplasms / drug therapy. Nasopharyngeal Neoplasms / pathology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / pathology
  • [MeSH-minor] Adult. Biopsy. Humans. Lymphoma, Non-Hodgkin / drug therapy. Lymphoma, Non-Hodgkin / pathology. Male. Remission Induction

  • Genetic Alliance. consumer health - Lymphoblastic lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Rinsho Ketsueki. 1999 Nov;40(11):1193-7 [10624131.001]
  • [Cites] J Clin Oncol. 2000 Feb;18(3):547-61 [10653870.001]
  • [Cites] Am J Surg Pathol. 2000 Nov;24(11):1480-90 [11075849.001]
  • [Cites] Am J Clin Pathol. 2001 Jun;115(6):868-75 [11392884.001]
  • [Cites] Head Neck. 2001 Jul;23(7):547-58 [11400243.001]
  • [Cites] Leuk Lymphoma. 2001 Sep-Oct;42(5):1005-13 [11697617.001]
  • [Cites] Chin Med J (Engl). 2000 Feb;113(2):148-50 [11775540.001]
  • [Cites] Leukemia. 2003 Nov;17(11):2220-4 [14576732.001]
  • [Cites] Blood. 2004 Sep 15;104(6):1624-30 [15178574.001]
  • [Cites] Zhonghua Zhong Liu Za Zhi. 2004 Jul;26(7):425-9 [15355649.001]
  • [Cites] Am J Clin Pathol. 1983 Mar;79(3):387-91 [6338702.001]
  • [Cites] Cancer. 1985 Aug 15;56(4):768-76 [4016670.001]
  • [Cites] Laryngoscope. 1987 Mar;97(3 Pt 1):291-300 [3821348.001]
  • [Cites] Am J Surg Pathol. 1987 Jun;11(6):418-29 [3496014.001]
  • [Cites] AJR Am J Roentgenol. 1987 Oct;149(4):785-91 [3498332.001]
  • [Cites] J Clin Oncol. 1989 Sep;7(9):1275-80 [2769328.001]
  • [Cites] Cancer. 1990 Sep 15;66(6):1190-7 [2205355.001]
  • [Cites] Strahlenther Onkol. 1996 Jul;172(7):356-66; discussion 367-8 [8693402.001]
  • [Cites] Eur J Cancer B Oral Oncol. 1996 Jan;32B(1):19-23 [8729614.001]
  • [Cites] Leuk Lymphoma. 1996 Nov;23(5-6):577-82 [9031089.001]
  • [Cites] No Shinkei Geka. 2005 Nov;33(11):1107-11 [16277225.001]
  • [Cites] J Egypt Natl Canc Inst. 2005 Mar;17(1):15-9 [16353078.001]
  • [Cites] J Cutan Pathol. 2006 Sep;33(9):649-53 [16965342.001]
  • [Cites] Leuk Lymphoma. 2006 Oct;47(10):2132-9 [17071487.001]
  • [Cites] Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2007 Jun;103(6):814-9 [17531941.001]
  • [Cites] Ann Hematol. 2008 Aug;87(8):677-9 [18365194.001]
  • [Cites] Arch Dermatol. 2008 Sep;144(9):1155-62 [18794461.001]
  • [Cites] Ann Hematol. 2009 May;88(5):441-7 [18931844.001]
  • (PMID = 20730608.001).
  • [ISSN] 1936-0568
  • [Journal-full-title] Head and neck pathology
  • [ISO-abbreviation] Head Neck Pathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2996508
  •  go-up   go-down


74. Omoti CE, Halim NK: Adult malignant lymphomas in University of Benin Teaching Hospital, Benin City, Nigeria--incidence and survival. Niger J Clin Pract; 2007 Mar;10(1):10-4
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adult malignant lymphomas in University of Benin Teaching Hospital, Benin City, Nigeria--incidence and survival.
  • We aim to determine the incidence and survival of the lymphoma patients in the Niger Delta region of Nigeria.
  • STUDY DESIGN: A study of 205 cases of lymphoma patients from 1993 to 2003.
  • Non-Hodgkin's Lymphoma (NHL) was the most frequent (83%) while Hodgkin's Lymphoma (HL) had an incidence of 17%.
  • The 1 year survival for patients with NHL and HL was 35.3% and 42.9% respectively.
  • We found a strong association between haemoglobin (Hb) and white blood cell count (WBC) at presentation and lyear survival in NHL patients (P=0.0003; P=0.0001) and HL patients (P=0.0001; P=0.0104) respectively.
  • Also, the mean Erythrocyte sedimentation rate (ESR) for lymphoma patients alive at lyear was significantly lower than those that died within 1 year (P=0.0001).
  • CONCLUSION: We conclude that NHL was the most common of the lymphoma seen in young adulthood in the Niger Delta region of Nigeria.
  • [MeSH-major] Hodgkin Disease / epidemiology. Lymphoma / epidemiology. Lymphoma, Non-Hodgkin / epidemiology
  • [MeSH-minor] Adolescent. Adult. Aged. Female. Hospitals, University. Humans. Incidence. Male. Middle Aged. Nigeria / epidemiology. Prospective Studies. Survival Analysis

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17668708.001).
  • [ISSN] 1119-3077
  • [Journal-full-title] Nigerian journal of clinical practice
  • [ISO-abbreviation] Niger J Clin Pract
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Nigeria
  •  go-up   go-down


75. Jantunen E, Itälä M, Lehtinen T, Kuittinen O, Koivunen E, Leppä S, Juvonen E, Koistinen P, Wiklund T, Nousiainen T, Remes K, Volin L: Early treatment-related mortality in adult autologous stem cell transplant recipients: a nation-wide survey of 1482 transplanted patients. Eur J Haematol; 2006 Mar;76(3):245-50

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Early treatment-related mortality in adult autologous stem cell transplant recipients: a nation-wide survey of 1482 transplanted patients.
  • PATIENTS: Altogether 1482 adult patients received ASCT in six Finnish centres 1990-2003.
  • The most common diagnoses were non-Hodgkin's lymphoma (NHL) (n = 542), multiple myeloma (MM) (n = 528), breast cancer (BC) (n = 132), Hodgkin's lymphoma (n = 86) and chronic lymphocytic leukaemia (CLL) (n = 63).
  • The highest risk was observed in patients with AL amyloidosis (24%) followed by NHL (4.4%) and MM (1.9%).
  • CONCLUSIONS: This nation-wide survey indicated a low early TRM in ASCT recipients in general, but higher risks in patients with AL amyloidosis or NHL.
  • [MeSH-minor] Amyloidosis / etiology. Amyloidosis / mortality. Breast Neoplasms / mortality. Breast Neoplasms / therapy. Cause of Death. Data Collection. Finland. Humans. Leukemia, Lymphocytic, Chronic, B-Cell / mortality. Leukemia, Lymphocytic, Chronic, B-Cell / therapy. Lymphoma / mortality. Lymphoma / therapy. Multiple Myeloma / mortality. Multiple Myeloma / therapy. Survival Rate. Transplantation, Autologous

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16412136.001).
  • [ISSN] 0902-4441
  • [Journal-full-title] European journal of haematology
  • [ISO-abbreviation] Eur. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] Denmark
  •  go-up   go-down


76. Thomas DA, Faderl S, O'Brien S, Bueso-Ramos C, Cortes J, Garcia-Manero G, Giles FJ, Verstovsek S, Wierda WG, Pierce SA, Shan J, Brandt M, Hagemeister FB, Keating MJ, Cabanillas F, Kantarjian H: Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia. Cancer; 2006 Apr 1;106(7):1569-80
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia.
  • BACKGROUND: Adult Burkitt-type lymphoma (BL) and acute lymphoblastic leukemia (B-ALL) are rare entities composing 1% to 5% of non-Hodgkin lymphomas NHL) or ALL.
  • Prognosis of BL and B-ALL has been poor with conventional NHL or ALL regimens, but has improved with dose-intensive regimens.
  • CONCLUSIONS: The addition of rituximab to hyper-CVAD may improve outcome in adult BL or B-ALL, particularly in elderly patients.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antineoplastic Agents / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Burkitt Lymphoma / drug therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy


77. Chrisman Jde R, Koifman S, de Novaes Sarcinelli P, Moreira JC, Koifman RJ, Meyer A: Pesticide sales and adult male cancer mortality in Brazil. Int J Hyg Environ Health; 2009 May;212(3):310-21
MedlinePlus Health Information. consumer health - Pesticides.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pesticide sales and adult male cancer mortality in Brazil.
  • Single and multiple linear regression coefficients were obtained to assess the relationship between per capita sales of pesticides in 1985, specific-site cancer mortality rates (prostate, soft tissue, larynx, leukemia, lip, esophagus, lung, pancreas, bladder, liver, testis, stomach, brain, non-Hodgkin's lymphoma, and multiple myeloma) during 1996-1998, and several covariates.
  • Moderate to weak correlations were observed for the cancers of larynx, lung, testis, bladder, liver, stomach, brain, and NHL and multiple myeloma.
  • [MeSH-minor] Adult. Aged. Brazil / epidemiology. Commerce. Factor Analysis, Statistical. Humans. Incidence. Linear Models. Male. Middle Aged

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18838335.001).
  • [ISSN] 1618-131X
  • [Journal-full-title] International journal of hygiene and environmental health
  • [ISO-abbreviation] Int J Hyg Environ Health
  • [Language] eng
  • [Grant] United States / FIC NIH HHS / TW / D43TW00640
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Pesticides
  •  go-up   go-down


78. Sanders JE, Guthrie KA, Hoffmeister PA, Woolfrey AE, Carpenter PA, Appelbaum FR: Final adult height of patients who received hematopoietic cell transplantation in childhood. Blood; 2005 Feb 1;105(3):1348-54
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Final adult height of patients who received hematopoietic cell transplantation in childhood.
  • Girls (P = .0001) and children diagnosed with acute myelogenous leukemia (AML), chronic myelogenous leukemia (CML), or myelodysplastic syndromes (MDS) (compared with acute lymphoblastic leukemia [ALL] or non-Hodgkin lymphoma [NHL]; P = .02) also showed more rapid growth than their counterparts.
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Female. Human Growth Hormone / blood. Human Growth Hormone / deficiency. Human Growth Hormone / therapeutic use. Humans. Infant. Male. Middle Aged. Whole-Body Irradiation

  • Genetic Alliance. consumer health - Transplantation.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Blood. 2005 Oct 1;106(7):2592-3; author reply 2593 [16172255.001]
  • (PMID = 15454481.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 12629-01-5 / Human Growth Hormone
  •  go-up   go-down


79. Hwang IG, Yoo KH, Lee SH, Park YH, Lim TK, Lee SC, Park S, Park BB, Ko YH, Kim K, Koo HH, Kim WS: Clinicopathologic features and treatment outcomes in malignant lymphoma of pediatric and young adult patients in Korea: comparison of korean all-ages group and Western younger age group. Clin Lymphoma Myeloma; 2007 Nov;7(9):580-6
MedlinePlus Health Information. consumer health - Lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinicopathologic features and treatment outcomes in malignant lymphoma of pediatric and young adult patients in Korea: comparison of korean all-ages group and Western younger age group.
  • PURPOSE: The aim of this study is to define distinctive clinicopathologic features of malignant lymphoma in pediatric and young adult patients, particularly in Korea.
  • PATIENTS AND METHODS: From May 1993 to November 2005, 294 pediatric and young adult patients (age range, 0-31 years) with malignant lymphoma were analyzed in this study at Samsung Medical Center.
  • RESULTS: Hodgkin disease appears more common in the younger age group than in the all-ages group (15% vs. 5.3%; P = .001).
  • Among patients with non-Hodgkin lymphoma (NHL), T/natural killer cell immunophenotype is more common in the present younger age group than the all-ages group (45.5% vs. 25%; P = .001) and Western younger age group (45.5% vs. 13.3%; P = .001).
  • Lymphoblastic lymphoma and T-anaplastic large-cell lymphoma included relatively higher proportions in the younger age group.
  • CONCLUSION: The incidence of Hodgkin disease and T-cell NHL is relatively higher in pediatric and young-adult population group than the all-ages group.
  • However, treatment outcome of the younger age group, excluding lymphoblastic lymphoma, seems to be similar to those in any age group.
  • [MeSH-major] Lymphoma / epidemiology. Lymphoma / pathology
  • [MeSH-minor] Adolescent. Adult. Asian Continental Ancestry Group / statistics & numerical data. Child. European Continental Ancestry Group / statistics & numerical data. Humans. Immunophenotyping. Korea / epidemiology. Neoplasm Staging. Survival Analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18186966.001).
  • [ISSN] 1557-9190
  • [Journal-full-title] Clinical lymphoma & myeloma
  • [ISO-abbreviation] Clin Lymphoma Myeloma
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


80. Asfour IA, El-Tehewi MM, Ahmed MH, Abdel-Sattar MA, Moustafa NN, Hegab HM, Fathey OM: High-dose sodium selenite can induce apoptosis of lymphoma cells in adult patients with non-Hodgkin's lymphoma. Biol Trace Elem Res; 2009 Mar;127(3):200-10
Hazardous Substances Data Bank. SODIUM SELENITE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High-dose sodium selenite can induce apoptosis of lymphoma cells in adult patients with non-Hodgkin's lymphoma.
  • The present study was undertaken to explore the effect of administration of high doses of sodium selenite on the apoptosis of lymphoma cells in patients with non-Hodgkin's lymphoma (NHL).
  • Forty patients with newly diagnosed NHL were randomly divided into two groups.
  • Flow cytometry was used for monitoring of lymphoma cells apoptosis at the time of diagnosis and after therapy in the two groups.
  • Sodium selenite administration resulted in significant increase in percentage of apoptotic lymphoma cells after therapy in group II (78.9 +/- 13.3% versus 58.9 +/- 18.9%, p < 0.05).
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Apoptosis. Lymphoma, Non-Hodgkin / drug therapy. Sodium Selenite / administration & dosage
  • [MeSH-minor] Adult. Cell Line, Tumor. Female. Humans. Male. Middle Aged

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18953506.001).
  • [ISSN] 1559-0720
  • [Journal-full-title] Biological trace element research
  • [ISO-abbreviation] Biol Trace Elem Res
  • [Language] eng
  • [Publication-type] Journal Article; Randomized Controlled Trial
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; HIW548RQ3W / Sodium Selenite
  •  go-up   go-down


81. Miller E, Metser U, Avrahami G, Dvir R, Valdman D, Sira LB, Sayar D, Burstein Y, Toren A, Yaniv I, Even-Sapir E: Role of 18F-FDG PET/CT in staging and follow-up of lymphoma in pediatric and young adult patients. J Comput Assist Tomogr; 2006 Jul-Aug;30(4):689-94
MedlinePlus Health Information. consumer health - Lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Role of 18F-FDG PET/CT in staging and follow-up of lymphoma in pediatric and young adult patients.
  • OBJECTIVE: To assess the role of 18F-Fluorodeoxyglucose (18F-FDG) PET/CT in pediatric patients with Hodgkin disease (HD) and non-Hodgkin lymphoma (NHL).
  • MATERIALS AND METHODS: 31 patients, mean age 12.9 +/- 5.1, HD (n = 24), and NHL (n = 7) underwent 18F-FDG PET/CT at diagnosis (n = 31 studies) and later in the course of the disease (n = 75 studies).
  • CONCLUSIONS: PET/CT is associated with change in staging in approximately 1 out of 3 pediatric patients with HD and NHL.
  • [MeSH-major] Lymphoma / radiography. Lymphoma / radionuclide imaging. Tomography, Emission-Computed. Tomography, X-Ray Computed
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Female. Fluorodeoxyglucose F18. Humans. Image Interpretation, Computer-Assisted. Male. Neoplasm Staging. Predictive Value of Tests. Retrospective Studies

  • MedlinePlus Health Information. consumer health - CT Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16845304.001).
  • [ISSN] 0363-8715
  • [Journal-full-title] Journal of computer assisted tomography
  • [ISO-abbreviation] J Comput Assist Tomogr
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


82. Caruso V, Di Castelnuovo A, Meschengieser S, Lazzari MA, de Gaetano G, Storti S, Iacoviello L, Donati MB: Thrombotic complications in adult patients with lymphoma: a meta-analysis of 29 independent cohorts including 18 018 patients and 1149 events. Blood; 2010 Jul 1;115(26):5322-8
MedlinePlus Health Information. consumer health - Lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Thrombotic complications in adult patients with lymphoma: a meta-analysis of 29 independent cohorts including 18 018 patients and 1149 events.
  • In this meta-analysis we sought to obtain accurate estimates of the thrombotic risk in lymphoma patients.
  • The IR of thrombosis observed in subjects with non-Hodgkin lymphoma (NHL) was 6.5% (95% CI, 6.1%-6.9%), significantly greater than that observed for patients with Hodgkin lymphoma (4.7%; 95% CI, 3.9%-5.6%).
  • Within NHL, patients with high-grade disease had a greater risk of events (IR 8.3%; 95% CI, 7.0%-9.9%) than low-grade disease (IR 6.3%; 95% CI, 4.5%-8.9%).
  • This meta-analysis shows that the IR of thrombosis in lymphoma patients is quite high, especially in those with NHL at an advanced stage of the disease.
  • These results may help better defining lymphoma populations at high thrombotic risk, to whom prophylactic approaches could be preferentially applied.
  • [MeSH-major] Lymphoma / complications. Thrombosis / complications. Thrombosis / epidemiology
  • [MeSH-minor] Adult. Cohort Studies. Hodgkin Disease / complications. Humans. Lymphoma, Non-Hodgkin / complications. Risk

  • MedlinePlus Health Information. consumer health - Blood Clots.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20378755.001).
  • [ISSN] 1528-0020
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Journal Article; Meta-Analysis; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


83. Omoti CE, Halim NK: Adult lymphomas in Edo state, Niger Delta region of Nigeria--clinicopathological profile of 205 cases. Clin Lab Haematol; 2005 Oct;27(5):302-6
MedlinePlus Health Information. consumer health - Lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adult lymphomas in Edo state, Niger Delta region of Nigeria--clinicopathological profile of 205 cases.
  • Non-Hodgkin's lymphoma (NHL) occurred predominantly in young adults (20-39 years).
  • The intermediate grade NHL (41.2%) formed the largest group of which diffuse large cell lymphoma (DLCL) was the most commonly observed histopathologic type followed by the large cell immunoblastic type.
  • [MeSH-major] Lymphoma / epidemiology
  • [MeSH-minor] Adolescent. Adult. Age Distribution. Aged. Female. Hematologic Tests. Hodgkin Disease / diagnosis. Hodgkin Disease / epidemiology. Hodgkin Disease / pathology. Humans. Lymph Nodes / pathology. Lymphoma, Large B-Cell, Diffuse / epidemiology. Lymphoma, Non-Hodgkin / classification. Lymphoma, Non-Hodgkin / diagnosis. Lymphoma, Non-Hodgkin / epidemiology. Lymphoma, Non-Hodgkin / pathology. Male. Middle Aged. Neoplasm Staging. Nigeria / epidemiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16178909.001).
  • [ISSN] 0141-9854
  • [Journal-full-title] Clinical and laboratory haematology
  • [ISO-abbreviation] Clin Lab Haematol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


84. Quijano S, López A, Manuel Sancho J, Panizo C, Debén G, Castilla C, Antonio García-Vela J, Salar A, Alonso-Vence N, González-Barca E, Peñalver FJ, Plaza-Villa J, Morado M, García-Marco J, Arias J, Briones J, Ferrer S, Capote J, Nicolás C, Orfao A, Spanish Group for the Study of CNS Disease in NHL: Identification of leptomeningeal disease in aggressive B-cell non-Hodgkin's lymphoma: improved sensitivity of flow cytometry. J Clin Oncol; 2009 Mar 20;27(9):1462-9
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Identification of leptomeningeal disease in aggressive B-cell non-Hodgkin's lymphoma: improved sensitivity of flow cytometry.
  • PURPOSE: Here, we evaluate the sensitivity and specificity of a new 11-parameter flow cytometry (FCM) approach versus conventional cytology (CC) for detecting neoplastic cells in stabilized CSF samples from newly diagnosed aggressive B-cell non-Hodgkin's lymphoma (B-NHL) at high risk of CNS relapse, using a prospective, multicentric study design.
  • Interestingly, in Burkitt lymphoma, presence of CNS disease by FCM could be predicted with a high specificity when increased serum beta2-microglobulin and neurological symptoms coexisted, while peripheral blood involvement was the only independent parameter associated with CNS disease in diffuse large B-cell lymphoma, with low predictive value.
  • CONCLUSION: FCM significantly improves the sensitivity of CC for the identification of leptomeningeal disease in aggressive B-NHL at higher risk of CNS disease, particularly in paucicellular samples.
  • [MeSH-major] Flow Cytometry / methods. Lymphoma, B-Cell / cerebrospinal fluid. Meningeal Neoplasms / cerebrospinal fluid
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. B-Lymphocytes / pathology. Female. Humans. Leukocytes / pathology. Male. Middle Aged. Sensitivity and Specificity. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19224854.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Investigator] Rodríguez-Otero P; Pérez-Ceballos E; Monteserin MC; Diaz-Arias J; Pérez M; Domingo-Domenech E; Poderós C; Provencio M; Vallejo C; Forés R; Gómez E; de la Cruz M; Palacios A; Fernández S; Marin M; Hernández JA; Molero T; Romero-Picos E; Mateos MC; Peñarrubia M; Caballero D; Conde E
  •  go-up   go-down


85. Jantunen E, Itälä M, Siitonen T, Koivunen E, Leppä S, Juvonen E, Kuittinen O, Lehtinen T, Koistinen P, Nyman H, Nousiainen T, Volin L, Remes K: Late non-relapse mortality among adult autologous stem cell transplant recipients: a nation-wide analysis of 1,482 patients transplanted in 1990-2003. Eur J Haematol; 2006 Aug;77(2):114-9
MedlinePlus Health Information. consumer health - After Surgery.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Late non-relapse mortality among adult autologous stem cell transplant recipients: a nation-wide analysis of 1,482 patients transplanted in 1990-2003.
  • Data on the incidence and causes of late (>100 d) non-relapse mortality (NRM) in autologous stem cell transplant (ASCT) recipients is limited.
  • We have analysed NRM in a cohort of 1,482 adult patients who received ASCT in 1990-2003 in six Finnish transplant centres.
  • The most common diagnoses included non-Hodgkin's lymphoma (NHL) (n = 542), multiple myeloma (MM) (n = 528), breast cancer (n = 132); Hodgkin's lymphoma (HL) (n = 86) and chronic lymphocytic leukaemia (CLL) (n = 63).
  • The risk of NRM was highest in patients with CLL (9.5%) and those with HL (8.1%) followed by MM and NHL (4.9% and 4.8%, respectively).
  • [MeSH-minor] Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Breast Neoplasms / drug therapy. Breast Neoplasms / surgery. Cardiovascular Diseases / mortality. Cause of Death. Cohort Studies. Combined Modality Therapy. Female. Finland / epidemiology. Follow-Up Studies. Hodgkin Disease / drug therapy. Hodgkin Disease / surgery. Humans. Infection / mortality. Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy. Leukemia, Lymphocytic, Chronic, B-Cell / surgery. Lymphoma, Non-Hodgkin / drug therapy. Lymphoma, Non-Hodgkin / surgery. Male. Middle Aged. Multiple Myeloma / drug therapy. Multiple Myeloma / surgery. Neoplasms, Second Primary / mortality. Transplantation Conditioning / mortality. Transplantation, Autologous / mortality. Transplantation, Autologous / statistics & numerical data. Whole-Body Irradiation / adverse effects

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16856906.001).
  • [ISSN] 0902-4441
  • [Journal-full-title] European journal of haematology
  • [ISO-abbreviation] Eur. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Denmark
  •  go-up   go-down


86. Miles RR, Raphael M, McCarthy K, Wotherspoon A, Lones MA, Terrier-Lacombe MJ, Patte C, Gerrard M, Auperin A, Sposto R, Davenport V, Cairo MS, Perkins SL, SFOP/LMB96/CCG5961/UKCCSG/NHL 9600 Study Group: Pediatric diffuse large B-cell lymphoma demonstrates a high proliferation index, frequent c-Myc protein expression, and a high incidence of germinal center subtype: Report of the French-American-British (FAB) international study group. Pediatr Blood Cancer; 2008 Sep;51(3):369-74
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pediatric diffuse large B-cell lymphoma demonstrates a high proliferation index, frequent c-Myc protein expression, and a high incidence of germinal center subtype: Report of the French-American-British (FAB) international study group.
  • BACKGROUND: Diffuse large B-cell lymphoma (DLBCL) makes up 10-20% of pediatric non-Hodgkin lymphoma, and these patients have a significantly better prognosis than adults with DLBCL.
  • The difference in prognosis may be related to clinical, phenotypic, and/or biological differences between adult and pediatric DLBCL.
  • In adult DLBCL, the germinal center (GC) phenotype is associated with a better prognosis than the activated B-cell (ABC) phenotype.
  • While multiple studies have addressed the phenotype and expression patterns of adult DLBCL, relatively little is known about these biological variables in pediatric DLBCL.
  • The goal of this study was to investigate the proliferative index, the relative frequencies of the GC and non-GC subtypes, and the expression of Bcl2 and c-Myc protein in a cohort of children with DLBCL treated in a uniform manner.
  • PROCEDURE: We performed immunohistochemistry (IHC) for MIB1, CD10, Bcl6, MUM1, Bcl2, and c-Myc on DLBCL tissue from children treated uniformly in the FAB LMB96 trial (SFOP LMB96/CCG5961/UKCCSG/NHL 9600).
  • RESULTS: Compared to published adult DLBCL studies, pediatric DLBCL demonstrated moderate to high proliferation rates (83%), increased c-Myc protein expression (84%), decreased Bcl2 protein expression (28%), and an increased frequency of the GC phenotype (75%).
  • CONCLUSIONS: These findings suggest that there are significant biologic differences between pediatric and adult forms of DLBCL, which may contribute to the superior prognosis seen in the pediatric population relative to adult disease.

  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2008 Wiley-Liss, Inc.
  • [Cites] Blood. 2001 Aug 15;98(4):945-51 [11493437.001]
  • [Cites] Leukemia. 2007 Dec;21(12):2563-6 [17597802.001]
  • [Cites] Leuk Lymphoma. 2001 Sep-Oct;42(5):1099-106 [11697627.001]
  • [Cites] Mod Pathol. 2002 Jul;15(7):771-6 [12118116.001]
  • [Cites] Arch Pathol Lab Med. 2003 Feb;127(2):208-12 [12562237.001]
  • [Cites] Cancer Treat Rev. 2003 Apr;29(2):91-8 [12670451.001]
  • [Cites] J Exp Med. 2003 Sep 15;198(6):851-62 [12975453.001]
  • [Cites] Histopathology. 2003 Dec;43(6):509-28 [14636252.001]
  • [Cites] Blood. 2004 Jan 1;103(1):275-82 [14504078.001]
  • [Cites] Br J Cancer. 2004 Jan 26;90(2):372-6 [14735179.001]
  • [Cites] Am J Clin Pathol. 2004 Mar;121(3):384-92 [15023043.001]
  • [Cites] Am J Surg Pathol. 2004 Apr;28(4):464-70 [15087665.001]
  • [Cites] Am J Clin Oncol. 2004 Jun;27(3):312-6 [15170155.001]
  • [Cites] Am J Pathol. 2004 Jul;165(1):159-66 [15215171.001]
  • [Cites] Cancer Genet Cytogenet. 2004 Sep;153(2):115-21 [15350300.001]
  • [Cites] Semin Oncol. 1980 Sep;7(3):332-9 [7414342.001]
  • [Cites] Blood. 1994 Mar 15;83(6):1460-6 [8123837.001]
  • [Cites] N Engl J Med. 1996 May 9;334(19):1238-48 [8606720.001]
  • [Cites] Blood. 1997 Jul 1;90(1):244-51 [9207459.001]
  • [Cites] J Clin Oncol. 1998 May;16(5):1931-9 [9586912.001]
  • [Cites] Blood. 1998 Nov 1;92(9):3152-62 [9787151.001]
  • [Cites] Blood. 1999 Nov 15;94(10):3294-306 [10552938.001]
  • [Cites] Pathol Int. 1999 Dec;49(12):1043-52 [10632924.001]
  • [Cites] J Clin Oncol. 2000 Feb;18(3):510-18 [10653866.001]
  • [Cites] Nature. 2000 Feb 3;403(6769):503-11 [10676951.001]
  • [Cites] Am J Clin Pathol. 2000 Apr;113(4):512-8 [10761452.001]
  • [Cites] Pediatr Dev Pathol. 2000 Jul-Aug;3(4):374-90 [10890253.001]
  • [Cites] J Clin Oncol. 2000 Nov 15;18(22):3845-53 [11078498.001]
  • [Cites] Blood. 2001 Jun 1;97(11):3370-9 [11369626.001]
  • [Cites] J Clin Oncol. 2005 Apr 20;23(12):2797-804 [15728226.001]
  • [Cites] Mod Pathol. 2005 Aug;18(8):1113-20 [15920553.001]
  • [Cites] Br J Haematol. 2005 Oct;131(1):39-49 [16173961.001]
  • [Cites] J Pathol. 2006 Apr;208(5):714-23 [16400625.001]
  • [Cites] Blood. 2006 May 15;107(10):4047-52 [16424389.001]
  • [Cites] N Engl J Med. 2006 Jun 8;354(23):2431-42 [16760443.001]
  • [Cites] Blood. 2007 Apr 1;109(7):2736-43 [17138821.001]
  • [Cites] Blood. 2007 Apr 1;109(7):2773-80 [17132719.001]
  • [Cites] Blood. 2007 Jun 1;109(11):4930-5 [17299093.001]
  • [Cites] Histopathology. 2001 Aug;39(2):156-62 [11493332.001]
  • (PMID = 18493992.001).
  • [ISSN] 1545-5017
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / U10 CA098543-06; None / None / / U10 CA098413-05; United States / NCI NIH HHS / CA / U10 CA098413-05; United States / NCI NIH HHS / CA / U10 CA098543; None / None / / U10 CA098543-06
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / MYC protein, human; 0 / Neoplasm Proteins; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / Proto-Oncogene Proteins c-myc
  • [Other-IDs] NLM/ NIHMS123042; NLM/ PMC2712231
  •  go-up   go-down


87. Gross TG, Termuhlen AM: Pediatric non-Hodgkin's lymphoma. Curr Oncol Rep; 2007 Nov;9(6):459-65
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pediatric non-Hodgkin's lymphoma.
  • Non-Hodgkin's lymphoma (NHL) accounts for 7% of cancer in children and adolescents in the United States, or approximately 1000 cases annually.
  • NHL in the pediatric population differs from that observed in adult patients with respect to staging systems, histologic subtypes of disease, treatment, and outcomes.
  • Although more than 90% of pediatric NHL is of high-grade histology, more than 80% of patients achieve long-term event-free survival with modern therapy.
  • This review focuses on current treatments for pediatric NHL and some of the differences between NHL observed in pediatric and adult patients.
  • [MeSH-major] Lymphoma, Non-Hodgkin / therapy
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Humans. Survivors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ReprintIn] Curr Hematol Malig Rep. 2008 Jul;3(3):167-73 [20425462.001]
  • [Cites] Pediatr Blood Cancer. 2006 Aug;47(2):210-4 [16123999.001]
  • [Cites] Blood. 2007 Apr 1;109(7):2773-80 [17132719.001]
  • [Cites] Pediatr Dev Pathol. 2005 Jan-Feb;8(1):52-60 [15719203.001]
  • [Cites] Blood. 2000 Jan 15;95(2):416-21 [10627444.001]
  • [Cites] J Clin Oncol. 1989 Feb;7(2):186-93 [2915234.001]
  • [Cites] Pediatr Blood Cancer. 2005 Jan;44(1):70-6 [15368550.001]
  • [Cites] Blood. 2006 May 15;107(10):4047-52 [16424389.001]
  • [Cites] J Exp Med. 2003 Sep 15;198(6):851-62 [12975453.001]
  • [Cites] Ann Oncol. 2000 Jan;11(1):53-8 [10690387.001]
  • [Cites] J Pediatr Hematol Oncol. 2003 Feb;25(2):109-13 [12571460.001]
  • [Cites] Pediatr Dermatol. 2004 May-Jun;21(3):212-7 [15165197.001]
  • [Cites] Cancer Cell. 2002 Feb;1(1):75-87 [12086890.001]
  • [Cites] Blood. 2005 Feb 1;105(3):948-58 [15486066.001]
  • [Cites] Neurosurg Focus. 2006 Nov 15;21(5):E8 [17134124.001]
  • [Cites] Blood. 2002 Jun 15;99(12):4379-85 [12036865.001]
  • [Cites] J Clin Oncol. 2001 Apr 15;19(8):2319-33 [11304786.001]
  • [Cites] J Clin Oncol. 2006 Jan 20;24(3):491-9 [16421426.001]
  • [Cites] N Engl J Med. 1996 May 9;334(19):1238-48 [8606720.001]
  • [Cites] Blood. 2001 Jun 1;97(11):3370-9 [11369626.001]
  • [Cites] Oncogene. 2001 Sep 10;20(40):5623-37 [11607814.001]
  • [Cites] Blood. 2003 Jun 1;101(11):4279-84 [12576316.001]
  • [Cites] J Clin Oncol. 2005 Sep 20;23(27):6481-8 [16170157.001]
  • [Cites] Blood. 2002 Oct 1;100(7):2399-402 [12239148.001]
  • [Cites] Cancer. 2001 Oct 1;92(7):1959-66 [11745271.001]
  • [Cites] J Clin Oncol. 1993 Jun;11(6):1024-32 [8501488.001]
  • [Cites] Blood. 2007 Apr 1;109(7):2736-43 [17138821.001]
  • [Cites] Leuk Lymphoma. 2001 Jul;42(3):399-405 [11699405.001]
  • [Cites] J Clin Oncol. 2003 May 1;21(9):1782-9 [12721255.001]
  • [Cites] J Clin Oncol. 1999 Dec;17(12):3835-49 [10577857.001]
  • [Cites] Blood. 1999 Nov 15;94(10):3294-306 [10552938.001]
  • [Cites] Med Pediatr Oncol. 1999 Dec;33(6):536-44 [10573576.001]
  • [Cites] Inflamm Bowel Dis. 2007 Aug;13(8):1024-30 [17480018.001]
  • [Cites] Br J Haematol. 2005 Oct;131(1):39-49 [16173961.001]
  • [Cites] Cancer. 2006 Apr 1;106(7):1569-80 [16502413.001]
  • [Cites] Blood. 1999 Apr 15;93(8):2697-706 [10194450.001]
  • [Cites] N Engl J Med. 2006 Jun 8;354(23):2431-42 [16760443.001]
  • [Cites] N Engl J Med. 1997 Oct 30;337(18):1259-66 [9345074.001]
  • [Cites] Blood. 2001 Jun 15;97(12):3699-706 [11389005.001]
  • [Cites] Cancer Res. 1971 Nov;31(11):1860-1 [5121694.001]
  • [Cites] Lancet Oncol. 2006 May;7(5):379-91 [16648042.001]
  • [Cites] Pediatr Blood Cancer. 2006 Aug;47(2):130-40 [16358311.001]
  • [Cites] Blood. 2002 Mar 15;99(6):1959-64 [11877266.001]
  • [Cites] J Clin Oncol. 2005 Jan 20;23(3):541-7 [15659500.001]
  • (PMID = 17991353.001).
  • [ISSN] 1534-6269
  • [Journal-full-title] Current oncology reports
  • [ISO-abbreviation] Curr Oncol Rep
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 49
  •  go-up   go-down


88. van 't Veer JT, Kraan HF, Drosseart SH, Modde JM: Determinants that shape public attitudes towards the mentally ill: a Dutch public study. Soc Psychiatry Psychiatr Epidemiol; 2006 Apr;41(4):310-7
MedlinePlus Health Information. consumer health - Mental Disorders.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Genetic Predisposition to Disease. Humans. Male. Middle Aged. Models, Theoretical. Netherlands. Social Distance

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Psychiatr Serv. 2001 Jul;52(7):953-8 [11433114.001]
  • [Cites] Br J Psychiatry. 2000 Jul;177:4-7 [10945080.001]
  • [Cites] Eur Psychiatry. 2001 Dec;16(8):451-8 [11777735.001]
  • [Cites] Am J Public Health. 1999 Sep;89(9):1328-33 [10474548.001]
  • [Cites] Soc Psychiatry Psychiatr Epidemiol. 1996 Nov;31(6):321-6 [8952371.001]
  • [Cites] Schizophr Res. 2004 Aug 1;69(2-3):175-82 [15469191.001]
  • [Cites] Int J Law Psychiatry. 2001 Jul-Oct;24(4-5):469-86 [11521421.001]
  • [Cites] Z Kinder Jugendpsychiatr Psychother. 2002 May;30(2):97-103 [12053879.001]
  • [Cites] Soc Psychiatry Psychiatr Epidemiol. 2003 Dec;38(12):715-9 [14689176.001]
  • [Cites] J Abnorm Psychol. 1973 Oct;82(2):268-72 [4754367.001]
  • [Cites] Soc Psychiatry Psychiatr Epidemiol. 1997 Apr;32(3):143-8 [9130866.001]
  • [Cites] Int J Soc Psychiatry. 1994 Autumn;40(3):205-13 [7822113.001]
  • [Cites] Br J Psychiatry. 1996 Feb;168(2):191-8 [8837909.001]
  • [Cites] Int J Soc Psychiatry. 1999 Autumn;45(3):216-29 [10576088.001]
  • [Cites] J Psychopharmacol. 2004 Mar;18(1):75-82 [15107188.001]
  • [Cites] Am Psychol. 1992 Apr;47(4):511-21 [1595982.001]
  • [Cites] Acta Psychiatr Scand. 2003 Oct;108(4):304-9 [12956832.001]
  • (PMID = 16501885.001).
  • [ISSN] 1433-9285
  • [Journal-full-title] Social psychiatry and psychiatric epidemiology
  • [ISO-abbreviation] Soc Psychiatry Psychiatr Epidemiol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


89. Bosetti C, Levi F, Ferlay J, Lucchini F, Negri E, La Vecchia C: Incidence and mortality from non-Hodgkin lymphoma in Europe: the end of an epidemic? Int J Cancer; 2008 Oct 15;123(8):1917-23
Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Incidence and mortality from non-Hodgkin lymphoma in Europe: the end of an epidemic?
  • Non-Hodgkin lymphomas (NHL) are among the few neoplasms whose incidence and mortality have been rising in Europe and North America over the last few decades.
  • To update trends from NHL, we considered mortality data up to 2004 in several European countries, and for comparative purpose in the USA and Japan.
  • In most European countries, NHL mortality rose up to the mid 1990s, and started to level off or decline in the following decade.
  • Overall, in the European Union, mortality from NHL declined from 4.3/100,000 to 4.1 in men and from 2.7 to 2.5 in women between the late 1990s and the early 2000s.
  • Similarly, NHL mortality rates declined from 6.5/100,000 to 5.5 in US men and from 4.2 to 3.5 in US women.
  • In most countries considered, NHL incidence rates rose up to 1995-99, while they tended to level off or decline thereafter, with particular favorable patterns in countries from northern Europe.
  • Thus, the epidemic of NHL observed during the second half of the 20th century has now started to level off in Europe as in other developed areas of the world.
  • [MeSH-major] Disease Outbreaks. Lymphoma, Non-Hodgkin / epidemiology
  • [MeSH-minor] Adult. Europe / epidemiology. Female. Humans. Incidence. Male. Middle Aged. Mortality / trends

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18688859.001).
  • [ISSN] 1097-0215
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


90. Ulcickas Yood M, Quesenberry CP Jr, Guo D, Caldwell C, Wells K, Shan J, Sanders L, Skovron ML, Iloeje U, Manos MM: Incidence of non-Hodgkin's lymphoma among individuals with chronic hepatitis B virus infection. Hepatology; 2007 Jul;46(1):107-12
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Incidence of non-Hodgkin's lymphoma among individuals with chronic hepatitis B virus infection.
  • Although hepatitis C virus (HCV) infection has been shown to be associated with development of non-Hodgkin's lymphoma (NHL), few studies have investigated the association between chronic HBV infection and NHL.
  • The purpose of this study was to compare the incidence of NHL between patients with and without chronic hepatitis B virus (HBV) infection.
  • Using each health system's population-based tumor registry, we identified all cases of NHL diagnosed through December 31, 2002.
  • We excluded any individual with a history of NHL or human immunodeficiency virus (HIV).
  • We fit Cox proportional hazards models to calculate hazard ratios comparing the incidence of NHL between chronic HBV-infected patients (N = 3,888) and patients without HBV (N = 205,203) drawn from the source populations.
  • We identified 8 NHL cases in the chronic HBV infection cohort and 111 cases in the comparison cohort.
  • Patients with chronic HBV infection were 2.8 times more likely to develop NHL than matched comparison patients (adjusted hazard ratio = 2.80, 95% confidence interval = 1.16-6.75), after controlling for age, race, sex, income, Charlson comorbidity index, study site, and HCV infection.
  • CONCLUSION: chronic HBV-infected patients were nearly 3 times more likely to develop NHL than comparison patients.
  • [MeSH-major] Hepatitis B, Chronic / complications. Lymphoma, Non-Hodgkin / epidemiology
  • [MeSH-minor] Adult. Carcinoma, Hepatocellular / epidemiology. Cohort Studies. Female. Humans. Incidence. Liver Neoplasms / epidemiology. Male. Middle Aged. Reproducibility of Results. United States / epidemiology

  • Genetic Alliance. consumer health - Hepatitis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17526021.001).
  • [ISSN] 0270-9139
  • [Journal-full-title] Hepatology (Baltimore, Md.)
  • [ISO-abbreviation] Hepatology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


91. Chiu BC, Soni L, Gapstur SM, Fought AJ, Evens AM, Weisenburger DD: Obesity and risk of non-Hodgkin lymphoma (United States). Cancer Causes Control; 2007 Aug;18(6):677-85
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Obesity and risk of non-Hodgkin lymphoma (United States).
  • OBJECTIVE: Few studies have explored the potential association between body mass index (BMI) and non-Hodgkin lymphoma (NHL) according to histologic subtypes, or have evaluated BMI at different periods in the subject's life, and the results of these studies have been inconsistent.
  • SUBJECTS: A population-based, case-control study of 387 patients with NHL and 535 controls conducted in Nebraska between 1999 and 2002.
  • METHODS: Information on usual adult weight, weight at the ages 20-29, 40-49, and 60-69 years, height, physical activity, and other lifestyle factors was collected by telephone interview.
  • RESULTS: Higher adult BMI was associated with risk of NHL (OR=1.4; 95% CI=0.9-2.0) comparing the obese group (BMI >or= 30.0 kg/m(2)) with the normal weight group (BMI=18.5-24.9 kg/m(2)).
  • An excess risk of NHL was associated with high BMI at ages 40-49 years (OR=1.6; 95% CI=1.0-2.5), and to a lesser extent, at ages 20-29 years (OR=1.4; 95% CI=0.8-2.5).
  • Obesity at ages 40-49 years was also associated with a higher risk of small lymphocytic lymphoma (OR=4.5; 95% CI=1.5-13.3), diffuse large B-cell NHL (OR=1.8; 95% CI=0.9-3.9) and follicular NHL (OR=1.8; 95% CI=0.9-3.5).
  • CONCLUSION: Obesity is associated with risk of NHL overall.
  • Obesity at ages 40-49 years is also associated with a higher risk of NHL overall, and particularly small lymphocytic, follicular, and diffuse large B-cell NHL.
  • [MeSH-major] Body Mass Index. Lymphoma, Non-Hodgkin / etiology. Obesity / complications
  • [MeSH-minor] Adult. Aged. Case-Control Studies. Confidence Intervals. Diet Records. Female. Humans. Interviews as Topic. Male. Middle Aged. Nebraska / epidemiology. Odds Ratio. Risk Factors


92. Cvetković Z, Vucić V, Cvetković B, Petrović M, Ristić-Medić D, Tepsić J, Glibetić M: Abnormal fatty acid distribution of the serum phospholipids of patients with non-Hodgkin lymphoma. Ann Hematol; 2010 Aug;89(8):775-82
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Abnormal fatty acid distribution of the serum phospholipids of patients with non-Hodgkin lymphoma.
  • The data about the fatty acid (FA) status of non-Hodgkin lymphoma (NHL) patients are poor.
  • Therefore, the aim of this study was to investigate the FA profile of serum phospholipids in NHL patients related to the aggressiveness and clinical stage of NHL.
  • We analyzed the FA profile of serum phospholipids in 47 newly diagnosed, untreated NHL patients and in 29 healthy subjects.
  • Significantly higher (p < 0.001) levels of palmitic (16:0), oleic (18:1 n-9) and arachidonic acids (20:4 n-6), saturated and monounsaturated FA were found in NHL patients, while linoleic acid (18:2 n-6) and the levels of total polyunsaturated FA (PUFA), n-3 PUFA, eicosapentaenoic (20:5 n-3) and docosahexaenoic (DHA, 22:6 n-3) were significantly reduced (p < 0.01).
  • The level of oleic acid in patients with indolent NHL was significantly lower (p < 0.05) than in more aggressive types of disease.
  • Contents of palmitoleic acid, docosatetraenoic (22:4 n-6), and PUFA was lower in very aggressive NHL.
  • Our results showed an abnormal FA profile in serum phospholipids in NHL patients.
  • [MeSH-major] Fatty Acids / blood. Lymphoma, Non-Hodgkin / blood. Phospholipids / blood
  • [MeSH-minor] Adult. Aged. Diet. Female. Humans. Male. Middle Aged. Surveys and Questionnaires. Young Adult

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20127484.001).
  • [ISSN] 1432-0584
  • [Journal-full-title] Annals of hematology
  • [ISO-abbreviation] Ann. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Fatty Acids; 0 / Phospholipids
  •  go-up   go-down


93. Bellizzi KM, Miller MF, Arora NK, Rowland JH: Positive and negative life changes experienced by survivors of non-Hodgkin's lymphoma. Ann Behav Med; 2007 Oct;34(2):188-99
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Positive and negative life changes experienced by survivors of non-Hodgkin's lymphoma.
  • BACKGROUND: The impact of cancer on adult survivors of aggressive non-Hodgkin's Lymphoma (NHL) is understudied.
  • PURPOSE: We examined positive and negative life changes (health behaviors, relationships, financial situation) experienced by survivors of NHL and their association with physical and mental function.
  • METHODS: Using the Los Angeles County Cancer Surveillance Program, 744 questionnaires were mailed to adult survivors of NHL: 308 provided complete data for analyses (M age=59.8, SD=14.9).
  • RESULTS: Perceptions of positive and negative life changes were common in our sample, with 77.9% of NHL survivors reporting at least one positive change and 78.6% reporting at least one negative change.
  • CONCLUSIONS: In designing interventions to improve the mental and physical function of NHL survivors, the greatest benefit may likely be achieved by reducing the negative effects of cancer.
  • [MeSH-major] Life Change Events. Lymphoma, Non-Hodgkin / psychology. Survivors / psychology
  • [MeSH-minor] Activities of Daily Living / psychology. Adaptation, Psychological. Adult. Aged. Aged, 80 and over. Family Relations. Female. Health Behavior. Humans. Male. Middle Aged. Quality of Life. Sick Role. Socioeconomic Factors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17927557.001).
  • [ISSN] 0883-6612
  • [Journal-full-title] Annals of behavioral medicine : a publication of the Society of Behavioral Medicine
  • [ISO-abbreviation] Ann Behav Med
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / PC / N01-PC-35139; United States / NCI NIH HHS / PC / N02-PC-15105; United States / PHS HHS / / U55/CCR 921930-02
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  •  go-up   go-down


94. Karunanayake CP, McDuffie HH, Dosman JA, Spinelli JJ, Pahwa P: Occupational exposures and non-Hodgkin's lymphoma: Canadian case-control study. Environ Health; 2008;7:44
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Occupational exposures and non-Hodgkin's lymphoma: Canadian case-control study.
  • BACKGROUND: The objective was to study the association between Non-Hodgkin's Lymphoma (NHL) and occupational exposures related to long held occupations among males in six provinces of Canada.
  • Males with newly diagnosed NHL (ICD-10) were stratified by province of residence and age group.
  • RESULTS: Based on conditional logistic regression modeling, the following factors independently increased the risk of NHL: farmer and machinist as long held occupations; constant exposure to diesel exhaust fumes; constant exposure to ionizing radiation (radium); and personal history of another cancer.
  • Men who had worked for 20 years or more as farmer and machinist were the most likely to develop NHL.
  • CONCLUSION: An increased risk of developing NHL is associated with the following: long held occupations of faer and machinist; exposure to diesel fumes; and exposure to ionizing radiation (radium).
  • The risk of NHL increased with the duration of employment as a farmer or machinist.
  • [MeSH-major] Lymphoma, Non-Hodgkin / epidemiology. Occupational Diseases / epidemiology. Occupational Exposure / adverse effects
  • [MeSH-minor] Adult. Aged. Agriculture. Canada / epidemiology. Case-Control Studies. Dose-Response Relationship, Drug. Dose-Response Relationship, Radiation. Hazardous Substances / poisoning. Humans. Incidence. Logistic Models. Male. Middle Aged. Neoplasms, Radiation-Induced / epidemiology. Radiation, Ionizing. Surveys and Questionnaires. Vehicle Emissions / poisoning

  • MedlinePlus Health Information. consumer health - Occupational Health.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Lancet. 1979 Jun 30;1(8131):1394-5 [87845.001]
  • [Cites] J Occup Med. 1982 Feb;24(2):135-41 [7057282.001]
  • [Cites] J Epidemiol Community Health. 1983 Dec;37(4):279-80 [6361201.001]
  • [Cites] N Engl J Med. 1984 Aug 30;311(9):565-70 [6611504.001]
  • [Cites] Am Ind Hyg Assoc J. 1984 Dec;45(12):809-11 [6549104.001]
  • [Cites] Scand J Work Environ Health. 1985 Oct;11(5):347-52 [4070999.001]
  • [Cites] Br J Ind Med. 1986 Jan;43(1):6-17 [3947563.001]
  • [Cites] JAMA. 1986 Sep 5;256(9):1141-7 [3801091.001]
  • [Cites] J Natl Cancer Inst. 1987 May;78(5):899-910 [3471999.001]
  • [Cites] Br J Ind Med. 1988 Jan;45(1):19-24 [3342183.001]
  • [Cites] Am J Ind Med. 1988;13(3):363-79 [3354585.001]
  • [Cites] Am J Ind Med. 1988;13(4):429-38 [3284337.001]
  • [Cites] Scand J Work Environ Health. 1988 Aug;14(4):246-51 [3175557.001]
  • [Cites] Eur J Haematol. 1989 Mar;42(3):298-302 [2924893.001]
  • [Cites] Arch Environ Health. 1989 Mar-Apr;44(2):94-101 [2930251.001]
  • [Cites] Br J Ind Med. 1989 Aug;46(8):516-20 [2775671.001]
  • [Cites] Br J Cancer. 1989 Sep;60(3):385-8 [2789947.001]
  • [Cites] Cancer. 1989 Dec 15;64(12):2609-13 [2819671.001]
  • [Cites] Am J Ind Med. 1989;16(6):631-43 [2556914.001]
  • [Cites] J Natl Cancer Inst. 1990 May 16;82(10):840-8 [2332902.001]
  • [Cites] J Natl Cancer Inst. 1990 Sep 5;82(17):1392-6 [2201784.001]
  • [Cites] Epidemiology. 1990 Sep;1(5):349-56 [2078610.001]
  • [Cites] Am J Public Health. 1991 Jun;81(6):758-60 [2029048.001]
  • [Cites] Br J Ind Med. 1991 Aug;48(8):511-4 [1878307.001]
  • [Cites] Br J Ind Med. 1991 Aug;48(8):515-30 [1878308.001]
  • [Cites] Am J Hematol. 1991 Oct;38(2):147-9 [1951308.001]
  • [Cites] Cancer Res. 1992 May 1;52(9):2447-55 [1568215.001]
  • [Cites] Epidemiology. 1992 May;3(3):266-70 [1317221.001]
  • [Cites] Cancer Res. 1992 Oct 1;52(19 Suppl):5474s-5476s [1394156.001]
  • [Cites] Cancer Res. 1992 Oct 1;52(19 Suppl):5485s-5488s [1394159.001]
  • [Cites] Cancer Res. 1992 Oct 1;52(19 Suppl):5496s-5500s [1394162.001]
  • [Cites] Cancer Res. 1992 Oct 1;52(19 Suppl):5501s-5502s [1394163.001]
  • [Cites] Cancer Res. 1992 Oct 1;52(19 Suppl):5510s-5515s [1394165.001]
  • [Cites] J Natl Cancer Inst. 1992 Dec 16;84(24):1866-74 [1460670.001]
  • [Cites] Am J Ind Med. 1993 Feb;23(2):301-12 [8427258.001]
  • [Cites] Cancer Res. 1993 May 15;53(10 Suppl):2421 [8329071.001]
  • [Cites] BMJ. 1993 May 1;306(6886):1153-8 [8499814.001]
  • [Cites] Cancer Res. 1994 May 1;54(9):2386-9 [8162585.001]
  • [Cites] Scand J Work Environ Health. 1994 Oct;20(5):331-8 [7863296.001]
  • [Cites] Occup Environ Med. 1995 Jun;52(6):374-9 [7627313.001]
  • [Cites] Am J Ind Med. 1996 May;29(5):501-6 [8732923.001]
  • [Cites] Am J Public Health. 1997 Jan;87(1):71-9 [9065230.001]
  • [Cites] J Natl Cancer Inst. 1997 Feb 19;89(4):314-8 [9048836.001]
  • [Cites] Int J Occup Med Environ Health. 1996;9(4):309-21 [9117190.001]
  • [Cites] BMJ. 1997 May 17;314(7092):1451-5 [9167561.001]
  • [Cites] Epidemiology. 1997 Sep;8(5):551-8 [9270958.001]
  • [Cites] Health Inf Manag. 1997 Mar-May;27(1):31-8 [10169442.001]
  • [Cites] Cancer Causes Control. 1997 May;8(3):406-19 [9498902.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1998 Jul;7(7):621-5 [9681531.001]
  • [Cites] Int J Cancer. 1999 Mar 1;80(5):641-5 [10048959.001]
  • [Cites] Int J Occup Med Environ Health. 1999;12(2):135-42 [10465904.001]
  • [Cites] J Occup Environ Med. 2005 Aug;47(8):806-16 [16093930.001]
  • [Cites] J Occup Environ Med. 2006 Mar;48(3):264-74 [16531830.001]
  • [Cites] Eur J Cancer Prev. 2006 Oct;15(5):453-7 [16912575.001]
  • [Cites] Cancer Causes Control. 2006 Oct;17(8):1045-52 [16933055.001]
  • [Cites] Am J Epidemiol. 2007 Jun 1;165(11):1255-64 [17327216.001]
  • [Cites] Int Arch Occup Environ Health. 2007 Aug;80(8):663-70 [17334774.001]
  • [Cites] Cancer Causes Control. 2007 Nov;18(9):989-99 [17653830.001]
  • [Cites] Int J Cancer. 2008 Jan 1;122(1):144-54 [17708556.001]
  • [Cites] Ann Oncol. 2000;11 Suppl 1:69-73 [10707783.001]
  • [Cites] Epidemiology. 2001 Jan;12(1):78-87 [11138825.001]
  • [Cites] Am J Ind Med. 2001 May;39(5):463-76 [11333408.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2001 Nov;10(11):1155-63 [11700263.001]
  • [Cites] Pediatr Radiol. 2002 Apr;32(4):232-7; discussion 242-4 [11956701.001]
  • [Cites] J Occup Environ Med. 2002 May;44(5):469-74 [12024692.001]
  • [Cites] Lancet. 2003 Jul 12;362(9378):139-46 [12867117.001]
  • [Cites] J Natl Cancer Inst. 1969 Nov;43(5):1159-64 [5353243.001]
  • [Cites] Lancet. 1976 Oct 23;2(7991):916 [62154.001]
  • [Cites] Cancer. 1977 Apr;39(4 Suppl):1802-6 [322845.001]
  • (PMID = 18687133.001).
  • [ISSN] 1476-069X
  • [Journal-full-title] Environmental health : a global access science source
  • [ISO-abbreviation] Environ Health
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Hazardous Substances; 0 / Vehicle Emissions
  • [Other-IDs] NLM/ PMC2531101
  •  go-up   go-down


95. Cross AJ, Ward MH, Schenk M, Kulldorff M, Cozen W, Davis S, Colt JS, Hartge P, Cerhan JR, Sinha R: Meat and meat-mutagen intake and risk of non-Hodgkin lymphoma: results from a NCI-SEER case-control study. Carcinogenesis; 2006 Feb;27(2):293-7
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Meat and meat-mutagen intake and risk of non-Hodgkin lymphoma: results from a NCI-SEER case-control study.
  • Non-Hodgkin Lymphoma (NHL) incidence has risen dramatically over past decades, but the reasons for most of this increase are not known.
  • This study was conducted as a population-based case-control study in Iowa, Detroit, Seattle and Los Angeles and was designed to determine whether meat, meat-cooking methods, HCAs or PAHs from meat were associated with NHL risk.
  • This study consisted of 458 NHL cases, diagnosed between 1998 and 2000, and 383 controls.
  • Logistic regression, comparing the fourth to the first quartile, found no association between red meat or processed meat intake and risk for NHL [odds ratio (OR) and 95% confidence interval (CI): 1.10 (0.67-1.81) and 1.18 (0.74-1.89), respectively].
  • A marginally significant elevated risk for NHL was associated with broiled meat [OR and 95% CI: 1.32 (0.99-1.77); P trend = 0.09], comparing those who consumed broiled meat with those who did not.
  • The degree to which meat was cooked was not associated with the risk for NHL, although one of the HCAs, DiMeIQx (2-amino-3,4,8-trimethylimidazo[4,5-f]quinoxaline), was associated with an inverse risk.
  • Fat intake was associated with a significantly elevated risk for NHL [OR and 95% CI: 1.60 (1.05-2.45); P trend = 0.12]; in contrast, animal protein was inversely associated with risk for NHL [OR and 95% CI: 0.39 (0.22-0.70); P trend = 0.004].
  • Overall, our study suggests that consumption of meat, whether or not it is well-done, does not increase the risk of NHL.
  • Furthermore, neither HCAs nor B[a]P from meat increase the risk of NHL.
  • [MeSH-major] Lymphoma, Non-Hodgkin / etiology. Meat. SEER Program / statistics & numerical data
  • [MeSH-minor] Adult. Aged. Amines / adverse effects. Case-Control Studies. Cooking. Female. Humans. Incidence. Male. Middle Aged. Odds Ratio. Polycyclic Hydrocarbons, Aromatic / adverse effects. Risk Factors. United States / epidemiology

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16113054.001).
  • [ISSN] 0143-3334
  • [Journal-full-title] Carcinogenesis
  • [ISO-abbreviation] Carcinogenesis
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / PC / N01-PC-65064; United States / NCI NIH HHS / PC / N01-PC-67008; United States / NCI NIH HHS / PC / N01-PC-67009; United States / NCI NIH HHS / PC / N01-PC-67010; United States / NCI NIH HHS / PC / N02-PC-71105; United States / Intramural NIH HHS / /
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, N.I.H., Intramural
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Amines; 0 / Polycyclic Hydrocarbons, Aromatic
  •  go-up   go-down


96. Laden F, Bertrand KA, Altshul L, Aster JC, Korrick SA, Sagiv SK: Plasma organochlorine levels and risk of non-Hodgkin lymphoma in the Nurses' Health Study. Cancer Epidemiol Biomarkers Prev; 2010 May;19(5):1381-4
Hazardous Substances Data Bank. DDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Plasma organochlorine levels and risk of non-Hodgkin lymphoma in the Nurses' Health Study.
  • Numerous studies have reported positive associations of environmental exposure to polychlorinated biphenyls (PCB) and p,p'-dichlorodiphenyldichloroethylene (p,p'-DDE) with the risk of non-Hodgkin lymphoma (NHL).
  • In a case-control study nested within the Nurses' Health Study, a prospective cohort of U.S. women, we measured concentrations of PCBs and p,p'-DDE in blood samples from 145 women diagnosed with NHL at least 6 months after blood draw and 290 age- and race-matched controls.
  • We also evaluated these associations for major histologic subtypes of NHL.
  • There was no consistent evidence of an association of p,p'-DDE, total PCBs, immunotoxic, or individual PCB congeners with risk of NHL.
  • These results do not support the hypothesis of a positive association between PCB exposure and development of NHL.

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2010 AACR
  • [Cites] Environ Res. 2001 Oct;87(2):99-107 [11683593.001]
  • [Cites] Leuk Lymphoma. 2001 Aug;42(4):619-29 [11697490.001]
  • [Cites] Environ Health Perspect. 2004 Jun;112(8):854-61 [15175172.001]
  • [Cites] Arch Environ Contam Toxicol. 1989 Jul-Aug;18(4):495-500 [2505694.001]
  • [Cites] Epidemiology. 1992 May;3(3):266-70 [1317221.001]
  • [Cites] Environ Health Perspect. 1997 Jan;105(1):13-4 [9074863.001]
  • [Cites] Epidemiology. 2010 Mar;21(2):172-80 [20087190.001]
  • [Cites] J Natl Cancer Inst. 1998 Sep 2;90(17):1292-9 [9731736.001]
  • [Cites] Cancer Res. 2005 Dec 1;65(23):11214-26 [16322272.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2007 Mar;16(3):373-6 [17337641.001]
  • [Cites] Cancer Res. 2007 Jun 1;67(11):5545-52 [17545638.001]
  • [Cites] Int J Cancer. 2007 Dec 15;121(12):2767-75 [17722095.001]
  • [Cites] Occup Environ Med. 2008 Feb;65(2):132-40 [17699548.001]
  • [Cites] Lancet. 1997 Jul 26;350(9073):240-4 [9242800.001]
  • (PMID = 20406963.001).
  • [ISSN] 1538-7755
  • [Journal-full-title] Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
  • [ISO-abbreviation] Cancer Epidemiol. Biomarkers Prev.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA098122; United States / NCI NIH HHS / CA / R01 CA098122-04; United States / NCI NIH HHS / CA / CA098122; United States / NIMH NIH HHS / MH / T32 MH073122; United States / NIEHS NIH HHS / ES / T32 ES007155
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Environmental Pollutants; 0 / Hydrocarbons, Chlorinated; 0 / Insecticides; 4M7FS82U08 / Dichlorodiphenyl Dichloroethylene; DFC2HB4I0K / Polychlorinated Biphenyls
  • [Other-IDs] NLM/ NIHMS181677; NLM/ PMC2866053
  •  go-up   go-down


97. Han X, Zheng T, Foss F, Holford TR, Ma S, Zhao P, Dai M, Kim C, Zhang Y, Bai Y, Zhang Y: Vegetable and fruit intake and non-Hodgkin lymphoma survival in Connecticut women. Leuk Lymphoma; 2010 Jun;51(6):1047-54
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Vegetable and fruit intake and non-Hodgkin lymphoma survival in Connecticut women.
  • We investigated whether an increased intake of vegetables and fruits favors NHL survival.
  • A cohort of 568 female cases of incident NHL diagnosed during 1996-2000 in Connecticut was followed up for a median of 7.7 years.
  • Our results show that a pre-diagnostic high intake of vegetables appeared to favor overall survival (HR = 0.74, 95% CI 0.57-0.98) among patients with NHL who survived longer than 6 months.
  • When different types of vegetables and fruits were investigated separately, their impacts were found to vary in NHL subtypes.
  • Our study suggests that increasing vegetable and citrus fruit consumption could be a useful strategy to improve survival in NHL patients.

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 1999 Dec;17(12):3835-49 [10577857.001]
  • [Cites] J Clin Oncol. 2009 Feb 20;27(6):919-26 [19114692.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2000 May;9(5):477-85 [10815692.001]
  • [Cites] Cancer. 2000 Sep 15;89(6):1205-13 [11002214.001]
  • [Cites] J Nutr Educ. 2001 Jul-Aug;33(4):215-23 [11953243.001]
  • [Cites] J Clin Oncol. 2002 Aug 1;20(15):3302-16 [12149305.001]
  • [Cites] Cancer Causes Control. 2003 Sep;14(7):687-94 [14575367.001]
  • [Cites] Br J Cancer. 2003 Dec 1;89(11):2087-92 [14647142.001]
  • [Cites] Am J Epidemiol. 2004 Jan 15;159(2):148-54 [14718216.001]
  • [Cites] Am J Epidemiol. 2004 Mar 1;159(5):454-66 [14977641.001]
  • [Cites] Eur J Cancer. 1992;28(2-3):495-501 [1591072.001]
  • [Cites] N Engl J Med. 1993 Sep 30;329(14):987-94 [8141877.001]
  • [Cites] Cancer Causes Control. 1994 Sep;5(5):422-32 [7999964.001]
  • [Cites] Int J Cancer. 1996 Jan 26;65(3):308-13 [8575849.001]
  • [Cites] JAMA. 1996 May 1;275(17):1315-21 [8614116.001]
  • [Cites] Blood. 1997 Jun 1;89(11):3909-18 [9166827.001]
  • [Cites] Am J Clin Nutr. 1999 Sep;70(3 Suppl):475S-490S [10479220.001]
  • [Cites] Ann Hematol. 2005 Jan;84(1):1-12 [15480663.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2005 Feb;14(2):512-20 [15734980.001]
  • [Cites] J Clin Oncol. 2005 Dec 20;23(36):9295-303 [16361628.001]
  • [Cites] Int J Cancer. 2006 Jun 1;118(11):2871-6 [16385566.001]
  • [Cites] Am J Clin Nutr. 2006 Jun;83(6):1401-10 [16762953.001]
  • [Cites] J Clin Oncol. 2007 Jun 10;25(17):2345-51 [17557947.001]
  • [Cites] Cent Eur J Public Health. 2008 Mar;16(1):17-20 [18459474.001]
  • [Cites] Leuk Lymphoma. 2008 May;49(5):917-23 [18464111.001]
  • [Cites] Am Fam Physician. 2008 Jun 1;77(11):1573-8 [18581838.001]
  • [Cites] Cad Saude Publica. 2008;24 Suppl 2:S285-93 [18670708.001]
  • [Cites] Eur J Cancer. 2008 Sep;44(14):2058-73 [18657412.001]
  • [Cites] Nutr Clin Pract. 2008 Oct-Nov;23(5):468-76 [18849551.001]
  • [Cites] Int J Oral Maxillofac Surg. 2009 Jan;38(1):31-9 [18951763.001]
  • [CommentIn] Leuk Lymphoma. 2010 Jun;51(6):963-4 [20536344.001]
  • (PMID = 20350273.001).
  • [ISSN] 1029-2403
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] ENG
  • [Grant] United States / NCRR NIH HHS / RR / UL1 RR024139; United States / NCI NIH HHS / CA / T32 CA105666; United States / NCI NIH HHS / CA / R01 CA062006-06; United States / FIC NIH HHS / TW / D43 TW007864; United States / FIC NIH HHS / TW / D43 TW008323; United States / NCRR NIH HHS / RR / UL1 RR024139-06; United States / NCI NIH HHS / CA / R01 CA062006; United States / NCI NIH HHS / CA / T32 CA105666-08; United States / NCI NIH HHS / CA / CA105666-08
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ NIHMS291589; NLM/ PMC3110752
  •  go-up   go-down


98. Fan Y, Huang ZY, Luo LH, Yu HF: [Efficacy of GDP regimen (gemcitabine, dexamethasone, and cisplatin) on relapsed or refractory aggressive non-Hodgkin's Lymphoma: a report of 24 cases]. Ai Zheng; 2008 Nov;27(11):1222-5
Hazardous Substances Data Bank. DEXAMETHASONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Efficacy of GDP regimen (gemcitabine, dexamethasone, and cisplatin) on relapsed or refractory aggressive non-Hodgkin's Lymphoma: a report of 24 cases].
  • BACKGROUND & OBJECTIVE: The prognosis of relapsed or refractory aggressive non-Hodgkin's lymphoma (NHL) after front-line therapy remains poor.
  • Gemcitabine is effective in treating lymphoma and, when combined with cisplatin, is effective for some solid tumors.
  • This study was to evaluate the efficacy of GDP regimen (gemcitabine, dexamethasone, and cisplatin) on relapsed or refractory aggressive NHL, and observe the adverse events.
  • METHODS: Patients with relapsed or refractory aggressive NHL, measurable disease, and had received previously at least one chemotherapy regimen were enrolled and treated with GDP regimen (gemcitabine 1000 mg/m2 on Days 1 and 8, dexamethasone 20-40 mg on Days 1-3, and cisplatin 25 mg/m2 on Days 1-3) every 3 weeks.
  • The overall response rate (RR) was 58.3% for assessable patients; it was 57.1% for B-cell NHL patients and 60.0% for T-cell NHL patients (P=0.889).
  • The 1-year overall survival rate was 41.7%; it was 42.9% in B-cell NHL patients and 40.0% in T-cell NHL patients (P=0.986).
  • Non-hematologic toxicities were mild.
  • CONCLUSION: GDP regimen is an effective and relatively nontoxic salvage chemotherapy regimen for relapsed or refractory aggressive NHL.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Drug Resistance, Multiple. Drug Resistance, Neoplasm. Lymphoma, Non-Hodgkin / drug therapy
  • [MeSH-minor] Adult. Aged. Cisplatin / adverse effects. Cisplatin / therapeutic use. Deoxycytidine / adverse effects. Deoxycytidine / analogs & derivatives. Deoxycytidine / therapeutic use. Dexamethasone / adverse effects. Dexamethasone / therapeutic use. Female. Humans. Leukopenia / chemically induced. Male. Middle Aged. Neoplasm Recurrence, Local. Remission Induction. Salvage Therapy. Stem Cell Transplantation. Survival Rate. Thrombocytopenia / chemically induced. Young Adult

  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19000458.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0W860991D6 / Deoxycytidine; 7S5I7G3JQL / Dexamethasone; Q20Q21Q62J / Cisplatin; GDP protocol
  •  go-up   go-down


99. Shi H, Guo J, Duff DJ, Rahmatpanah F, Chitima-Matsiga R, Al-Kuhlani M, Taylor KH, Sjahputera O, Andreski M, Wooldridge JE, Caldwell CW: Discovery of novel epigenetic markers in non-Hodgkin's lymphoma. Carcinogenesis; 2007 Jan;28(1):60-70
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Discovery of novel epigenetic markers in non-Hodgkin's lymphoma.
  • Non-Hodgkin's lymphoma (NHL) is a group of malignancies with heterogeneous genetic and epigenetic alterations.
  • Discovery of molecular markers that better define NHL should improve diagnosis, prognosis and understanding of the biology.
  • We developed a CpG island DNA microarray for discovery of aberrant methylation targets in cancer, and now apply this method to examine NHL cell lines and primary tumors.
  • This methylation profiling revealed differential patterns in six cell lines originating from different subtypes of NHL.
  • Methylation of 6 of these genes was then further examined in 75 primary NHL specimens composed of four subtypes representing different stages of maturation.
  • This promoter hypermethylation inversely correlated with DLC-1 gene expression in primary NHL samples.
  • [MeSH-major] Biomarkers, Tumor / genetics. DNA Methylation. Epigenesis, Genetic. Gene Expression Regulation, Neoplastic. Lymphoma, Non-Hodgkin / genetics
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Blotting, Western. CpG Islands. GTPase-Activating Proteins. Gene Expression Profiling. Genome, Human. Humans. Leukemia, Lymphocytic, Chronic, B-Cell / genetics. Leukemia, Lymphocytic, Chronic, B-Cell / metabolism. Leukemia, Lymphocytic, Chronic, B-Cell / pathology. Lymphoma, B-Cell / genetics. Lymphoma, B-Cell / metabolism. Lymphoma, B-Cell / pathology. Lymphoma, Large B-Cell, Diffuse / genetics. Lymphoma, Large B-Cell, Diffuse / metabolism. Lymphoma, Large B-Cell, Diffuse / pathology. Microarray Analysis. Middle Aged. Promoter Regions, Genetic. Reverse Transcriptase Polymerase Chain Reaction. Tumor Suppressor Proteins / genetics. Tumor Suppressor Proteins / metabolism

  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16774933.001).
  • [ISSN] 0143-3334
  • [Journal-full-title] Carcinogenesis
  • [ISO-abbreviation] Carcinogenesis
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA097880; United States / NCI NIH HHS / CA / CA100055; United States / NCI NIH HHS / CA / P50 CA097274
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DLC1 protein, human; 0 / GTPase-Activating Proteins; 0 / Tumor Suppressor Proteins
  •  go-up   go-down


100. Batuecas Caletrío A, Gómez González JL, Muñoz Herrera A, Blanco Pérez P, Serradilla López JM, Gil Melcón M, Ocio San Miguel EM: [Non Hodgkin's lymphoma in the ENT field]. Acta Otorrinolaringol Esp; 2005 May;56(5):215-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Non Hodgkin's lymphoma in the ENT field].
  • [Transliterated title] Linfomas no Hodgkin en patología cérvico-facial.
  • OBJECTIVES: Non Hodgkin's lymphoma (NHL) is a frecuent tumor in the ENT field althougt there are not too many publications with a large number of patients.
  • PATIENTS AND METHODS: We have studied 300 patiens with NHL and analysed the head and neck affectation, the presence in Waldeyer's ring, the first symptoms and the stage of the disease.
  • CONCLUSION: There is an evident relationship between NHL and the Oto-Rhino-laringology area and it is necessary consider it in the differential diagnosis of head and neck adenopathies.
  • [MeSH-major] Lymphoma, Non-Hodgkin. Otorhinolaryngologic Neoplasms
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Child. Female. Humans. Male. Middle Aged

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15960125.001).
  • [ISSN] 0001-6519
  • [Journal-full-title] Acta otorrinolaringológica española
  • [ISO-abbreviation] Acta Otorrinolaringol Esp
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down






Advertisement